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ABSTRACT 
Certain drugs, which contain nitrosatable amines (secondary or tertiary 
amines) or amides can react with nitrite in the stomach to form N-nitroso 
compounds. Experimental data from animal studies suggest that exposure to 
these compounds might reduce fetal birthweight. We examined the relation 
between prenatal exposure to drugs classified as nitrosatable and dietary intake 
of nitrates/nitrites and small-for-gestational (SGA) births. Data were analyzed 
from the National Birth Defects Prevention Study (NBDPS) control participants 
(mothers of babies without major birth defects), that included 526 mothers who 
delivered infants with birthweight <10th percentile and 5970 mothers of control 
infants (birthweight ≥10th percentile for gestational age) during 1997-2005. 
Information was collected by telephone interview on type and frequency of 
medication use, diet, supplementation, demographic characteristics, and 
maternal health. Overall, prenatal use of nitrosatable drugs was not associated 
with SGA except for a few notable exceptions. Relative to women who reported 
no nitrosatable drug use anytime during pregnancy, women who took 
nitrosatable amides during the third trimester of pregnancy were more likely to 
have SGA births (adjusted odds ratio [OR] 1.4 [95% confidence interval [CI] 1.0, 
2.1]). This association was stronger among full term SGA births (OR 1.6 [95% CI 
1.1, 2.3]). Dietary nitrites modified the associations between nitrosatable drugs 
and SGA but lower odds of SGA were observed among women with higher 
nitrite intake. Higher intake of dietary vitamin C (≥85 mg/day) in combination with 
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daily vitamin C supplementation reduced the associations between SGA and 
secondary amine use during the second trimester of pregnancy (aOR 1.0 [95% 
CI 0.65, 1.6]) compared with <85mg of dietary vitamin C and less than daily use 
of vitamin C supplement (OR 4.0 [95% CI 1.5, 10.9]). Prenatal exposure to 
nitrosatable drugs and higher intake of dietary nitrites did not appear to be 
associated with SGA. Supplemental and dietary vitamin C may modify the risk of 
SGA birth in relation to nitrosatable drug use during pregnancy. 
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NOMENCLATURE 
AP Attributable proportion due to interaction 
 
BMI Body mass index 
 
CBDRP Centers for birth defects research and prevention 
 
CI Confidence interval 
 
CO Carbon monoxide 
 
EDD Estimated date of delivery 
 
FFQ Food frequency questionnaire 
 
GDM Gestational diabetes mellitus 
 
IUGR Intrauterine growth restriction 
 
NBDPS National Birth Defects Prevention Study 
 
NDMA N-nitrosodimethylamine 
 
NO2 Nitrogen dioxide 
 
NRT Nicotine replacement therapy 
 
O3 Ozone 
 
OR Odds ratio  
 
PAH Polyaromatic hydrocarbons 
 
RERI Relative excess risk due to interaction 
 
SGA Small for gestational age 
 
SIMEX Simulation extrapolation 
 
SO2 Sulphur dioxide 
 
SSRI Selective serotonin reuptake inhibitors 
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1. INTRODUCTION 
 
 Birthweight is regarded as the single most important determinant of an 
infant’s survival and subsequent health. In 2009, the infant mortality rates were 
24 times higher (53.05 per 1,000) for low birthweight (less than 2500 grams) 
infants than for infants with birthweight 2500 grams or more.1 Infants born small 
for gestational age (SGA) are also at increased risk of mortality during the first 
year of life. SGA is usually defined as infants whose birthweight  or crown-heel 
length is less than expected for their gestational age and sex.2 These infants 
may have a persistent short stature in childhood and adulthood. However, most 
infants present early postnatal or catch-up growth from birth to two years of age, 
and rapid weight gain during childhood. SGA infants are also at higher risk of 
developing poor cognitive and neurologic disorders in childhood and chronic 
diseases in adulthood such as cardiovascular disease, insulin resistance, 
diabetes mellitus, dyslipidemia, and renal disease.3-6  
 Size at birth is dependent on the fetus’s trajectory of growth and the 
maternal placental capacity to supply sufficient nutrients to maintain that 
trajectory. Evidence suggests that reduced substrate delivery to the fetus 
caused by placental insufficiency or poor maternal nutrition may play a role in 
the etiology of small-for-gestational-age (SGA).7 Several aspects of maternal 
diet have been hypothesized to influence fetal growth including dietary 
patterns;8-10 vegetable and fruit consumption;11-13 and Vitamin C and folic acid 
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supplementation.12, 14-16 Kwong et al. demonstrated that low protein diet fed to 
pregnant rats during the preimplantation period induced structural and functional 
abnormalities in organ and tissue development, and reduced fetal growth rate 
and birthweight in offspring.17 Small variations in maternal dietary patterns 
during early pregnancy have been associated with a reduced risk of SGA birth.18 
However, limited studies have examined the association between dietary 
consumption of nitrates and nitrites and SGA.  
  Exposure to nitrates and nitrites can occur from diet, drinking water, 
certain medications, and environmental or occupational sources of which dietary 
consumption accounts for a significant portion of daily nitrite exposure.19 Nitrates 
are commonly found in vegetables and root crops; and nitrite is used for curing 
of meat products. Approximately 5% of the nitrates ingested are converted to 
nitrite in the saliva and a portion of the nitrite is further reduced to nitric oxide in 
the stomach.20, 21 Nitric oxide is also produced endogenously by endothelial cells 
from L-arginine and it plays an important role in implantation, embryo 
development, and placental vascular development.22 On the other hand, higher 
nitric oxide levels have been shown to arrest embryo development and 
alterations in nitric oxide production may impact fetal growth. 
 N-nitroso compounds might also contribute to fetal growth restriction. 
These compounds are formed when nitrosating agents such as ingested nitrates 
and nitrites react with nitrosatable amine (secondary or tertiary amine) or amide 
containing drugs in the acidic environment of the stomach.23, 24 A variety of 
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prescription and non-prescription drugs, which contain secondary or tertiary 
amines or amides, are commonly used during pregnancy. Approximately 24 
percent of the control mothers in the National Birth Defects Prevention Study 
(NBDPS) reported use of one or more drugs classified as nitrosatable during the 
first trimester of pregnancy.25 N-nitroso compounds are known to cause adverse 
pregnancy outcomes such as congenital malformations and reduced fetal weight 
in animal models. The role of these compounds on fetal growth and risk of SGA 
birth needs to be further examined. 
  The long-term goal of the proposed study was to examine whether dietary 
nitrate or nitrite intake and nitrosatable drug use is associated with SGA births. 
The objective of this study was to investigate the independent and joint effects of 
dietary nitrite or total nitrite and nitrosatable drugs on risk of having SGA infants 
and the role of Vitamin C, a known nitrosation inhibitor, in lowering this risk. Data 
was used from the NBDPS control mothers who delivered infants without major 
congenital malformations with estimated dates of delivery from 1997 to 2005. 
    Specific aims were:  
1. To assess whether nitrosatable amine or amide drug use during   
pregnancy increases the risk of SGA births (Chapter II). 
Drugs were classified into secondary or tertiary amine, and amide    
depending on nitrosatability, functional group, and indication. 
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2. To examine the association between maternal dietary consumption of 
nitrite/total nitrite (dietary nitrite + 5% dietary nitrate) during pregnancy 
and risk of SGA birth (Chapter III). 
Daily nitrite and total nitrite intake were estimated based on the nitrate 
and nitrite content in each food item per serving size and frequency of 
intake. 
3. To determine if joint effects of nitrosatable drug and dietary nitrite or 
total nitrite intake increases the risk of SGA birth (Chapter III). 
4. To evaluate the effect of dietary or supplemental Vitamin C on the 
relation nitrosatable drug use during pregnancy and SGA (Chapter 
IV). 
 The causes and mechanisms of SGA are multifactorial. Several maternal 
risk factors have been identified to be associated with SGA.  Kramer reviewed 
approximately 900 published studies and categorized maternal risk factors 
identified to be associated with intrauterine growth restriction (IUGR) into 
following groups: genetic and constitutional factors (maternal height, 
prepregnancy weight); obstetrical factors (parity, history of low birthweight infant, 
general morbidity and illness, malaria); nutritional factors (gestational weight 
gain); and substance abuse factors (cigarette smoking, tobacco chewing, and 
alcohol consumption).26  A review of maternal and environmental risk factors 
associated with SGA is covered below.  
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Maternal demographic and obstetric factors 
 Maternal demographic predictors such as height, prepregnancy weight 
and low gestational weight gain may contribute to risk of SGA birth.11, 27-29 Lang 
and colleagues observed that mothers who were less than 5 feet tall had higher 
risk for SGA (OR 1.9 [95% I 1.5, 2.4]) compared to mothers who were 5’5’’-
5’7’’tall. Those weighing less than 100 pounds prior to pregnancy were twice as 
likely [95% CI 1.8, 3.2] to have SGA infants compared to those weighing 126-
160 pounds.27  Similar findings were noted by Kramer et al. with regard to 
maternal risk factors associated with IUGR. Each 10 cm change in maternal 
height (OR 1.29 [95% CI 1.10, 1.53]), and 10 gram increase in prepregnancy 
weight (OR 1.65 [95% CI 1.45, 1.87]) was significantly associated with IUGR.28 
In addition, Thompson et al. noted that mothers of SGA infants were significantly 
shorter (161.5 cm v. 164.8 cm, p < 0.001) and lighter (59.8 kg v. 66.5 kg, p < 
0.001) compared to mothers of appropriate for gestational age infants.29    
Lower gestational weight gain during pregnancy might also increase the 
risk of SGA birth.27, 28, 30 Women who had less than 0.40 pounds of weekly 
weight gain during pregnancy  were three times more likely [95% CI 2.2, 3.6] to 
have SGA birth compared to those with higher weight gain.27 Scott et al. noted 
similar observations among multiparous women; low weight gain during 
pregnancy elevated the risk of SGA birth (OR 1.78 [95% CI 1.1, 2.8]) and 
contributed to 10.2% of the total SGA babies in the population.30 Furthermore, 
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Kramer et al. found an increase in risk for IUGR (OR 1.32 [95% CI 1.20, 1.44]) 
with each 5 kg decline in gestational weight gain.28 
Racial and ethnic disparities have been observed in the prevalence of low 
birthweight and SGA births. The risk of low birthweight has been consistently 
higher among Black than White infants, a disparity that has existed for 
decades.31-35 Differences in birthweight of offspring have also been reported 
between US born and African born Black women. Using data from the Illinois 
vital records from 1980-1995, David & Collins reported that the prevalence of 
low birthweight was 13.2% among infants born to U.S. born Black women, and 
7.1% among African born Black women compared to 4.3% among U.S. born 
White women (OR 3.1 [95% CI 2.9, 3.2] and OR 1.6 [95% CI 1.4, 1.9], 
respectively).32 Kramer et al. noted similar findings in a large cohort of White and 
Black singleton livebirths in U.S. from 1998-2000.35 Compared to White women, 
the risk of SGA births was higher among U.S. born than foreign born Black 
women (OR 2.05 [95% CI 2.04, 2.06] v. OR 1.49 [95% CI 1.47, 1.51]).    
Maternal obstetrical factors that include parity, pregnancy induced 
hypertension, and history of low birthweight infants have been identified as 
significant predictors of SGA. Several studies have reported nulliparous women 
to be at increased risk for SGA birth compared to multiparous women.11, 27, 29, 36, 
37 Previous history of a pregnancy with low birthweight has been associated with 
a higher risk of having a SGA infant.30, 36 Pregnancy induced hypertension, 
especially preeclampsia has known to be associated with IUGR.28-30, 38 Women 
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diagnosed with gestational hypertension were 49% more likely to have an infant 
with IUGR (OR 1.49; 95% CI 1.14, 1.93) compared to those without 
hypertension.38 The risk of IUGR increased with severity of preeclampsia, ORs 
of 1.97 (95% CI 1.43, 2.73) and 1.95 (95% CI 1.14, 3.37), respectively, were 
noted among women with preeclampsia and severe preeclampsia. Thompson et 
al. also noted an increased risk for IUGR with increasing severity of pregnancy 
induced hypertension with ORs ranging from 1.5 to 5.5.29 Other studies reported 
similar findings with risk elevated among women who had preeclampsia.28, 30  
Substance abuse factors 
Smoking 
Smoking during pregnancy is a known risk factor for IUGR. Several 
mechanisms have been suggested through which smoking may affect fetal 
growth.39 First, carbon monoxide produced from tobacco smoke may cause fetal 
hypoxia due to increased carboxyhemoglobin levels. Second, nicotine induces 
an increase in maternal catecholamines and subsequently results in uterine 
vasoconstriction. Third, cyanide compounds in tobacco smoke may interfere with 
fetal oxidative metabolism. A positive association between smoking and IUGR 
has previously been reported.39-42 Horta et al. examined the association between 
maternal smoking during pregnancy and risk of IUGR among 5,166 infants born 
during 1993 in Pelotas, Brazil.39 Mothers who reported smoking during 
pregnancy were 2.1 times more likely [95% CI 1.69, 2.53] to deliver an SGA 
infant. The risk for IUGR doubled with increase in number of cigarettes smoked 
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(<1 to ≥ 20 cigarettes/day) with ORs ranging from 1.1 to 2.5. In addition, mothers 
who stopped smoking during the first trimester had slightly lower risk than those 
who continued smoking until the second or third trimester of pregnancy. Chiolero 
et al. noted similar findings in a population based cohort of 6,284 singleton births 
in the Canton of Vaud, Switzerland from 1993-1994.41 A higher proportion of 
mothers with SGA infants reported smoking during pregnancy (18.8%) 
compared to controls (9.9%). The odds of delivering an SGA infant (OR 1.4 
[95% CI 1.1, 1.9]) was higher among smokers compared to non-smokers.  
Although there is strong evidence that smoking cessation during 
pregnancy might improve neonatal outcomes such as birthweight but only one in 
four women may quit smoking during pregnancy.43 Several studies found that 
reduction in smoking during pregnancy was associated with an increase in infant 
birthweight.44-46 Li et al. reported that mean birthweight of infants born to women 
who reduced smoking during pregnancy was 92g higher than among women 
who did no change their smoking behavior during pregnancy.45 
Furthermore, infants born to women exposed to environmental tobacco 
smoke are subjected to most of the same toxic compounds as those contained 
in mainstream smoke, but the pattern and amount of exposure may vary. 
Studies have shown that prenatal exposure to environmental tobacco smoke 
elevated the risk of delivering a low birthweight infant.47-51 However, inconsistent 
findings have been reported regarding the associations between SGA and 
maternal exposure to environmental tobacco smoke. 
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Alcohol intake 
The impact of chronic heavy alcohol consumption during pregnancy on 
fetal growth is well documented. Fetal alcohol syndrome, a characteristic 
disorder of fetal growth restriction with mental retardation and facial anomalies 
has been linked with heavy maternal alcohol consumption during pregnancy.52 
However, the effect of light or moderate alcohol intake on fetal growth is unclear. 
Majority of studies have found no association between prenatal exposure to low 
levels of alcohol and risk of SGA birth,53-57 while few studies have reported an 
increased risk.42, 58, 59 In a retrospective cohort study, Windham et al. examined 
the association between moderate maternal alcohol consumption during 
pregnancy and birthweight.42 Women who reported an average of three or more 
drinks per week had increased odds of delivering a SGA infant (OR 2.3 [95% CI 
1.2, 4.6]). Using data from the Pregnancy Risk Assessment Monitoring System, 
Whitehead & Lipscomb noted that heavy drinking (≥ 14 drinks/week) during the 
last three months of pregnancy was associated with a four-fold risk [95% CI 
1.11, 16.11] of SGA birth; however, only 28 women reported heavy drinking 
during this period.59 Chiaffarino et al. confirmed findings from the previous 
studies.58 Among women who reported three or more drinks/day, the risk of SGA 
birth was 3.2 [95% CI 1.7, 6.2] from exposure during the first trimester, 2.7 [95% 
CI 1.4, 5.3] and 2.9 [95% CI 1.5, 5.7], respectively, from exposure during the 
second trimester and third trimester of pregnancy.        
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Environmental risk factors 
The impact of ambient air pollutants such as sulphur dioxide (SO2), 
nitrogen dioxide (NO2), ozone (O3), carbon monoxide (CO), polyaromatic 
hydrocarbons (PAHs), and fine and coarse particulate matter with aerodynamic 
diameters of ≤ 2.5 µM (PM2.5) and ≤ 10 µM (PM10), respectively, and their 
potential interactive effects on fetal growth has previously been examined; 
however, inconsistent findings have been reported by different studies. 
Sulphur dioxide 
While few studies reported positive association between maternal SO2 
exposure and low birthweight,60-63 other studies found null associations.64-68 In 
an ecologic study conducted in Czech Republic, Bobak & Leon observed 
increased risk for low birth weight with every 50 µg/m3 increase in exposure to 
SO2.
60 Examining exposure to SO2 by each trimester of pregnancy, Lee et al. 
noted significant risk for low birthweight among mothers exposed during the 
second trimester of pregnancy (OR 1.06 [95% CI 1.02, 1.11]).62 Dugandzic et al. 
also observed elevated risk for low birthweight with first trimester exposure to 
SO2 (OR 1.15 [95% CI 1.00, 1.31]).
61 Further, Liu et al. found that exposure to 
SO2 during the first month of pregnancy was significantly associated with low 
birthweight (OR 1.11 [95% CI 1.01, 1.22] per 5 ppb increase in SO2 
concentration).63 The risk for IUGR was also higher with SO2 exposure during 
the same period (OR 1.07 [95% CI 1.01], 1.33 per 5 ppb increase in SO2 
concentration).   
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Nitrogen dioxide 
The association between NO2 exposure during pregnancy and SGA has 
been explored previously. The risk for SGA births was elevated with maternal 
exposure to NO2 during the first month of pregnancy (OR 1.05 [95% CI 1.01, 
1.10] per 10 ppb increase in NO2);
63 second trimester (OR 1.37 [95% CI 1.01, 
1.85] per 10 µg/m3 increase in NO2 concentrations
 ); 69 and third trimester of 
pregnancy (OR 1.01 [95% CI 1.00, 1.02]).70 Conversely, other studies found no 
increased risk for SGA with NO2 exposure during pregnancy.
71, 72 
Carbon monoxide and ozone 
Most studies have found null findings with exposure to ambient levels of 
carbon monoxide or ozone during pregnancy.68, 70, 73 Only two studies noted 
slightly elevated risk of SGA with CO exposure during the first month (OR 1.06 
[95% CI 1.01, 1.10] per 1 ppm increase in CO concentration)63 and the first 
trimester of pregnancy (OR 1.08 [95% CI 1.04, 1.12] per interquartile increase in 
CO concentration).65  
Particulate matter 
 Exposure to fine and coarse particulate matter, PM2.5 and PM10, 
respectively, has been linked with fetal growth retardation. PM10 is emitted from 
residential heating and power plants, while PM2.5 is emitted from cars, utility, or 
wood burning. Early fetal exposure to particulate matter can lead to altered 
trophoblast formation and inappropriate vascularization of the placenta.74 In a 
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population based study, Dejmek et al. evaluated the impact of exposure to 
elevated levels of PM2.5 and PM10 on risk of IUGR in a highly polluted area of 
Teplice, Northern Bohemia.75 The risk for IUGR in relation to PM10 exposure 
during the first month of gestation was elevated for medium and high 
concentration levels of PM10 (OR 1.62 [95% CI 1.07, 2.50] and OR 2.64 [95% CI 
1.48, 4.71], respectively). For PM2.5, the OR was increased in the highest tertile 
of exposure (OR 2.11 [95% CI 1.20, 3.70]). Another study conducted in the 
same cohort reported an elevated risk for IUGR (OR 1.19 [95% CI 1.06, 1.33]) 
with each 10 µg/m3 increase in PM10 concentration during the first month of 
pregnancy.76 A recent study prospectively evaluated the impact of maternal 
exposure to air pollutants on fetal growth using ultrasound measurements as a 
direct estimate of growth.77 Exposure to PM10 was significantly associated with 
SGA (OR 1.38 [95% CI 1.00, 1.90]).     
 Additionally, Mannes et al. assessed the relation between SGA and 
exposure to average levels of particulate matter during pregnancy among births 
reported in metropolitan Sydney from 1998-2000.70 Exposure to PM2.5 during the 
second trimester slightly elevated the risk of SGA birth (OR 1.03 [95% CI 1.01, 
1.05]), whereas PM10 exposure was not significantly associated with SGA (OR 
1.01 [95% CI 1.00, 1.04]). Parker et al. noted similar observations in a California 
birth cohort of 18,247 infants born to women exposed to PM2.5 during 
pregnancy.73 The odds of SGA with exposure to the highest quartile (>18.4 
µg/m3) of PM2.5 was 1.23 [95% CI 1.03, 1.50]. In contrast, other studies have 
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reported null associations between maternal exposure to PM10 or PM2.5 and 
SGA.68, 72, 78 
Polycyclic aromatic hydrocarbons (PAHs)  
PAHs are ubiquitous air pollutants generated by incomplete combustion 
of fossil fuels. They are human carcinogens and mutagens, and potential 
developmental toxicants.76, 79 PAHs are readily absorbed on the surface of 
particulate matter forming DNA adducts that have been associated with reduced 
gestational length and decreased birthweight.63, 79 
The association between PAH exposure and IUGR is unclear; although, 
some studies have reported positive findings. Dejmek et al. assessed the impact 
of PAH exposure on IUGR in Teplice and Prachatice regions of Czech 
Republic.76 A significant increased risk was observed for IUGR (OR 1.22 [95% 
CI 1.07, 1.39]) with each 10 ng increase of PAH concentrations in air.  Another 
study conducted in Poland reported that infants who had higher than median 
levels of PAH DNA adducts were more likely to have decreased birthweight, 
length, and head circumference.79 Choi et al. also noted that prenatal exposure 
to PAH was significantly associated with reduced birthweight   (p < 0.01) in two 
different cohorts, Krakow Caucasians and NYC African Americans.80 A follow up 
study in the NYC cohort observed a 2 fold increase in risk of IUGR per natural 
log unit increase in PAH exposure among full term African American infants.81    
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The aforementioned studies that examined the relation between different 
environmental pollutants and SGA had several limitations. First, different 
measurement metrics were used for exposure assessment. Second, most 
studies failed to account for residential mobility; and third, average estimates of 
the pollutants were used for a given period that may have attenuated the results. 
Furthermore, exposure to air pollution is fairly common and majority of the air 
pollutants are highly correlated. Hence misclassification of exposure may have 
occurred. 
 The etiology and pathophysiology of SGA is not well established. Nitric 
oxide produced endogenously or formed from conversion of ingested nitrates 
and nitrites might play a role in the etiology of fetal growth restriction. Inoue et al. 
observed that an increase in serum nitrate/nitrite concentrations following 
administration of diethylenetriamine-nitric oxide significantly decreased placental 
and fetal weight in pregnant rats.82 Studies have detected elevated nitric oxide 
levels in placenta and umbilical cord blood of pregnancies with intrauterine 
growth restriction compared to normal pregnancies.83, 84 Further, another study 
noted that maternal and fetal nitrate and nitrite concentrations were significantly 
lower among women with SGA infants than those with  appropriate for 
gestational age births implying that nitric oxide synthesis may be decreased in 
pregnancies with SGA infants.85 
 Certain medications, classified as containing nitrosatable amines 
(secondary or tertiary amines) or amides are precursors to the formation of N-
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nitroso compounds. These compounds can be formed in vivo when nitrosatable 
amines or amides react with nitrosating agents such as nitrite in the stomach.24 
Endogenous formation of these compounds contributes to 40-75% of human 
exposure; however, exposure may also occur from exogenous sources, such as 
processed meat products, cured meats, smoked fish, alcohol, and tobacco.86-88 
Studies have shown N-nitroso compounds to cause congenital malformations in 
animal models but their effect on fetal growth is not known. Some drugs 
classified as tertiary amines form n-nitrosodimethylamine (NDMA) in the 
presence of nitrite.89 An experimental study conducted in mice noted that 
acetoxymethyl-methylnitrosamine, which has the same active intermediate 
metabolite as NDMA, was associated with an increase in the number of weight-
retarded fetuses.90 Annola et al. detected transplacental transfer of NDMA in 
perfused human placentas from women who recently delivered full-term babies 
indicating that maternal exposure to NDMA may possibly affect fetal health.91   
Furthermore, in pregnant mice exposed to both ethylenethiourea (a nitrosatable 
compound) and nitrite, fetal weight was significantly reduced when both 
compounds were administered together, but no effect was observed when given 
separately.92 These findings suggest that N-nitroso compounds, formed from 
combination of nitrosatable compound and nitrite, might influence fetal growth. 
 Numerous epidemiologic studies have examined the relation between 
maternal drug use during pregnancy and birthweight or SGA; but none of the 
studies evaluated the risk of SGA in relation to drugs classified as nitrosatable. 
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Only one published study examined the effect of nitrosatable drug exposure on 
fetal weight. Olshan and Faustman examined the relation between nitrosatable 
drugs use during the first four months and anytime during pregnancy and 
adverse pregnancy outcomes.93 A significantly reduced risk was observed for 
low birthweight (<2000 grams) in relation to nitrosatable drug exposure during 
the given time periods.  
A detailed review of drugs categorized by indication and classified as 
secondary or tertiary amines or amides and its association with SGA is covered 
below.   
Secondary amines 
Antidepressants 
Depression is a common disorder among women of childbearing age with 
an estimated prevalence of 10 to 20%.94 There has been a significant increase 
in prescription of antidepressants to women during pregnancy. Approximately 4 
to 10% of women reported taking antidepressants during pregnancy, selective 
serotonin reuptake inhibitors (SSRI) was the commonly used antidepressant.94 
Although antidepressants reduce complications associated with depression; the 
safety of antidepressant use during pregnancy remains uncertain.  
Several studies have reported positive associations between prenatal use 
of antidepressants and adverse pregnancy outcomes. Using data from the Slone 
Epidemiology Center Birth Defects Study, Toh et al. reported 7.2% of women 
exposed to antidepressants, specifically SSRI, anytime during pregnancy to 
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have increased risk (OR 1.7 [95% CI 1.0, 2.7]) of delivering an SGA offspring.95 
In addition, the risk for SGA was higher (OR 3.0 [95% CI 1.7, 5.5]) among those 
who continued use beyond the first trimester. Malm et al. observed similar 
observations in a population based study in which maternal SSRI use during 
pregnancy was compared between different trimesters and its effect on 
pregnancy outcome was evaluated.96 Women who purchased SSRI during the 
second and third trimester (n=360) had increased risk for SGA births (OR 2.4 
[95% CI 1.1, 5.3]), whereas exposure to SSRI during the first trimester or 
periconceptional period (n= 1,010) was not significantly associated with SGA 
(OR 1.9 [95% CI 1.0, 3.8]).       
In a prospective cohort study, Chamber et al. evaluated pregnancy 
outcomes among women exposed to fluoxetine, an SSRI drug, during 
pregnancy.97 Using the California Teratogen Information Service and Clinical 
Research Program, 228 pregnant women that received information on the 
teratogenic effects of fluoxetine and reported taking the drug were identified to 
be exposed and those who called regarding other nonteratogenic drugs (n= 254) 
were considered to be not exposed. The mean birthweight was significantly 
lower among those exposed to fluoxetine during late gestation (third trimester) 
compared to those exposed early or not exposed. In addition, the proportion of 
full term infants with birthweight at or below the 10 percentile were higher among 
those exposed later during pregnancy. Conversely, Wen et al. observed the risk 
for low birthweight to be elevated (OR 1.58 [95% CI 1.19, 2.11]) among women 
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who received an SSRI prescription a year prior to delivery compared to those 
who were not prescribed an SSRI.98  
Colvin et al. also confirmed positive associations between exposure to 
SSRI during pregnancy and low birthweight.99 The study linked data from 
population based health datasets in Western Australia and a national 
pharmaceutical claims dataset from 2002-2005. Approximately 3.8 percent of 
96,968 pregnant women were dispensed a SSRI during pregnancy. Women 
dispensed an SSRI anytime during pregnancy were more likely to have low 
birthweight infant (OR 1.4 [95% CI 1.3, 1.6]) and the associations remained 
significant after controlling for other factors. The risk for low birthweight was also 
higher among women prescribed selective SSRI drugs including fluoxetine (OR 
1.53 [95% CI 1.10, 2.14]), paroxetine (OR 1.44 [95% CI 1.12, 1.86]), and 
citalopram (OR 1.58 [95% CI 1.31, 1.91]). Furthermore, Kallen noted an 
increased risk for low birthweight among women who reported any 
antidepressant and SSRI use during pregnancy (OR 1.98 [95% CI 1.55, 2.52] 
and OR 1.98 [95% CI 1.42, 2.76], respectively).100 However, no elevated risk 
was observed for SGA with any antidepressant or SSRI use (OR 0.83 [95% CI 
0.53, 1.30] and OR 0.80 [95% CI 0.44, 1.44]).                 
In contrast, other studies found no statistically significant difference in 
birthweight or risk for SGA birth among women exposed to SSRI during 
pregnancy.94, 101, 102 A recent Canadian study compared the incidence of SGA 
among women who contacted Motherrisk Program regarding antidepressant use 
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and those who requested information on other non-teratogenic drugs.101 The risk 
for SGA was not significantly different among women exposed to 
antidepressants compared to controls (OR 1.19; 95% CI 0.86, 1.64). In addition, 
a retrospective cohort study of 228,876 singleton pregnancies among women 
enrolled in the Tennessee Medicaid Program, found no significant association 
between women receiving antidepressants during pregnancy and birthweight.94  
Although, several studies reported associations between maternal SSRI 
use during pregnancy and increased incidence of low birthweight or SGA; other 
studies failed to detect a significant association. Additionally, the increased risk 
observed may not be attributable to the treatment itself but rather the indication 
for treatment since maternal depression has been linked with adverse neonatal 
outcomes. However, two studies that controlled for maternal depression 
reporting conflicting results.102, 103 Wisner et al. conducted a prospective 
observational study to determine whether SSRI treatment in pregnant women 
with major depressive disorder was associated with increased risk for adverse 
neonatal outcomes.102 Neither the mean birthweight nor the proportion of infants 
with birthweight below the 10th percentile differed across the exposure groups. In 
contrast, using propensity score matching to control for maternal illness severity, 
Oberlander et al. reported increased incidence of birthweight below the 10th 
percentile among pregnant women with depression exposed to SSRI compared 
to non-exposed women.103  
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Asthma medication  
Asthma is one of the most common, potentially serious chronic disease in 
women of reproductive age, and occurs in 3.7% to 8.4% of all pregnancies.104 
Maternal asthma during pregnancy has been linked with an increased risk of 
pregnancy complications such as reduced infant size, intrauterine growth 
restriction, and prematurity as a result of poorly controlled asthma or some of the 
asthma medications used for treatment.105 β2 adrenergic agonists such as 
Albuterol are commonly used in management of asthma to relieve acute 
symptoms. Previous studies suggest that short acting β2 agonists used for 
bronchodilation are generally considered safe during pregnancy. However, they 
are often used in conjunction with anti-inflammatory medications such as inhaled 
corticosteroids or leukotriene inhibitors that may increase the risk for adverse 
pregnancy outcomes.  
In a prospective cohort study, Bakhireva et al. examined the effect of β2 
agonists on fetal growth among 654 infants born to women with asthma and 303 
infants born to those without asthma.106 The mean birthweight of full term infants 
was similar among women exposed to β2 agonists (3552 g) and controls (3540 
g). No significant difference was observed in the incidence of SGA births among 
the exposed group compared to non-asthmatic controls (OR 0.57 [95% CI 0.16, 
2.12]). Similar findings were observed in a prospective cohort study conducted 
among members of the San Diego Kaiser Permanente Medical Care 
Program.107 Pregnant women with asthma treated with bronchodilators (n= 259) 
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were identified and compared to 101 women with asthma and not exposed to 
bronchodilators.  Risk of SGA birth was not significantly increased among 
pregnant women with asthma using inhaled bronchodilators compared to those 
with asthma and not using the drug or compared to controls. Bracken et al. also 
noted no significant increased risk for low birthweight among 401 pregnant 
women exposed to short acting β2 agonists during the third trimester (OR 0.97 
[95% CI 0.65, 1.47]).108 Additionally, in a cohort of 2,123 asthmatic patients 
recruited from 16 centers of the National Institute Child Health and Human 
Development Maternal Fetal Medicines Unit Network, Schatz et al. confirmed 
null associations between maternal use of inhaled β2 agonists and incidence of 
SGA infants.109  
Data from the above reviewed studies indicate that management of 
asthma during pregnancy with β2 agonists does not increase the risk of low 
birthweight or SGA birth.  
 Decongestants, pseudoephedrine 
Decongestants are commonly used for the treatment of upper respiratory 
infections, allergy, and asthma during pregnancy. Approximately 22% of 
pregnant women reported rhinitis, and 25% visited the physician due to 
respiratory illness.110 Decongestants are one of the most frequently used over 
the counter medications in pregnancy. Pseudoephedrine, the most commonly 
taken oral decongestant was reported to be used by at least 15% of women 
during pregnancy among 7,563 case and control mothers in the Slone 
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Epidemiology Center Birth Defects Study and 2,970 control mothers in the 
National Birth Defects Prevention Study.111  While use of over the counter 
medications normally decreases during pregnancy, Werler et al. noted the 
frequency of pseudoephedrine use among pregnant women to increase from 
pre-pregnancy to the second trimester.111 
Despite the frequent use of decongestants during pregnancy, few studies 
have evaluated the safety of decongestants during pregnancy and its effect on 
fetal growth. In a Swedish population based health study, Kallen & Olausson 
examined pregnancy outcomes among women who reported oral decongestant 
use during pregnancy.110 During the study period (1995 – 2002), 2,474 women 
reported use of oral decongestant during early pregnancy, and 1,771 women 
used prescription decongestants later in pregnancy. Women who reported use 
of decongestants during the first trimester had increased risk of SGA births (OR 
1.07 [95% CI 1.07, 1.42]), while use of decongestants during the second and 
third trimester was associated with a reduced risk of SGA (OR 0.71 [95% CI 
0.47, 1.08]). The discordant results observed may be due to multiple testing or 
the indication of use, probably pregnancy rhinitis. Kallen & Olausson also 
studied concomitant drug use among those exposed to oral decongestants 
during pregnancy.110 The majority of women exposed to oral decongestants also 
reported use of antihistamines and asthma medication during pregnancy which 
indicated the presence of an allergic rhinitis. Approximately 30% of women using 
oral decongestants during early pregnancy also used antibiotics or cough 
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medications indicating the possibility of an upper respiratory infection. Although 
conflicting results were observed with oral decongestants use, findings may be 
confounded by other concomitant drug use and indication.    
Antidiabetic, biguanides 
Metformin, an oral hypoglycemic agent, classified as secondary or tertiary 
amines, is commonly used in the management of gestational diabetes mellitus 
(GDM). The overall incidence of GDM is reported as 3-6% but has steadily 
increased over time and varied widely between the racial groups. Insulin is 
generally considered as the standard management for gestational diabetes 
mellitus, when diet and exercise fail to achieve normal glucose levels.112 
However, less compliance has been achieved with insulin therapy among 
pregnant women. Oral hypoglycemic agents are used as an alternative 
treatment option among women with GDM. Furthermore, the convenience of oral 
medication, simple dosages, and low costs increased their use during 
pregnancy. There is limited evidence on the safety of oral hypoglycemic agents, 
specifically metformin therapy. 
Previous studies have compared pregnancy outcomes in women with 
GDM treated with metformin or insulin therapy.113-115 In a prospective cohort 
study, Moore et al. randomly assigned pregnant women with GDM receiving 
prenatal care at University of Mississippi Medical Center to receive metformin or 
insulin therapy.114 There was no statistically significant difference observed in 
birthweight of infants between the metformin and insulin group (p <0.806). 
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Rowan et al. noted similar findings in a randomized open trial comparing 
metformin with insulin therapy among 751 pregnant women with GDM.115 
Women were randomly assigned to open treatment with metformin (with 
supplemental insulin if required) or insulin. Of 326 women assigned to metformin 
therapy, 92.6% continued metformin use until delivery. The proportion of infants 
with birthweight below the 10 percentile differed slightly between the two groups 
(7.2% v. 9.7%), however no statistically significant difference was observed. 
Furthermore, Hughes & Rowan reported birthweight to be similar among infants 
born to women with GDM treated with metformin and those not exposed to 
metformin.113 
Findings from the above reviewed studies suggest that metformin therapy 
used for the management of GDM during pregnancy is not associated with 
increased risk of low birthweight or SGA infants. 
Cardiovascular medications  
Certain cardiovascular drug groups such as diuretics, beta blockers, 
calcium channel blockers, and antihypertensives classified as either secondary 
or tertiary amines or amides have presented conflicting results in relation to its 
association with SGA. 
Diuretics, thiazide 
Diuretics classified as secondary amines or amides are used for 
treatment of hypertension and cardiac diseases. The use of diuretics during 
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pregnancy has been associated with increased birthweight, possibly due to the 
diabetogenic side effects of these drugs.116, 117 Olesen et al. observed conflicting 
results between the effect of thiazide and loop diuretics on birthweight.118 Two 
retrospective cohort studies were conducted. Women who purchased 
prescription diuretics during pregnancy were identified from the Northern Jutland 
Prescription Database, Denmark, and the Medicines Monitoring Unit Database, 
Scotland. Danish women who purchased prescription loop diuretics during 
pregnancy had infants with higher birthweight, mean difference of 105 grams 
[95% CI 2.6, 206.9] compared to those who did not use diuretics. Those who 
purchased thiazide diuretics during pregnancy were at higher risk of low 
birthweight infants (OR 2.6 [95% CI 1.4, 5.0]). The risk for low birthweight was 
also elevated among Scottish women exposed to thiazide diuretics during 
pregnancy (OR 2.4; 95% CI 0.8, 7.8). However, higher prevalence of diabetes 
(10.3%) among Danish women who purchased loop diuretics might explain the 
discordant results observed between thiazide and loop diuretics. Furthermore, 
the prevalence of hypertension was higher (15.8%) among women who 
purchased thiazide diuretics. Thus, the increased risk observed for low 
birthweight may be linked to indication for prescription rather than the treatment 
itself.  
Beta blockers  
Beta blockers, classified as secondary or tertiary amines or amides 
according to nitrosatability, are widely used in the treatment of chronic 
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hypertension, migraine, heart failure, tremors, and other conditions. Previous 
studies have reported positive associations between β blocker treatment during 
pregnancy and SGA.  
In a population based study, Petersen et al. investigated the associations 
between β blocker exposure during pregnancy and risk of being born SGA in a 
Danish birth cohort, comprising 974,805 births between 1995 and 2008.119 
Redeeming prescriptions of β blockers during pregnancy was found to be 
significantly associated with increased risk of SGA birth (OR 1.97 [95% CI 1.75, 
2.23]). Specifically, labetalol, a β blocker considered to be safe during 
pregnancy was significantly associated with SGA (OR 2.02 [95% CI 1.72, 2.37]). 
Exposure to other β blockers (metoprolol, atenolol, propranolol, pindolol, and 
sotalol) also increased the risk of delivering a SGA infant (OR 2.01 [95% CI 
1.66, 2.43]). Using a population health dataset in Taiwan, Ho et al. evaluated the 
effect of antiglaucoma medications during pregnancy on risk of having low 
birthweight infants.120 Mothers prescribed topical β blockers for glaucoma during 
pregnancy had an elevated risk of having a low birthweight infant (OR 1.48 [95% 
CI 0.86, 2.56]) compared to those not taking these drugs. 
Several studies examined the effect of timing of atenolol (β blocker) 
exposure on fetal growth.121-123 Atenolol is a selective β1 blocker primarily used 
in the treatment of hypertension and angina or chest pain. Using data from the 
antenatal hypertensive pregnancy database of two district hospitals in England, 
Bayliss et al. evaluated the effect of atenolol exposure during early pregnancy 
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on birthweight. Infants born to women taking atenolol during the first trimester 
had significantly lower birthweight compared to those not taking any medication 
(p <0.01).121 Additionally, the risk for having SGA infants was higher among 
those exposed to atenolol < 15 weeks of gestation (OR 2.81 [95% 1.27, 6.24]). 
The birthweight of infants was also significantly lower among women taking 
atenolol, labetalol, or methyldopa drugs during the second trimester of 
pregnancy. Similar findings were noted by Lip et al. who found mean birthweight 
to be significantly lower among women taking atenolol during pregnancy 
compared to controls (p <0.001).122  
Lydakis et al. investigated the effect of duration of atenolol monotherapy 
in a retrospective cohort study of 312 pregnancies in 223 women attending an 
Antenatal Hypertension Clinic.123 Atenolol was given in 78 (25%) pregnancies 
and 91 pregnancies (29.2%) received no antihypertensive drugs. Women who 
received atenolol in early pregnancy (<20 weeks) had significantly lighter and 
smaller babies, when compared to those exposed to atenolol later during 
pregnancy (>30 weeks). There was a significantly higher proportion of SGA 
babies (70%) in the group with early onset of treatment (<20 weeks).  
  With increasing use of β blockers during pregnancy, specifically atenolol 
and other β blockers (labetalol, propranalol, metoprolol) prescribed for 
hypertension and cardiac disease management, the safety of these drugs during 
pregnancy need to be examined. Although the aforementioned studies found 
positive associations between various β blockers and SGA, especially with 
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exposure during early pregnancy, findings need to be corroborated by future 
studies.    
Gastrointestinal H2 blocker 
Pregnancy is commonly complicated by gastroesophageal reflux disease 
with this condition affecting 30% to 50% of pregnant women.124 H2 receptor 
antagonists such as ranitidine, famotidine, and cimetidine inhibit gastric 
secretion and generally used for the treatment of peptic ulcer and acid reflux 
disease. They are classified as secondary or tertiary amines according to 
nitrosatability. Although these drugs are known to cross the placenta by passive 
diffusion, animal toxicological studies have failed to show teratogenic effects. 
Published literature regarding the safety of intrauterine exposure to H2 blockers 
is limited, although most studies reported null associations with low birthweight 
or SGA. 
Using data from the European Network of Teratology Information 
Services, Garbis et al., in a prospective cohort study, evaluated pregnancy 
outcomes in 553 pregnancies exposed to H2 blockers during pregnancy.
125 The 
majority of women (n = 501) reported use of H2 blockers during the first 
trimester, while 51 women reported usage during the second or third trimester. 
Mean birthweight of infants born at term was not significantly different between 
the exposed and control group (p <0.850). In a large hospital cohort, Matok et al. 
investigated the safety of H2 blockers during pregnancy among members of 
Clalit Health Services in Israel from 1998 to 2007.126 Exposure to H2 blockers 
     
 
 
29 
 
was evaluated by each trimester, and 1,148 women were dispensed these drugs 
during the first trimester. Use of H2 blockers during first, second, and third 
trimester was not associated with increased risk of low birthweight infant. 
Similar findings were noted by Magee et al. in a prospective cohort study 
conducted at the Motherrisk Program, Canada.127 Women who contacted about 
gestational exposure to H2 blockers were identified as exposed and those who 
enquired about non-teratogenic drugs as controls. H2 blockers were most often 
used during the first trimester (88%) and 13% reported use throughout 
pregnancy. No difference was observed between the two groups for incidence of 
SGA (p 0.19). Furthermore, Ruigomez et al. reported null association between 
first trimester exposure to H2 blockers (cimetidine, ranitidine, and omeprazole) 
and SGA in two cohorts identified from the United Kingdom general practice 
research database and the Italian Friuli-Venezia Giulia health database.128 
Previous studies found no increased risk for SGA with exposure to H2 blockers 
during pregnancy. H2 blockers may be considered safe to be used during 
pregnancy, however a possible teratogenic risk cannot be ruled out.  
Migraine 
Migraine headaches affect 16% to 21% of the general population.129 It is 
more frequently seen in fertile women and attacks can occur in relation to 
menstruation or ovulation. In pregnancy, the frequency of migraine tends to 
decrease throughout gestation, especially during the second and third 
trimesters.130 Triptans, classified as secondary or tertiary amines or amides, are 
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derivatives of tryptamines, and act as serotonin agonists by binding to its various 
receptors. Triptans are generally considered safe during pregnancy except 
drugs such as ergotamine and dihydroergotamine are contradicted during 
pregnancy. Studies concerning the possible adverse effects of triptans, most 
notably sumatriptans, first class of drugs of triptans have yielded conflicting 
results.   
Using data from the Swedish Medical Register, Kallen & Lygner 
evaluated delivery outcomes among women using drugs for migraine during 
pregnancy.131 Approximately 912 women reported use of drugs indicated for 
migraine during pregnancy, and majority of them reported use of sumatriptan (n 
= 658). Risk for low birthweight was slightly elevated among mothers reporting 
use of drugs for migraine (OR 1.04 [95% CI 0.67, 1.61]), and the risk was most 
notable with sumatriptan exposure (OR 1.18 [95% CI 0.70, 1.97]) although the 
95% CI did not reach statistical significance. Olesen et al. noted similar 
observations between sumatriptan exposure during pregnancy and low 
birthweight.132 Linking data from the Pharmaco-Epidemiological Prescription 
Database of North Jutland and the Danish Medical Registry, 34 pregnant women 
exposed to sumatriptan were identified and compared to 89 control individuals 
with migraine not using the drug and 15,955 healthy women. The odds of having 
an infant with low birthweight was increased (OR 2.3 [95% CI 0.3, 17.6]) among 
migraine patients receiving sumatriptan treatment compared to healthy controls. 
However, lower risk was noted when migraine patients were used as controls 
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(OR 0.9 [95% CI 0.1, 11.8]). Findings observed may be confounded by the drug 
indication and severity of the disease.  
In contrast, Kallen et al. reported negative associations between first 
trimester exposure to drug prescribed for migraine and SGA.133 In a large cohort 
study of 1,211,670 women, use of triptans or ergots during the first trimester was 
reported by 3,286 women, while use after first trimester occurred in 1,394 
women. Women exposed to migraine drugs during the first trimester had lower 
risk for delivering an SGA infant (OR 0.95 [95% CI 0.75, 1.20]). An increased 
risk for SGA was also observed with exposure during the second and/or third 
trimester (OR 1.20 [95% CI 0.86, 1.68]) although the confidence intervals were 
not significant. However, the positive associations observed may be due to other 
drug groups notably ergots and also confounded by the maternal disease.   
Tertiary amines 
Antiepileptics 
Epilepsy is a common neurologic disorder in pregnant women with a 
prevalence of 0.3-0.7%.134 Epilepsy is considered a risk factor for several 
pregnancy outcomes like preeclampsia, placental bleeding, and preterm birth. 
However, it is unclear whether the complications are due to epilepsy or the use 
of antiepileptic drugs.  
Studies have reported conflicting results with regard to antiepileptic drug 
use and SGA. In a retrospective cohort study, Hvas et al. investigated birth 
outcomes among pregnant women who received prenatal care at Aarhus 
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University Hospital, Denmark from 1989 to 1997.135 The mean birthweight was 
observed to be reduced by 208 g [95% CI 116, 300] among women with 
epilepsy receiving anticonvulsant treatment compared to women without 
epilepsy. The reduction was most pronounced among children of women 
receiving carbamazepine and oxcarbazepine monotherapy. The risk for SGA 
was increased (OR 2.3 [95% CI 1.3, 4.0]) among those who received 
antiepileptic therapy compared to controls. Fonager et al. also reported mean 
birthweight to be 46 g lower [95% CI -110, 18] among women exposed to 
anticonvulsants around conception and during pregnancy compared to those not 
exposed.136 The risk for low birthweight was higher among those exposed to 
anticonvulsants compared to controls (OR 1.5 [95% CI 0.6, 3.7]). In addition, a 
meta-analysis study noted birthweight to be reduced in children of women who 
received antiepileptic treatment during pregnancy.137     
Using data from the Medical Birth Registry of Norway, Veiby et al. 
investigated delivery outcomes in a large cohort of 2,861 women with epilepsy 
and compared to 369,267 women without epilepsy from 1999-2005.138 The 
majority of epileptic women (66%, n= 1900) did not report use of antiepileptic 
drugs while 961 women reported use during pregnancy. Risk of SGA was 
significantly increased among women exposed to antiepileptic drugs compared 
to those not exposed (OR 2.0 [95% CI 1.4, 2.7]). Exposure to carbamazepine 
during pregnancy also elevated the risk for delivering an SGA offspring (OR 2.7 
[95% CI 1.7, 4.0]). Similar findings were noted by Viinikainen et al. in a 
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retrospective cohort study of 24,778 infants born from 1989-2000 at Kuopio 
University Hospital, Finland.139 Exposure to monotherapy with carbamazepine 
revealed a trend towards SGA infants, but the difference was not statistically 
significant.  
Conversely, other studies reported no difference in mean birthweight and 
no increased risk was observed for SGA among epileptic women who received 
antiepileptic drugs compared to those without epilepsy.140, 141 Katz et al. 
retrospectively analyzed 100 consecutive pregnancies from 1990-2000 among 
women with epilepsy.140 The mean birthweight of infants was observed to be 
similar among women exposed and not exposed to antiepileptic drugs during 
pregnancy. Using data from two national population databases, Lin et al. 
evaluated the risk of adverse pregnancy outcomes among epileptic women who 
received antiepileptic treatment.141 No significant difference in the risk of SGA 
infant was observed between epileptic women who were given antiepileptic drug 
use and those without epilepsy (OR 1.45 [95% CI 0.98, 2.10]).  
Overall, antiepileptic drug use during pregnancy increased the risk for 
reduced birthweight and SGA infants.135-139 However, other studies did not find 
any significant difference.140, 141 Findings may be confounded by severity of 
epilepsy and smoking status. Antiepileptic drugs may reduce the availability of 
folate and low serum folates have been associated with low birthweight.135 
Further evaluation of the effect of antiepileptic drug treatment on birthweight is 
warranted.   
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Opioids 
Methadone, a synthetic opioid is generally used for the management of 
maternal opioid dependency during pregnancy. Several studies have shown 
intrauterine growth restriction to be a common feature in pregnancies of opioid 
dependent mothers. Wouldes & Woodward examined the association between 
maternal methadone dose during pregnancy and a range of infant outcomes.142 
Two groups of infants, methadone exposed (n = 32) and non-exposed (n =42) 
born at the National Women’s Hospital, New Zealand were followed 
longitudinally from the third trimester of pregnancy to 6-7 months of age. 
Significant linear associations were found between maternal methadone 
exposure and birthweight (p <0.01), especially with higher dose of methadone. 
Infants born to women exposed to high dose of methadone treatment (>58 
mg/day) were more likely to have a SGA infant (p <0.05). In addition, maternal 
methadone remained a significant predictor of birthweight after adjusting for 
maternal and infant confounding factors. Liu et al. also reported methadone 
treatment in opioid dependent mothers to be associated with birthweight. In a 
retrospective cohort study, neonatal parameters from pregnancies of opioid 
dependent mothers maintained on methadone treatment were compared to non-
smoking opioid dependent mothers.143 Infants born to opioid dependent mothers 
given methadone treatment had significantly lower birthweight compared to 
controls (p <0.001). Additionally, the number of infants with birthweight below 
the 10 percentile was significantly higher in the exposed group compared to 
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controls (27% v. 9%). Cleary et al. confirmed findings from the previous 
studies.144 A retrospective cohort study of 61,030 singleton births was conducted 
at a large maternity hospital from 2000-2007. Approximately 618 (1%) women 
received methadone at delivery. Methadone exposure was associated with an 
increased risk of being born small for gestational age (OR 2.21 [95% CI 1.85, 
2.64]) with adjustment for maternal risk factors.  
Methadone treatment among opioid dependent mothers significantly 
increased the risk for low birthweight or SGA. However, the beneficial effects of 
minimizing illicit drug use and maintaining the pregnancy may outweigh the risks 
of neonatal outcomes associated with methadone treatment.  
 Antihypertensives 
Hypertension during pregnancy increases the risk of perinatal mortality 
and morbidity. Antihypertensive drugs may help reduce maternal morbidity from 
the complications of high blood pressure and prolong the pregnancy. However, 
studies have hypothesized that reduction in mean arterial blood pressure could 
decrease placental perfusion and diminish fetal growth. The following drug 
groups are used for control of hypertension: beta blockers, alpha adrenergic 
blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, 
angiotensin receptor 2 antagonists, central acting adrenergic, and diuretics. 
Associations observed with beta blockers, specifically atenolol were discussed 
earlier.  
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  Two studies examined the effect of overall antihypertensive drug use on 
birth outcomes.145, 146 Using data from Swedish Medical Birth Register, 
Lennestal et al. investigated the association between antihypertensive drug use 
and delivery outcomes.145 Approximately 1,418 women reported 
antihypertensive drug use during early pregnancy and majority of them (84%) 
used drug from one category. While 14% reported use of drugs from two 
categories and 1.3% used drugs from three or four different groups of 
antihypertensives. Overall, antihypertensive drug use was associated with a 
higher risk for SGA births (OR 4.23 [95% CI 3.55, 5.03]). The risk for having low 
birthweight infants was also elevated (OR 4.72 [95% CI 4.11, 5.41]). Nakhai-
Pour et al. noted increased risk of SGA in relation to use of antihypertensives 
later during pregnancy.146 Using data from the Quebec Pregnancy Registry, drug 
exposure was compared between 7,445 babies born SGA and 48,889 control 
babies. Adjusting for potential confounders, antihypertensive drug use during the 
second or third trimester was associated with a 53% increased risk for SGA 
compared to those not exposed (OR 1.53 [95% CI 1.17, 1.99]). Risk of SGA 
births was also elevated with selective beta blockers, non-selective beta 
blockers, and central adrenergic drug use during the second or third trimester of 
pregnancy. No significant association was observed between antihypertensive 
use during the first trimester and SGA (OR 1.07 [95% CI 0.69, 1.97]).  
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Although the aforementioned studies supported an association between 
overall antihypertensive drug use and SGA, the effect of dosage and duration of 
antihypertensive drug use needs to be determined.     
Calcium channel blocker 
Calcium channel blockers are classified as tertiary amines or amides 
based on the nitrosatable groups present in their molecular structure. Magee et 
al. prospectively collected information from six teratogen databases and followed 
78 women who were exposed to calcium channel blockers during the first 
trimester.147 A trend towards decreased birthweight was observed among those 
exposed compared to controls (3018 g v. 3352 g, p = 0.08). The proportion of 
small for gestational age infants was higher in the treatment group compared to 
controls (6.6% v. 1.5%), although the difference was not statistically significant 
(p = 0.13). 
Antiinfective, macrolide 
Macrolides classified as tertiary amines or amides, act by inhibiting 
bacterial protein biosynthesis. They are primarily used in the treatment of 
respiratory infection, bacterial skin infection, and chlamydia infection. In 
pregnancy, they are used for the treatment of endocervical chlamydial infections 
produced by Mycoplasma pneumonia and by group B streptococcus and among 
women who are allergic to B lactam antibiotics.148 The most commonly used 
macrolides include erythromycin, azithromycin, clarithromycin, roxithromycin, 
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and spiramycin. Only a handful of studies have studied the relation between 
exposure to macrolides during pregnancy and low birthweight or SGA. 
Kallen et al. investigated delivery outcomes among women exposed to 
erythromycin during early pregnancy based on data obtained from the Swedish 
Medical Register.149 Approximately 1,844 women reported exposure to 
erythromycin before, and 1,831 after the first antenatal visit. No statistically 
significant risk was observed for SGA among infants born to women exposed to 
erythromycin during early pregnancy (OR 0.92 [95% CI 0.65, 1.30]). In a large 
population cohort of 180,120 pregnant women, Romoren et al. compared birth 
outcomes between women who took erythromycin, penicillin V, or amoxicillin in 
the first trimester of pregnancy and those who were not exposed to any systemic 
antibiotics during the same period.150 Among 5,729 women who reported 
erythromycin use anytime during pregnancy, the risk for low birthweight was 
lower among those exposed compared to controls (OR 0.85 [95% CI 0.68, 
1.05]). Similar findings were noted by Andrews et al. in a randomized control trial 
evaluating the efficacy of treatment with erythromycin plus metronidazole.151 
Women assigned to the treatment group had lower risk of having low birthweight 
infants compared to those in the placebo group (OR 0.88 [95% CI 0.60, 1.29]). 
In addition, Chun et al. reported no difference in birthweight among pregnant 
women exposed to roxithromycin during early pregnancy compared to 
controls.148  
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Antiemetics 
More than half of pregnant women suffer from nausea and vomiting 
during pregnancy, primarily during the first trimester.152 The condition occurs at 
an increased rate in young women, in multiparous women, and twin 
pregnancies. Antiemetics, classified as tertiary amine or amide are prescribed to 
control the severity of nausea and vomiting until it subsides. Oral antihistamines 
(diphenhydramine, promethazine, meclizine, cyclizine), dopamine modulators 
(metoclopramide), and serotonin 5HT3 receptor antagonists (ondansetron) are 
antiemetics available for the treatment of nausea and vomiting during 
pregnancy.  
Asker et al. examined neonatal outcomes among 676,198 births 
registered with the Swedish Medical Birth Registry from July 1, 1995 to 
December 31, 2002.152 During this period, 29,804 (4.5%) pregnant women 
reported use of antiemetic drugs, 86% of whom reported use before the first 
antenatal visit. Meclozine was the most frequently taken antiemetic drug (68%) 
and promethazine was the second most commonly reported drug. A lower risk 
was observed for low birthweight and SGA infants with any antiemetic drug use 
during pregnancy (OR 0.89 [95% CI 0.83, 0.96] and OR 0.90 [95% CI 0.82, 
0.99]). However, a slightly elevated risk was observed for low birthweight with 
promethazine use during pregnancy (OR 1.21 [95% CI 1.06, 1.39]). The better 
infant outcome observed with any antiemetic use may not be due to a direct 
drug effect but probably a well-functioning placenta. Placental hormones are 
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proposed to play a role in the etiology of nausea and vomiting and better 
placenta function increasing the probability of a good pregnancy outcome.     
Diav-Citrin et al. compared pregnancy outcomes among women exposed 
to loratadine, and other oral antihistamines during pregnancy.153 Women who 
contacted the Israeli Teratogen Information Service between 1995 and 2001 
with regard to information about loratadine, other oral antihistamines, and non 
teratogenic drugs were prospectively identified and followed. Approximately 210 
(77.9%) pregnancies were exposed to loratadine and 267 (64.6%) to oral 
antihistamines during the first trimester, and compared to 929 non teratogenic 
controls. The mean birthweight did not significantly differ between the three 
groups (p = 0.302).  
In the United States, metoclopramide is only used in severe cases of 
nausea and vomiting. While in some European countries and Israel 
metoclopramide is a commonly used antiemetic. In a retrospective cohort study, 
Matok et al. investigated the safety of metoclopramide use during the first 
trimester of pregnancy among 81,703 infants born to women registered with the 
Clalit Health Services, Israel.154 Exposure to metoclopramide was not associated 
with increased risk of low birthweight (OR 1.01 [95% CI 0.89, 1.14]) compared to 
those not exposed to the drug.  
The combination of doxylamine succinate (antihistamine) and pyridoxine 
(vitamin B6) was the most widely used preparation for treatment of nausea and 
vomiting in the 1960-1970s. However, due to litigations and despite evidence of 
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fetal safety, the drug was voluntarily removed from the market of United States 
in 1983. The drug continued to be used in Canada for treatment of the condition. 
Atanackovic et al. examined pregnancy outcomes in 225 women who took the 
drug combination at the recommended (n = 123) or higher than recommended 
(n = 102) doses.155 Birthweight was not associated with the drug dose and 
duration of treatment.  
Nicotine replacement therapy     
Maternal smoking during pregnancy is a known risk factor for fetal growth 
restriction and other adverse pregnancy outcomes. Nicotine replacement 
therapy (NRT), classified as tertiary amines, has been shown to be an effective 
smoking cessation therapy among non-pregnant smokers. However, its efficacy 
and safety during pregnancy and effect on fetal growth is not known.  
Lassen et al. examined the relation between NRT use during pregnancy 
and birthweight in offspring of 72,761 women enrolled in the Danish National 
Birth Cohort.156 No significant association was observed between the duration of 
NRT use and birthweight (β = 0.25 g [95% CI -2.31, 2.81], average change in 
birthweight with an increase of NRT use by 1 week). However, simultaneous use 
of more than one NRT product was associated with reduced birthweight (β =       
-10.73 g [95% CI -26.51, 5.05]), although the association was not significant. In 
contrast, using data from the 2004 Phase V Pregnancy Risk Assessment 
Monitoring System, Gaither et al. reported twice the risk of low birthweight (OR 
1.95 [95% CI 1.10, 3.46]) among women who were recommended NRT 
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compared to non-smokers.157 Although, the women prescribed NRT reported 
higher frequency of smoking and used NRT inconsistently. 
A systematic review of two studies that evaluated pregnancy and fetal 
outcomes in women using NRT during pregnancy found no significant difference 
in mean birthweight of infants between the NRT and placebo groups.158 
However, only one study that evaluated effects of nicotine gum reported higher 
mean birthweight and a decreased risk for low birthweight (p <0.001) among 
women in the NRT group.159 Furthermore, another meta-analysis study noted 
the pooled estimates for mean birthweight to be significantly higher among 
infants born to women in the NRT group.160 A mean difference of 158.2 g [95% 
CI -53.13, 369.52] with high level of heterogeneity (I2 = 76%) was observed. 
Findings from the previous studies suggested that NRT use during 
pregnancy may be not associated with low birthweight. Future studies should 
examine the dose, timing and duration of NRT use on infant weight. Since 
smoking is harmful to the fetus, NRT may be an effective alternative for smoking 
cessation.   
Amides 
Antiinfective, beta lactam 
Beta lactam antibiotics, classified as amides, represent the oldest class of 
antibiotics used for the treatment of infections. They are bactericidal, and act 
through the inhibition of bacterial cell wall synthesis. Amoxicillin, a β lactam 
antibiotic is used for the treatment of various infections such as tonsillitis, 
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pneumonia, otitis sinusitis, and urinary tract infections.161 It was among the 20 
most commonly reported prescription medication during the first trimester of 
pregnancy among the NBDPS participants from 1997-2003.162 While several 
studies have evaluated the effect of β lactam antibiotics on pregnancy 
outcomes, limited data is available on the safety of amoxicillin use during 
pregnancy.  
Using data from Danish population based registries, Jespen et al. 
examined the association between amoxicillin exposure during pregnancy and 
birth outcomes.163 A cohort of 401 primiparous women who redeemed a 
prescription for amoxicillin during pregnancy was compared to 10,237 women 
who did not redeem any prescription from three months before until the end of 
pregnancy. The mean birthweight of infants born to amoxicillin exposed mothers 
was 57 g [95% CI 9, 105] higher than compared to controls. The odds of having 
a low birthweight infant was also lower among mother exposed to amoxicillin 
compared to controls (OR 0.63 [95% CI 0.26, 1.53]). Two other studies that used 
the same Danish medical and prescription databases reported null associations 
between pivampicillin or pivmecillinam exposure, drugs closely related to 
amoxicillin, and low birthweight.164, 165 Larsen et al. reported the mean 
birthweight to be 35 g higher among women to pivampicillin compared to 
controls.164 No increased risk was observed for low birthweight (OR 0.93 [95% 
CI 0.55, 1.57]) with this drug exposure. Skriver et al. also noted no significant 
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risk for low birthweight among 2,031 pregnant women exposed to pivmecillinam 
during pregnancy (OR 0.79 [95% CI 0.52, 1.20]).165    
Because of the increasing resistance of bacteria to β lactam antibiotics, 
amoxicillin is prescribed in combination with a β lactamase inhibitor such as 
clavulanic acid.  Berkovitch et al. evaluated the safety of combination of 
amoxicillin and clavulanic acid in 191 women recruited from the teratogen 
information services in Israel.161 Pregnancy outcomes were compared between 
women exposed to the amoxicillin/clavulanic acid combination and amoxicillin 
only. No significant difference in birthweight was observed between the two 
groups. 
Antiinfective, sulfonamide 
Sulfonamides are used in the treatment of variety of infections, and are 
commonly used for the treatment of acute and uncomplicated urinary tract 
infections in women. Sulfonamides cross the placental barrier, and achieve 
blood levels in fetus as high as 90% of those in the maternal circulation.166 
Studies have reported inconsistent results between maternal exposure to 
sulfonamides and SGA or low birthweight.     
In a retrospective cohort study, Yang et al. evaluated birth outcomes in a 
50% random sample of women who gave birth in the Canadian province of 
Saskatchewan from 1997-2000.167 Approximately 447 women reported exposure 
to trimethoprim/ sulfamethoxazole during pregnancy. A significantly increased 
risk (OR 1.67, 95% CI 1.14, 2.46) for low birthweight was observed among the 
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exposed compared to controls. Using the Quebec Pregnancy Registry, Santos 
et al. examined the association between antiinfective drug exposure during the 
second and third trimester of pregnancy and risk of SGA births.168 No increased 
risk was observed for SGA with exposure to all combined antiinfective drugs 
(OR 0.97 [95% CI 0.91, 1.04]). However, the use of sulfamethoxazole during the 
second or third trimester of pregnancy was significantly associated with SGA 
(OR 1.61 [95% CI 1.16, 2.23]). In contrast, Ratanjamit et al. reported a reduced 
risk for low birthweight (OR 0.69 [95% CI 0.49, 0.98]) among women prescribed 
sulfamethizole 30 days before conception to the date of delivery compared to 
those not exposed during the same period.166  
Benzodiazepine  
Benzodiazepines, classified as amide or tertiary amines, are class of 
drugs primarily used for treating anxiety, but they are also effective in treating 
seizures and insomnia. These drugs cross the placenta and have the potential to 
accumulate in the fetus. Data on the effect of benzodiazepines with neonatal 
outcomes is sparse.      
In a retrospective cohort study, birth outcomes were examined among 
1,979 infants whose mothers reported use of benzodiazepines during early 
pregnancy, and 390 exposed later during pregnancy.169 An increased risk for 
SGA was observed among infants exposed, both in early and late pregnancy 
(OR 1.12 [95%CI 0.87, 1.44] and OR 1.39 [95%CI 0.80, 2.40], respectively), 
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although the ORs were not statistically significant. The weak associations 
observed in this study need to be confirmed by future studies. 
Dietary intake and SGA 
 Dietary nitrates and nitrites contribute a significant portion of daily nitrite 
exposure compared to other known sources of exposure (drug use and water 
consumption). Vegetables are main source of nitrates and cured meat, baked 
goods, and cereals are common sources of dietary nitrite.170  Previous 
epidemiologic studies have examined the role of maternal dietary patterns;8-10 
nutrient intake;14-16 and supplementation on fetal growth;14, 15, 18 but none studied 
the effect of dietary nitrate/nitrites on fetal weight. In a cohort of 1,714 women, 
Thompson et al. evaluated the effect of different maternal dietary patterns during 
pregnancy on the risk of delivering an SGA infant.9 Mothers who adopted a 
traditional diet during early pregnancy, that included mostly fruits and 
vegetables, were less likely to have an SGA infant (OR 0.86 [95% CI 0.75, 
0.99]). Knudsen et al. also explored the association between maternal dietary 
patterns and fetal growth among 44,612 women in Denmark.8 Two major dietary 
patterns, western and health conscious, were identified with the first pattern 
characterized by red and processed meat, and high fat dairy intake, while the 
second pattern included consumption of vegetables, fruits, poultry, and fish. 
Women with health conscious diet had lower risk of SGA (OR 0.74 [95% CI 
0.64, 0.86]) compared to those in the western diet group. Furthermore, using 
data from the United States Hispanic Health and Nutrition Examination Survey, 
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Wolff et al. evaluated dietary patterns among Mexican American women during 
pregnancy.10 Nutrient dense (fruits, vegetable, low fat dairy) and protein rich (low 
fat meat, processed meat, dairy desserts) dietary patterns were significantly 
associated with increased birthweight in offspring. 
Individual macronutrients and total energy intake during pregnancy may 
also influence fetal growth. Moore et al. assessed the relation between maternal 
dietary composition during pregnancy and birthweight among 557 women in 
Adelaide, South Australia.16 In early pregnancy, the proportion of energy derived 
from protein (17%) was positively associated with birthweight and placental 
weight. Each percent increase in protein was associated with a 16 g increase in 
birthweight [95%CI 2.8, 29.2] and 4.2g increase in placental weight [95% CI -0.4, 
8.5]. Godfrey et al. reported similar findings among 538 infants delivered at term 
at a maternity hospital in Southampton, England.14 Lower maternal intake of 
protein was associated with decreased birth parameters. Placental weight and 
birthweight decreased by 1.4g [95% CI 0.4, 2.4] and 3.1g [95% CI 0.3, 6.0], 
respectively, for each gram decrease in intake of dairy and meat protein during 
late pregnancy. In addition, mothers who reported high carbohydrate intake 
during early pregnancy had infants with lower placental and birthweight. 
Conversely, other studies noted null associations between maternal nutrient 
intake and birth size measures.15, 171 
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Vitamin C supplementation and SGA   
Vitamin C is known to inhibit nitrosation.  Mirvish et al. first demonstrated 
that ascorbic acid inhibits N-nitroso compound formation by rapid reduction of 
nitrite to nitrous oxide, followed by the production of dehydroascorbic acid.172  In 
a clinical trial conducted with human volunteers, increased doses of ascorbic 
acid (1.76 -1000mg) with combined exposures to nitrate and proline (a 
nitrosatable precursor) significantly reduced the excretion of N-nitroso 
compounds by 44 percent compared to exposures to nitrate and proline without 
concomitant administration of vitamin C.173 In our previous studies, we examined 
the effects of vitamin C supplementation on risk of selected birth defects among 
women exposed to nitrosatable drugs during pregnancy.174, 175  Relative to 
women with no vitamin C supplementation, daily use of vitamin C supplement in 
conjunction with tertiary amine exposure during the periconceptional period was 
associated with lower odds of anencephalic births.174 Lower ORs were observed 
for selected birth defects with daily vitamin C supplementation and nitrosatable 
drug use during the first trimester including transverse limb deficiency with 
secondary amines, cleft lip without cleft palate with tertiary amines, and several 
congenital heart defects with tertiary amines and amides.175  
Very few studies have examined the association between maternal 
vitamin supplementation during pregnancy and risk of SGA birth.15, 18, 176, 177 In a 
prospective cohort study, Alwan et al. noted no significant associations between 
use of multivitamins during pregnancy and SGA.176 The ORs marginally 
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decreased from 1.3 ([95% CI 0.8, 1.9]) to 0.9 ([95% CI 0.5, 1.7]) with vitamin 
supplement use from the first to third trimester of pregnancy. Another study 
indicated that maternal use of vitamin supplement during the last month of 
pregnancy was associated with a slightly lower risk of SGA birth (OR 0.76 [95% 
CI 0.55, 1.05]).18 Mathews et al. found total vitamin C (estimated from food and 
supplement) intake during early pregnancy to be positively associated with 
birthweight, with a mean difference of 100g noted between the lowest (< 55 
mg/day) and highest thirds (≥ 98 mg/day) of intake.15 Additionally, a systematic 
review study reported no significant difference in risk of SGA birth between the 
treatment group that received a combination of vitamin C and E compared to the 
placebo group (20.6% v. 20%, RR 0.94 [95% CI 0.74, 1.19]).177 However, none 
of the studies assessed the effect of vitamin C supplement use on risk of SGA in 
relation to nitrosatable drugs use during pregnancy. 
Methods 
 To examine the association between maternal dietary nitrate, nitrites, and 
nitrosatable drugs and risk of SGA births, data were used from the National Birth 
Defects Prevention Study (NBDPS) control mothers who delivered infants 
without major congenital malformations with estimated dates of delivery (EDD) 
from 1997 to 2005. The NBDPS, a large US population-based case control study 
of birth defects, has conducted interviews since 1997 with mothers of infants 
with congenital malformations and control mothers at several funded Centers 
across the nation. These ten Centers for Birth Defects Research and Prevention 
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(CBDRP) include Arkansas, California, Georgia, Iowa, Massachusetts, New 
York, Texas, New Jersey, North Carolina and Utah.178 
Study population  
 The present study focused only on NBDPS control mothers with EDD from 
1997 to 2005. The NBDPS controls included mothers who had live births without 
major birth defects and were residents of one of the geographic areas covered 
by the CBDRP population registries at the time of delivery. They were randomly 
sampled from birth certificates (Arkansas, for EDDs after 2000; Georgia, for 
EDDs after 2000; Iowa; Massachusetts; New Jersey; North Carolina; and Utah) 
or hospital records (Arkansas, for EDDs prior to 2001; California; Georgia, for 
EDDs prior to 2001; New York; and Texas).179 States that selected controls from 
hospitals utilized a systematic random sampling scheme so that infants selected 
were in proportion to the number of births at each hospital in the geographic 
area.178 Controls were excluded if they had a major birth defect, were not a 
resident of one of the geographic areas covered by CBDRP, were adopted or in 
foster care, had a deceased mother, or were stillborn. We included data only on 
mothers who delivered singleton births since multiple births have been identified 
as a major risk factor for SGA.  Previous studies have shown NBDPS control 
participants to be generally representative of their base populations.179 Since the 
study population includes infants without any major birth defects, it allows a 
clearer interpretation of the study results because SGA and low birthweight have 
been observed to be more common in infants with malformations.180, 181  
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Case definition  
SGA was defined as infants with birthweight less than 10th percentile for 
given gestational age, gender, and race/ethnicity. The 10th percentile cut off 
used for classification of SGA was based on the US singleton birthweight 
percentiles for gestational age by race, parity, and gender published by 
Overpeck et al.182 and Zhang & Bowes.183 Infants with gestational ages less than 
20 weeks or more than 44 weeks were excluded. Information on gestational age 
and birthweight at delivery were obtained from medical records or birth 
certificates of the participants. If not available, the following criteria were used for 
calculation of gestational age: 1) estimated due date reported by mother in the 
interview; 2) ultrasound <14 weeks; 3) last menstrual period; 4) ultrasound >14 
weeks; and/or 5) standard neonatal exam.  
Control definition 
Controls were defined as infants with birthweight at or greater than 10th 
percentile for given gestational age, gender, and race/ethnicity. Birthweight 
percentiles published by Zhang & Bowes and Overpeck et al. were utilized for 
classification of controls.182, 183 
Data Collection  
The NBDPS utilized a standard procedure for contacting case and control 
mothers and enrolling them in the study. The mothers were mailed a packet that 
included an introductory letter describing the study, frequently asked questions, 
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a ‘Right of Research Subjects’ fact sheet, a $20 money order, a response list, 
and a calendar that covered the duration of her pregnancy. Approximately 10 
days after the packets were mailed, interviewers contacted the mothers to 
answer any questions, conduct the interview or schedule a more convenient 
time for the interview. The interview was completed in single or multiple sessions 
at the mother’s request. Interviews were targeted for completion within 6 months 
of EDD until 24 months post-delivery. Women were not interviewed until six 
weeks after the EDD or delivery to reduce recall bias between women with 
preterm and full term births.  
The data collection process was based on the instrument used for the 
Birth Defects Risk Factor Study, the California Birth Defects Monitoring Program, 
and the Iowa Birth Defect Registry. The interviews were conducted in English or 
Spanish by trained female interviewers using a standard questionnaire after oral 
informed consent was obtained. It took approximately 1-1½ hours to complete 
and covered topics regarding maternal health (diseases and illnesses, fever, 
injuries, medications); pregnancy issues (pregnancy history, prenatal care); 
diet/substance abuse (vitamins, food supplements, dietary assessment, caffeine 
consumption, tobacco, alcohol, street drugs); home/work (residential addresses, 
occupation); demographic characteristics; and water use.178 Most questions 
were structured with pre-coded response lists and detailed questions about 
exposure three months prior to conception through the end of pregnancy were 
asked. The pregnancy calendar allowed mothers to recall exposures by date, 
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month, or trimester of pregnancy. Data from the NBDPS with EDDs from 1997-
2005 had a total of 6807 (66.2%) control mothers who participated in the 
interview and the median length of time from EDD to interview was 7.7 months. 
Assessment of nitrosatable drug exposure (Specific aim 1,3) 
 As a part of the NBDPS, women were interviewed about prescription and 
non-prescription drugs taken from three months prior to conception to the end of 
pregnancy for specific illness and diseases (e.g., asthma, diabetes, hypertension 
etc.) and about specific products used (e.g., ampicillin, phenytoin, metoprolol). 
The frequency of use and corresponding dates of usage were also obtained. 
The Slone Epidemiology Center Drug Dictionary was used to link the reported 
drugs to their active ingredients.184 Detailed methods used to classify drugs with 
respect to nitrosatability, functional groups and indications were described in 
previous publications.25, 174 The methodology used for classification included: 1) 
active ingredients for all orally administered drugs, and orally inhaled 
medications were identified; 2) these active ingredients were cross referenced 
against previously compiled lists of nitrosatable medicinal compounds published 
by Brambilla & Martelli and McKean Cowdin et al.;89, 185 3) identified nitrosatable 
compounds were categorized into nitrosatable groups based on the presence of 
amine (primary, secondary, tertiary) and amide functional groups in their 
chemical structure; 4) primary amines were excluded as they do not form stable 
N-nitroso compounds; 5) a few drugs were categorized into multiple drug groups 
depending on the functional group present (e.g., atenolol is both a secondary 
     
 
 
54 
 
amine and amide) and finally 6) each nitrosatable drug component was 
classified by the drug’s primary indication (e.g., antihistamine, antiepileptic) and 
pharmacologic class (e.g., opioid, macrolide).  
 We assessed nitrosatable drug exposure during the first, second, and 
third trimester among NBDPS control mothers with EDDs from 1997-2005. The 
same method was utilized for classification of drugs based on nitrosatability. For 
each nitrosatable drug component, information on whether the drug was taken 
and frequency of use was used to estimate exposure during each trimester of 
pregnancy. The drug components were further categorized into their respective 
nitrosatable drug groups (secondary amines, tertiary amine, and amides) and 
drug indication groups.  
Dietary assessment of nitrate and nitrite intake (Specific aim 2,3) 
 A 58-item food frequency questionnaire (FFQ) adapted from the Short 
Willett Food Frequency Questionnaire was used to collect information on dietary 
intake of mothers during the year prior to conception. In addition, women were 
asked about cereal intake and alcohol consumption three months prior to 
conception through the end of pregnancy. Question regarding intake of avocado, 
salsa, refried beans, and tortillas food items were also added to the 
questionnaire to incorporate the diverse diet of the NBDPS population. Studies 
of validity and reproducibility of the original Willett FFQ indicate that the dietary 
questionnaire provides useful information about women’s nutrient intake over 
one year period compared to four one week diet records.186 Furthermore, the 
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assessment of dietary intake of nutrients using the Willett FFQ was also 
comparable to nutrient intakes estimated using 24 hour recalls.187 
 The NBDPS nutrient calculations were based on the USDA National 
Nutrient Database for Standard Reference 19. Daily intake of each food 
component was calculated based on the serving size or frequency of use. Food 
items or groups listed in the NBDPS FFQ were assigned codes that correspond 
with the USDA unique codes. Since the USDA nutrient database did not include 
estimates of nitrates and nitrites, values were estimated for food items or group 
in the NBDPS questionnaire by Griesenbeck and colleagues.188 Dietary nitrates 
and nitrites estimates were calculated using a multi-step procedure that included 
1) food database creation 2) value selection and 3) estimate generation. First, a 
food database was created to identify nitrate values for each food item or group 
listed in the NBDPS FFQ based on estimates from published literature either 
from 1980 to present or 1970-1979. Second, the values of nitrate estimates were 
ranked depending on the source of published studies either in United States and 
Canada or other countries with traditionally Western diet. Third, a summary 
estimate for each food item was calculated as the weighted mean of the 
published values. Then, for each food item, the nitrate and nitrite estimates were 
calculated in grams per serving size using the summary estimate and standard 
serving size. The estimates were then multiplied by the number of servings per 
month, summed across all food items and then divided by 30 to calculate the 
average daily nitrate and nitrite intake. Additionally, the estimate for total dietary 
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nitrite was calculated as [dietary nitrite + (0.05 X nitrate intake)] based on the 
method suggested by Choi et al.189 In the present study, we examined the 
association between dietary nitrates, nitrites, and total nitrites and risk of SGA 
birth. Tertiles of nitrates, nitrites, and total nitrites were generated based on the 
control women’s distributions and restricted to total caloric intake between 500-
5000kcal.    
Assessment of vitamin C intake (Specific aim 4) 
 The NBDPS collects information on vitamin use (single, prenatal, and 
multivitamins) three months prior to conception through the end of pregnancy. 
We calculated the intake of vitamin C supplementation during the second and 
third trimester among NBDPS controls mothers with EDDs from 1997-2005 as 
was estimated for the first trimester in our previous publication.174 Vitamin C 
supplementation was further categorized into none, less than daily, and daily 
depending on the frequency of intake. Information on dietary intake of vitamin C 
was obtained from the FFQ and the NBDPS data tools. Estimates for dietary 
vitamin C were calculated based on the daily estimated dietary intake from the 
NBDPS Nutrient Database.  
Analysis plan and power calculations   
Analysis plan 
Data for all NBDPS control participants with EDDs from 1997-2005 was 
used.  With respect to specific aim 1, nitrosatable drugs exposure in relation to 
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SGA births was analyzed in the following ways 1) any drug taken during each 
trimester or anytime during pregnancy (binary variable yes/no) 2) drugs 
classified into nitrosatable groups (secondary amines, tertiary amine, amides) 
using the same exposure periods as in #1 3) nitrosatable drugs groups from #2 
categorized by indication or therapeutic class. Women who reported no 
nitrosatable drug use anytime during pregnancy was used as the referent group.   
Dietary, nitrates, nitrites, and total nitrites were categorized into tertiles based on 
the control’s women distribution. Unconditional binary logistic regression with 
adjustments for confounders was used to analyze the association between 
dietary nitrites and total nitrites with SGA (specific aim 2). All dietary analyses 
were restricted to participants who reported a daily caloric intake between 500-
5000 kcal. These limits were recommended by Willett and have been previously 
used by dietary studies and those utilizing the NBDPS database.174, 190-192 
For specific aim 3, we examined whether dietary nitrate or nitrite intake 
modified the association between nitrosatable drug exposure and SGA. 
Nitrosatable drug exposure was stratified by tertiles of dietary nitrites/total 
nitrites. Stratum specific odds ratios and respective 95% confidence intervals 
were calculated. With respect to specific aim 4, the effect of dietary and 
supplemental vitamin C on the relation between nitrosatable drug and SGA was 
analyzed by stratifying by categories of vitamin C supplementation (none, less 
than daily, daily), and dietary vitamin C intake (<85 mg/day or ≥85 mg/day, 
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based on NIH recommendation for pregnant women). Odds ratio and 95% 
confidence limits were obtained for each stratum. 
The potential interactions of nitrosatable drugs with dietary nitrites and 
total nitrites, and vitamin C with nitrosatable drugs as risk for SGA were 
examined. Multiplicative interaction was assessed by including the product terms 
of nitrosatable drugs X total dietary nitrite, nitrosatable drugs X vitamin C, and 
nitrosatable drugs X dietary vitamin C. We tested for additive interaction using a 
program developed by Andersson et al. that estimated measures of relative 
excess risk due to interaction (RERI) and attributable proportion due to 
interaction (AP).193  
To determine which potential confounding variables to include in the 
logistic regression models, the following approach was utilized. Covariates were 
included based on their association with SGA or exposure of interest from 
previous literature. Maternal race/ethnicity, education, and study center were 
identified as important predictors of nitrosatable drug use among control 
participants in the NBDPS in a previous publication and were included in the 
final model.25 Forward selection was also utilized for selection of the covariates. 
The following covariates were considered during the forward selection: maternal 
race/ethnicity; maternal age at delivery; maternal education; maternal smoking; 
prepregnancy body mass index; weight gain in kg during pregnancy; parity; 
infant gender; maternal hypertension before and during pregnancy; and state of 
residence. Nonsignificant covariates as well as those that did not change the 
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odds ratio by 10 percent or more were eliminated from the model. Only 
participants with complete information available for all covariates included in the 
final logistic models were used for both crude and adjusted analyses. 
In the multivariable analyses, the following main effects and interactions were 
considered: 
1. (nitrosatable drug groups) + (dietary nitrites) + (nitrosatable drugs groups) 
* (dietary nitrites) 
2. (nitrosatable drug groups) + (total nitrites) + (nitrosatable drugs groups) * 
(total nitrites) 
3. (nitrosatable drug groups) + (vitamin C supplement) + (nitrosatable drug 
groups) * (vitamin C supplement)  
4. (nitrosatable drug groups) + (dietary vitamin C) +  (nitrosatable drug 
groups) * (dietary vitamin C)  
 
Power calculations  
 Table 1.1 below shows the minimum detectable odds ratio for risk of SGA 
births by nitrosatable drug and dietary nitrite exposures. Malik et al. noted the 
prevalence of SGA infants to be 7.82% among NBDPS controls participants with 
deliveries from 1997-2002.194 This was used to estimate the number of SGA 
births in this study population. 
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Table 1.1 Minimum Detectable Odds ratio for SGA in Relation to Selected 
Exposures in NBDPS Controls   
 
Outcomes 
 
Cases 
 
Exposure(s) 
Odds ratio 
Power 
80% 90% 
SGA births 509 
Any nitrosatable drugs 1.35 1.41 
Secondary amines 1.45 1.53 
Tertiary amines 1.45 1.53 
Amides 1.56 1.67 
Dietary nitrite or total nitrite 1.31 1.37 
Number of controls (births at 10th percentile or above birth weight for gestational age) - 6027 
 
Prevalence of exposure in controls: nitrosatable drugs-23.6%, secondary amines-12.4%, tertiary 
amines-12.2%, amides-7.6%, dietary nitrite or total nitrite tertiles- 33.33% 
Two tailed significance level of 0.05 
 
 
Potential problems and alternative strategies 
The study had several limitations. In NBDPS, participants were 
interviewed about the frequency of foods consumed a year prior to conception 
which might have reduced recall accuracy resulting in misclassification of foods 
consumed during pregnancy.  However, the misclassification might have been 
non-differential with respect to the outcome (SGA) as the same period of dietary 
assessment was used for all NBDPS participants. Furthermore, studies have 
indicated that consumption of vegetables and meats, major source of nitrates 
and nitrites, respectively, did not significantly differ before and during pregnancy, 
and strong correlations have been reported between vegetable intake at the 
beginning and end of pregnancy.13, 195 
 Another limitation pertains to potential maternal recall bias of drug 
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exposures during pregnancy. Since the study utilized exposure data for all 
NBDPS controls who had births without congenital malformations, the possibility 
of recall bias is less likely. Previous studies among women with normal or 
adverse pregnancy outcomes have found little evidence for differential recall of 
drugs including analgesics, antibiotics, and antinauseants that have nitrosatable 
drug components.196, 197 To reduce recall bias, the NBDPS utilized a two-level 
approach to assess drug use by asking participants about drug use by indication 
and medication name. This approach has been shown to be more accurate than 
an open ended questionnaire.198, 199 Furthermore, women were not aware of 
nitrosatable drug components in drugs they consumed so recall bias would have 
been less likely. Information on dose of the drugs was not collected in NBDPS. 
However, drug dose might not correspond to the quantity of N-nitroso 
compounds formed since conversion of nitrosatable drugs to N-nitroso 
compounds is dependent on presence and concentration of nitrite in stomach, 
gastric pH, reaction time, and other catalysts and inhibitors of the reaction.89, 200  
Significance  
 Very few epidemiologic studies have examined the relation of prenatal 
exposure to nitrosatable drugs and dietary nitrites intake with SGA. The 
prevalence of nitrosatable drug use during the first trimester of pregnancy was 
approximately 24% among control participants in the NBDPS from 1997-2005.25 
Only one published study examined the association between nitrosatable drugs 
use during pregnancy and adverse pregnancy outcomes; a significantly reduced 
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risk was observed for birthweight (<2000 grams) due to nitrosatable drug 
exposure.93 However, the interaction of dietary nitrate/nitrite intake with 
nitrosatable drugs and possible role of N-nitroso compounds were not assessed 
in this study.  
  The mean birthweight of term singleton births in United States 
decreased by 52 g from 1990-2005.201 The proportion of neonates born SGA 
from 1990-2005 remained constant around 10.3%, however in low risk 
populations the prevalence of SGA slightly increased from 1990 (7.2%) to 2005 
(8.1%). Also, infants born SGA are at increased risk for development of several 
chronic diseases, metabolic disorders and other co-morbidities in adulthood. 
Despite accumulating evidence on the adverse health effects of being born 
SGA, the causes and mechanisms for fetal growth restriction are unclear.  
Findings from this study provide valuable information on the risk of SGA birth 
associated with maternal dietary consumption of nitrates and nitrites and 
nitrosatable drug use during pregnancy. If increased risk for SGA is observed, 
women prescribed medications that have nitrosatable components should be 
given alternative drugs that are not nitrosatable. Women should be counseled of 
the potential risk to the baby from use of over the counter medications, some of 
which may be nitrosatable. They should also be encouraged to take vitamin 
supplements containing vitamin C that may attenuate the risk. Although 
exposure to nitrates and nitrites through diet is unavoidable, reduction of 
nitrosatable drug use during pregnancy might lower the risk of SGA births. 
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2. NITROSATABLE DRUG EXPOSURE DURING PREGNANCY 
AND SMALL-FOR-GESTATIONAL-AGE BIRTHS 
 
Overview 
Several prescription and non-prescription medications contain 
nitrosatable amines (secondary or tertiary amines) or amides that are precursors 
to the formation of N-nitroso compounds. Results from experimental studies on 
animal models suggest that nitrosamines may reduce birthweight in offspring. 
Using data from the National Birth Defects Prevention Study (NBDPS) control 
participants, we examined the relation between prenatal exposure to drugs 
classified as nitrosatable and small-for-gestational (SGA) births among 526 
mothers of infants with birthweight <10th percentile and 5970 mothers of control 
infants during 1997-2005. Information was collected by telephone interview on 
type and frequency of medication use, demographic characteristics, and 
maternal health. Drugs reported were classified according to nitrosatability and 
primary indication of use. Overall, prenatal use of nitrosatable drugs was not 
associated with SGA except for a few notable exceptions. Relative to women 
who reported no nitrosatable drug use anytime during pregnancy, women who 
took nitrosatable amides during the third trimester of pregnancy were more likely 
to have SGA births (adjusted odds ratio [OR] 1.43 [95% confidence interval [CI] 
1.00, 2.05]). This association was strongest among women exposed to amides 
during the eighth and ninth month of pregnancy (OR 1.57 [95% CI 1.02, 2.44] 
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and OR 1.92 [95% CI 1.17, 3.17], respectively). Exposure to tertiary amine drugs 
including antihistamines during the third trimester and analgesic use during the 
first trimester was significantly associated with SGA. Findings suggest that 
maternal exposure to nitrosatable drugs during pregnancy may not be 
associated with SGA.  
Background 
 Birthweight is considered as an important predictor of perinatal morbidity 
and mortality. According to the National Vital Statistics report for 2009, infant 
mortality rates were about 24 times higher (53.05 per 1000) for low birthweight 
infants (less than 2500 grams) than for infants with birthweight 2500 grams or 
more.1 Infants born small-for-gestational-age (SGA) are usually defined as less 
than 10th percentile of birth weight for gestational age.2 SGA infants may have a 
persistent short stature in childhood and adulthood. However, most infants 
present early postnatal or catch-up growth from birth to two years of age, and 
rapid weight gain during childhood. They are also at increased risk of developing 
chronic diseases in adulthood such as cardiovascular disease, insulin 
resistance, diabetes mellitus, dyslipidemia, and renal disease.3-6 The causes 
and mechanisms of SGA are multifactorial. Numerous environmental 
contaminants including exposure to air pollutants60, 62, 63, 67-71, 75, 76, 78 and 
tobacco smoke47-51 have been associated with SGA; however, no published 
study has examined the relation of nitrosatable drugs with SGA.     
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 Certain medications classified as containing nitrosatable amines 
(secondary or tertiary amines) or amides are precursors to the formation of N-
nitroso compounds. These compounds can be formed in vivo when nitrosatable 
amines or amides react with nitrosating agents such as nitrite in the acidic 
environment of the stomach.24 Endogenous formation of N-nitroso compounds 
accounts for 45 to 75 percent of the total human exposure; however, exposure 
may also occur from exogenous sources, such as processed meat products, 
cured meats, smoked fish, alcohol, and tobacco.86-88  
 N-nitroso compounds, genotoxic compounds including nitrosamines and 
nitrosamides, are known to cause congenital malformations in animal models,90, 
202-204 and the role of these compounds on fetal weight warrants further 
research. Some drugs classified as nitrosatable tertiary amines form n-
nitrosodimethylamine (NDMA) in the presence of nitrite.89 Experimental 
evidence has shown that exposure of pregnant mice to acetoxymethyl-
methylnitrosamine, which has the same active intermediate metabolite as 
NDMA, was associated with a significant increase in number of weight retarded 
fetuses.90 Annola et al. detected transplacental transfer of NDMA in perfused 
human placentas from women who recently delivered full-term babies indicating 
that maternal exposure to NDMA may possibly affect fetal health.91 In addition, 
fetal weight was significantly reduced when pregnant mice were exposed to both 
ethylenethiourea (a nitrosatable compound) and nitrite but no effect was 
observed when exposed to these compounds separately.92 These findings 
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suggest that N-nitroso compounds might influence fetal growth. 
 Several prescription and non-prescription drugs that consist of secondary 
or tertiary amines or amides in their molecular structure are commonly used 
during pregnancy. Among control participants of the National Birth Defects 
Prevention Study (NBDPS), approximately 24 percent of the mothers reported 
use of one or more nitrosatable drugs during the first trimester of pregnancy.25 In 
addition, maternal exposure to nitrosatable drugs during one month prior to one 
month post-conception and first trimester of pregnancy was associated with 
several birth defects in offspring, including neural tube defects,174 limb 
deficiencies, and selected oral clefts and congenital heart defects.192   
 Although numerous epidemiologic studies have examined the role of 
maternal drug use during pregnancy on birthweight and risk of SGA birth, 
inconsistent results have been reported. A variety of prescription drugs such as 
antidepressants,95-97, 100-102 antidiabetics,113-115 antiepileptics,135, 138, 139, 141 beta 
lactam antibiotics,163-165 specific cardiovascular medications,119, 121, 123, 145, 146 and 
drugs used for the treatment of asthma,106-109 migraine,131-133 and infections166-168 
were found to be associated with SGA. A few over the counter medications 
including antiemetics,152, 154 decongestants,110 nicotine replacements,156, 157 and 
drugs indicated for acid reflux disease127, 128 were also linked with SGA. But 
none of the studies evaluated the risk of SGA in relation to drugs classified as 
nitrosatable. 
 Only one published study has investigated the association between 
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nitrosatable drugs and birthweight. Using data from the Collaborative Perinatal 
Project, Olshan and Faustman examined adverse pregnancy outcomes among 
6,061 mothers exposed to nitrosatable drugs anytime during pregnancy, with 
1,775 being exposed during the first four months, and 6,921 mothers were not 
exposed to these drugs. Exposure to nitrosatable drugs during the given time 
periods was associated with a significantly lower risk for low birthweight (<2000 
grams).93  
 Based on the previous animal and human evidence of the effects of 
nitrosatable compounds or drugs on fetal birthweight, we examined the relation 
between SGA and maternal exposure to nitrosatable drugs anytime during 
pregnancy or by each trimester of pregnancy. The nitrosatable drugs were 
classified by the type of functional group (secondary amines, tertiary amines, or 
amides) and indication of use.  
Methods 
 To investigate the association between prenatal exposure to nitrosatable 
drugs and SGA birth, we used data from control participants of the National Birth 
Defects Prevention Study (NBDPS). The NBDPS is a large population-based 
case control study of birth defects in the United States. Since the study’s 
inception in 1997, ten Centers for Birth Defects Research and Prevention 
(CBDRP) including Arkansas, California, Georgia, Iowa, Massachusetts, New 
York, and Texas (from 1998 to present); New Jersey (from 1998 to 2002); and 
North Carolina and Utah (from 2003 to present) have participated in the study.178 
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Study population 
 We focused on NBDPS control mothers who had live births without major 
birth defects with estimated dates of delivery (EDDs) between October 1, 1997, 
and December 31, 2005; and were residents of one of the geographic areas 
covered by the CBDRP population registries. They were randomly sampled from 
either birth certificates (Arkansas, for EDDs after 2000; Georgia, for EDDs after 
2000; Iowa; Massachusetts; New Jersey; North Carolina; and Utah) or hospital 
records (Arkansas, for EDDs prior to 2001; California; Georgia, for EDDs prior to 
2001; New York; and Texas).179 States that selected controls from hospitals 
utilized a systematic random sampling scheme so that infants selected were in 
proportion to the number of births at each hospital in the geographic area.178 The 
controls-infants were ineligible if they were stillborn, had a major birth defect, 
were adopted or in foster care, had a deceased mother, or were born outside the 
study area. We included data only on mothers who delivered singleton births 
since multiple births have been identified as a major risk factor for SGA. The 
institutional review boards in each state and the Center for Disease Control and 
Prevention approved the NBDPS protocol, and the institutional review board of 
Texas A&M University approved this study.    
Case and control definition  
Cases were defined as infants with birthweight less than the 10th 
percentile for given gestational age, gender, and race/ethnicity. Infants with 
birthweight at or greater than 10th percentile were identified as controls. The US 
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singleton birthweight percentiles for gestational age by maternal race, parity, and 
infant gender, published by Overpeck et al.182 and Zhang & Bowes,183 were used 
for classification of SGA. Infant with gestational ages less than 20 weeks or 
more than 44 weeks were excluded. In NBDPS, information on gestational age 
and birthweight at delivery were obtained from medical records or birth 
certificates of the participants. If not available, the following criteria was used for 
calculation of gestational age: 1) estimated due date reported by mother in the 
interview; 2) ultrasound <14 weeks; 3) last menstrual period; 4) ultrasound >14 
weeks; or 5) standard neonatal exam.  
Data collection  
The NBDPS utilized a standard procedure for contacting the mothers and 
enrolling them in the study. The interviews were targeted for completion within 
six months of EDD until 24 months post-delivery. In the original study, women 
were not interviewed until six weeks after the EDD or actual date of delivery to 
reduce recall bias between women with preterm and full term births. After oral 
informed consent was obtained, the interviews were conducted either in English 
or Spanish by trained female interviewers using a computer-assisted telephone 
interview. It took approximately 1-1½ hours to complete and covered topics 
regarding maternal health (including medications taken); pregnancy issues; 
diet/substance abuse; work history; demographic characteristics; and water 
use.178 Most questions were structured with pre-coded response lists and 
detailed questions about drug exposure from three months prior to conception 
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through the end of pregnancy were asked. A pregnancy calendar was provided 
that helped mothers to recollect exposures by date, month, or trimester of 
pregnancy. Data from the NBDPS with EDDs from 1997-2005 had a total of 
6807 (66.2%) control mothers who participated in the interview and the median 
length of time from EDD to interview was 7.7 months. 
Classification of nitrosatable drugs 
 As a part of the NBDPS interview, women were questioned about 
prescription and non-prescription drugs taken (medication name), the 
corresponding dates and frequency of use from three months prior to conception 
to the date of birth of index pregnancy. Information on drugs used for specific 
illness and diseases (e.g., asthma, diabetes, hypertension etc.), and about 
specific products (e.g., ampicillin, phenytoin, metoprolol) were collected. The 
Slone Epidemiology Center Drug Dictionary was used to link the reported drugs 
to their active ingredients.184  
 Detailed methods used to classify drugs with respect to nitrosatability, 
functional groups, and indications were described in previous publications.25, 174 
The methodology used for classification included: 1) active ingredients for all 
orally administered drugs, and orally inhaled medications were identified; 2) 
these active ingredients were cross referenced with a comprehensive list of 
nitrosatable medicinal compounds published by Brambilla & Martelli89 and 
McKean Cowdin et al.;185 3) identified nitrosatable compounds were categorized 
based on the presence of amine (secondary or tertiary) and amide functional 
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groups; and further 5) each nitrosatable drug component was classified by its 
primary indication (e.g., antihistamine, antiepileptic) and pharmacologic class 
(e.g., opioid, macrolide). A few drugs were categorized into multiple nitrosatable 
groups (e.g., atenolol is both a secondary amine and amide).  
 In this study, we focused on maternal exposure to nitrosatable drugs 
anytime or by each trimester (first, second, or third) of pregnancy. For each 
nitrosatable drug component, information on whether the drug was taken and 
frequency of use was used to estimate exposure for each month and trimester of 
pregnancy. Complete information on nitrosatable drug use anytime during 
pregnancy and covariates was available for 99.0% and 98.5% of participating 
case and control women.  
Statistical analyses 
  Data for all NBDPS control participants with EDDs from 1997-2005 were 
analyzed. The distributions of maternal characteristics were compared between 
case and control mothers using chi-squared test and univariate analyses were 
performed to examine the relation between each maternal risk factor and SGA. 
Logistic regression was used to estimate odds ratios (ORs) and 95% confidence 
intervals for SGA in relation to any nitrosatable drug use anytime during 
pregnancy or by each trimester or month of pregnancy. The specific nitrosatable 
drugs components (secondary amines, tertiary amines, or amides), and 
nitrosatable drugs categorized by indication of use or therapeutic class were 
analyzed separately for their association with SGA using the same exposure 
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periods. Women who reported no nitrosatable drug use anytime during 
pregnancy was used as the referent group. All analyses were performed using 
STATA 11.205   
 Covariates included in the logistic models were selected based on their 
association with SGA and maternal risk factors associated with nitrosatable 
drugs use from previous literature. Maternal race/ethnicity, education, and study 
center were important predictors of nitrosatable drug use among control 
participants of NBDPS as noted in a previous publication.25 Non-significant 
covariates as well as those that did not change the odds ratio by 10 percent or 
more were eliminated from the final model using forward selection. The following 
covariates were included in the final model: maternal race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic, Asian/Pacific Islander, other), 
maternal education (<12 years, 12 years, 13-15 years, >15 years), study center 
(Arkansas, Atlanta, California, Iowa, Massachusetts, New Jersey, New York, 
North Carolina, Texas, and Utah), maternal smoking (yes, no), and chronic 
hypertension prior to pregnancy (yes, no). Only participants with complete 
information available for all covariates included in the final logistic models were 
used for both crude and adjusted analyses. 
 A sensitivity analysis was performed for full term case and control infants 
with gestational ages restricted between 37 and 41 weeks. The above logistic 
regression analyses were repeated. We also examined the association between 
nitrosatable drugs and SGA among a subgroup of participants with cases 
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defined at less than 10th percentile and controls classified using birthweight cut 
offs at 50th percentile or more, published by Overpeck et al.182 and Zhang & 
Bowes.183  
Results 
 A total of 526 infants classified as SGA and 5,970 controls-infants with an 
EDD from 1997-2005 participated in the NBDPS. The median length of time 
from EDD to interview was eight months for both case and control participants. 
Compared to control mothers, case mothers were more likely to be Hispanic or 
Asian/Pacific Islander, had less than 12 years of education, delivered between 
20-24 years of age, and reported smoking during pregnancy (Table 2.1). A 
higher percentage of case mothers (10.5%) had body mass index (BMI) less 
than 18.5 kg/m3 than control mothers (4.8%). Case mothers were also more 
likely to have a lower gestational weight gain of <25lbs (34.0%) compared to 
control mothers (25.0%). The distributions of maternal characteristics including 
race/ethnicity, education, age at delivery, study center, BMI, smoking, gender, 
and gestational weight gain were significantly different between case and control 
mothers. 
 Prenatal use of nitrosatable drugs anytime during pregnancy was not 
found to be associated with SGA (OR 0.92 [95% CI 0.76, 1.12]) (Table 2.2). 
However, stronger associations were observed with SGA among women who 
reported nitrosatable drug usage during the third than the first or second trimester 
of pregnancy. Specifically women who took drugs classified as nitrosatable 
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Table 2.1 Selected Maternal Characteristics of Small-For-Gestational-Age Infants 
(Cases) and Controls in the National Birth Defects Prevention Study, 1997-2005 
 
Characteristics of 
Participants 
Controls 
n=5,970 
Cases 
n=526 
 
OR 
 
95% CI 
No. % No. % 
Race-ethnicity*       
 Non-Hispanic white 3573 59.9 289 54.9 1.00 Referent 
 Non-Hispanic black 685 11.5 44 8.4 0.79 0.57, 1.10 
 Hispanic 1310 21.9 141 26.8 1.33 1.08, 1.64 
 Asian/Pacific Islander 165 2.8 27 5.1 2.02 1.32, 3.09 
 All others 237 4.0 25 4.8 1.30 0.85, 2.00 
 Missing 0 0 0 0 - - 
Education (years)*       
 >15 1882 31.5 114 21.7 1.00 Referent 
 13-15 1597 26.8 142 27.0 1.47 1.14, 1.89 
 12 1448 24.3 140 26.6 1.60 1.23, 2.06 
 <12 960 16.1 126 24.0 2.17 1.66, 2.82 
 Missing 83 1.4 4 0.8 - - 
Age at delivery (years)*       
 <18 219 3.7 22 4.2 0.91 0.57, 1.46 
 18-19 420 7.0 42 8.0 0.91 0.64, 1.30 
 20-24 1356 22.7 149 28.3 1.00 Referent 
 25-29 1601 26.8 133 25.3 0.76 0.59, 0.97 
 30-34 1569 26.3 98 18.6 0.57 0.44, 0.74 
 >34 805 13.5 82 15.6 0.93 0.70, 1.23 
Study center*       
 Arkansas 747 12.5 78 14.8 1.00 Referent 
 California 760 12.7 62 11.8 0.78 0.55, 1.11 
 Georgia 674 11.3 55 10.5 0.78 0.54, 1.12 
 Iowa 742 12.4 62 11.8 0.80 0.56, 1.13 
 Massachusetts 492 8.2 49 9.3 0.95 0.66, 1.39 
 North Carolina 539 9.0 46 8.8 0.82 0.56, 1.20 
 New Jersey 675 11.3 82 15.6 1.16 0.84, 1.61 
 New York 648 10.9 44 8.4 0.65 0.44, 0.95 
 Texas 360 6.0 23 4.4 0.61 0.38, 0.99 
 Utah 333 5.6 25 4.8 0.72 0.45, 1.15 
Body mass index (kg/m
2
)*       
 <18.5 289 4.8 55 10.5 2.08 1.52, 2.84 
 18.5–24.9 3205 53.7 293 55.7 1.00 Referent 
 25.0–29.9 1308 21.9 95 18.1 0.79 0.62, 1.01 
 >29.9 948 15.9 54 10.3 0.62 0.46, 0.84 
 Missing 220 3.7 29 5.5 - - 
Smoking*       
 No 4809 81.5 392 75.0 1.00 Referent 
 Yes 1094 18.5 131 25.0 1.47 1.19, 1.81 
 Missing 0 0 0 0 - - 
Gender*       
 Male 2992 50.1 297 56.5 1.00 Referent 
 Female 2978 49.9 229 43.5 1.29 1.08, 1.54 
 Missing 0 0 0 0 - - 
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Table 2.1 Continued. 
  
Characteristics of 
Participants 
Controls  
n=5,970 
Cases  
n=526 
 
OR 
 
95% CI 
No. % No. % 
Parity       
 Nulliparous 2392 40.1 204 38.8 1.00 Referent 
 Primiparous 1993 33.4 187 35.6 1.10 0.89, 1.35 
 Multiparous 1585 26.6 135 25.7 1.00 0.80, 1.25 
Gestational weight gain*       
 <25lbs 1492 25.0 179 34.0 1.27 1.03, 1.57 
 25-35lbs 2088 35.0 197 37.5 1.00 Referent 
 >35lbs 2154 36.1 127 24.1 0.62 0.50, 0.79 
 Missing 236 4.0 23 4.4 - - 
Abbreviations: OR, odds ratio; CI, confidence interval. 
* p < 0.05; statistically significant difference  in distribution between cases and controls 
participants
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Table 2.2  Exposure to Nitrosatable Drugs During Pregnancy and Risk of Small-For-Gestational-Age Births, 
National Birth Defects Prevention Study, 1997-2005  
 
Timing of drug 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
b
 
 
 
95% CI 
 
Adjusted 
OR
b,c
 
 
 
95% CI 
 
No. 
 
%
a 
 
No. 
 
%
a
 
 
Anytime during 
pregnancy 
 
No nitrosatable drugs 338 64.9 3620 61.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
Any nitrosatable 183 35.1 2258 38.4 0.87 0.72, 1.05 0.92 0.76, 1.12 
   Secondary  amines 93 21.6 1295 26.4 0.77 0.61, 0.98 0.85 0.67, 1.09 
   Tertiary amines 86 20.3 1138 23.9 0.81 0.63, 1.04 0.86 0.66, 1.11 
   Amides 77 18.6 877 19.5 0.94 0.73, 1.22 0.96 0.74, 1.25 
 
First trimester 
 
No nitrosatable drugs 338 75.6 3620 72.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 109 24.4 1382 27.6 0.84 0.67, 1.06 0.91 0.72, 1.15 
   Secondary  amines 54 13.8 735 16.9 0.79 0.58, 1.06 0.86 0.63, 1.17 
   Tertiary amines 47 12.2 724 16.7 0.70 0.51, 0.95 0.76 0.55, 1.05 
   Amides 36 9.6 449 11.0 0.86 0.60, 1.23 0.90 0.63, 1.30 
 
Second trimester 
 
No nitrosatable drugs 338 75.1 3620 73.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 112 24.9 1283 26.2 0.93 0.75, 1.17 1.00 0.79, 1.26 
   Secondary amines 59 14.9 755 17.3 0.84 0.63, 1.12 0.93 0.69, 1.25 
   Tertiary amines 52 13.3 596 14.1 0.93 0.69, 1.27 0.98 0.72, 1.35 
   Amides 38 10.1 392 9.8 1.04 0.73, 1.48 1.07 0.75, 1.53 
 
Third trimester 
 
No nitrosatable drugs 338 77.0 3620 76.0 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 101 23.0 1143 24.0 0.95 0.75, 1.19 1.02 0.80, 1.29 
   Secondary amines 50 12.9 683 15.9 0.78 0.58, 1.07 0.87 0.63, 1.19 
   Tertiary amines 45 11.8 490 11.9 0.98 0.71, 1.36 1.04 0.74, 1.46 
   Amides 40 10.6 328 8.3 1.31 0.92, 1.85 1.43 1.00, 2.05 
Abbreviations: OR, odds ratio; CI, confidence interval. 
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Table 2.2 Continued. 
a
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for 
secondary or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in 
the denominator. 
b
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates. 
c
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, and study center. 
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Table 2.3 Exposure to Nitrosatable Drugs During Pregnancy and Risk of Full Terma Small-For-Gestational-Age 
Births, National Birth Defects Prevention Study, 1997-2005  
 
Timing of drug 
exposure 
 
Type of drug exposure 
  Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
Anytime during 
 
No nitrosatable drugs 306 63.8 3290 61.9 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
pregnancy Any nitrosatable 174 36.2 2027 38.1 0.92 0.76, 1.12 0.97 0.79, 1.19 
   Secondary  amines 86 21.9 1154 26.0 0.80 0.62, 1.03 0.88 0.68, 1.14 
   Tertiary amines 81 20.9 1023 23.7 0.85 0.66, 1.10 0.90 0.69, 1.18 
   Amides 74 19.5 784 19.2 1.01 0.78, 1.32 1.04 0.79, 1.36 
First trimester 
 
No nitrosatable drugs 306 74.5 3290 72.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 105 25.5 1241 27.4 0.91 0.72, 1.15 0.98 0.77, 1.25 
   Secondary  amines 52 14.5 654 16.6 0.85 0.63, 1.16 0.94 0.68, 1.29 
   Tertiary amines 46 13.1 656 16.6 0.75 0.55, 1.04 0.82 0.59, 1.14 
   Amides 34 10.0 400 10.8 0.91 0.63, 1.32 0.97 0.66, 1.42 
 
Second trimester 
 
No nitrosatable drugs 306 74.3 3290 74.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 106 25.7 1140 25.7 1.00 0.79, 1.26 1.06 0.83, 1.35 
   Secondary amines 53 14.8 672 17.0 0.85 0.63, 1.15 0.94 0.69, 1.29 
   Tertiary amines 48 13.6 529 13.9 0.98 0.71, 1.34 1.03 0.74, 1.44 
   Amides 38 11.1 348 9.6 1.17 0.82, 1.67 1.21 0.84, 1.75 
Third trimester 
 
No nitrosatable drugs 306 75.6 3290 76.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 99 24.4 1016 23.6 1.05 0.83, 1.33 1.13 0.88, 1.44 
   Secondary amines 48 13.6 605 15.5 0.85 0.62, 1.17 0.95 0.68, 1.31 
   Tertiary amines 43 12.3 439 11.8 1.05 0.75, 1.47 1.12 0.79, 1.58 
   Amides 39 11.3 289 8.1 1.45 1.02, 2.07 1.61 1.11, 2.33 
Abbreviations: OR, odds ratio; CI, confidence interval 
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 Table 2.3 Continued. 
a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
   b
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for 
secondary or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in 
the denominator. 
c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates. 
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, and study center. 
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amides during the third trimester of pregnancy were more likely to have SGA 
infants compared to women who did not take nitrosatable drugs anytime during 
pregnancy (OR 1.43 [95% CI 1.00, 2.05]). When analyses were restricted to full 
term case and control-births, a stronger association was observed between 
amide drug exposure during the third trimester of pregnancy and SGA (OR 1.61 
[95% CI 1.11, 2.33]) (Table 2.3). Focusing on nitrosatable drug exposure by 
each month of pregnancy, we found that women who reported nitrosatable 
amide use during the eighth and ninth month of pregnancy were more likely to 
have SGA births (OR 1.57 [95% CI 1.02, 2.44]; and OR 1.92 [95% CI 1.17, 
3.17], respectively) (Table 2.4). Similar findings were observed for full term case 
and control-infants (OR 1.75 [95% CI 1.11, 2.74]; and OR 1.91 [95% CI 1.15, 
3.20], respectively) with prenatal use of amides during the eighth and ninth 
month of pregnancy (Table 2.5). Exposure to nitrosatable amides during the 
sixth month of pregnancy was also significantly associated with SGA (OR 1.74 
[95% CI 1.10, 2.76]) (Table 2.5). 
 As part of a sensitivity analyses, we examined the relation between 
maternal exposure to nitrosatable drugs  birthweight cut offs at 50th percentile or 
more. Although, the associations observed did not change the overall 
conclusion, stronger associations were noted between exposure to amides 
during the third trimester of pregnancy and SGA (OR 1.53 [95% CI 1.04, 2.25]). 
Higher ORs were also observed for SGA with amide drug exposure during the 
eighth and ninth month of pregnancy (ORs 1.62 [95% CI 1.02, 2.59]); and OR      
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Table 2.4 Exposure to Nitrosatable Drugs by Each Month of Pregnancy and Risk of Small-For-Gestational-Age 
Births, National Birth Defects Prevention Study, 1997-2005   
 
Timing of drug 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
b
 
 
 
95% CI 
 
Adjusted 
OR
b,c
 
 
 
95% CI 
 
No. 
 
%
a 
 
No. 
 
%
a 
 
1
st
 month 
 
No nitrosatable drugs 338 83.0 3620 81.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 69 17.0 807 18.2 0.92 0.70, 1.20 0.98 0.74, 1.29 
   Secondary  amines 39 10.3 488 11.9 0.86 0.61, 1.21 0.92 0.65, 1.31 
   Tertiary amines 35 9.4 385 9.6 0.97 0.68, 1.40 1.06 0.73, 1.54 
   Amides 18 5.1 217 5.7 0.89 0.54, 1.46 0.93 0.56, 1.54 
2
nd
 month 
 
No nitrosatable drugs 338 82.4 3620 80.7 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 72 17.6 865 19.3 0.89 0.68, 1.16 0.96 0.73, 1.26 
   Secondary amines 31 8.4 474 11.6 0.70 0.48, 1.02 0.76 0.51, 1.12 
   Tertiary amines 33 8.9 430 10.6 0.82 0.57, 1.19 0.88 0.60, 1.29 
   Amides 26 7.1 220 5.7 1.27 0.83, 1.93 1.33 0.87, 2.05 
3
rd
 month 
 
No nitrosatable drugs 338 82.6 3620 80.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 71 17.4 880 19.6 0.86 0.66, 1.13 0.95 0.72, 1.26 
   Secondary amines 41 10.8 460 11.3 0.95 0.68, 1.34 1.05 0.74, 1.48 
   Tertiary amines 31 8.4 450 11.1 0.74 0.50, 1.08 0.82 0.55, 1.21 
   Amides 17 4.8 228 5.9 0.80 0.48, 1.32 0.92 0.55, 1.54 
 
4
th
 month 
 
No nitrosatable drugs 338 82.6 3620 80.9 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 71 17.4 856 19.1 0.89 0.68, 1.16 0.98 0.74, 1.29 
   Secondary  amines 40 10.6 512 12.4 0.84 0.60, 1.18 0.93 0.66, 1.33 
   Tertiary amines 31 8.4 411 10.2 0.81 0.55, 1.18 0.89 0.60, 1.32 
   Amides 20 5.6 218 5.7 0.98 0.61, 1.57 1.04 0.65, 1.68 
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Table 2.4 Continued. 
 
Timing of drug 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
b
 
 
 
95% CI 
 
Adjusted 
OR
b,c
 
 
 
95% CI 
 
No 
 
%
a 
 
No 
 
%
a 
5
th
 month 
 
No nitrosatable drugs 338 80.7 3620 81.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 81 19.3 833 18.7 1.04 0.81, 1.34 1.11 0.86, 1.45 
   Secondary amines 43 11.3 509 12.3 0.90 0.65, 1.26 0.99 0.71, 1.40 
   Tertiary amines 37 9.9 371 9.3 1.07 0.75, 1.52 1.13 0.78, 1.63 
   Amides 24 6.6 208 5.4 1.24 0.80, 1.91 1.32 0.84, 2.06 
6
th
 month 
 
No nitrosatable drugs 338 80.7 3620 81.2 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 81 19.3 837 18.8 1.04 0.80, 1.34 1.10 0.84, 1.42 
   Secondary amines 45 11.8 514 12.4 0.94 0.68, 1.30 1.02 0.73, 1.42 
   Tertiary amines 38 10.1 380 9.5 1.07 0.75, 1.52 1.09 0.76, 1.57 
   Amides 24 6.6 191 5.0 1.35 0.87, 2.09 1.48 0.94, 2.32 
 
7
th
 month 
 
No nitrosatable drugs 338 82.4 3620 80.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 72 17.6 890 19.7 0.87 0.66, 1.13 0.94 0.71, 1.23 
   Secondary  amines 41 10.8 547 13.1 0.80 0.57, 1.12 0.89 0.63, 1.26 
   Tertiary amines 33 8.9 380 9.5 0.93 0.64, 1.35 0.97 0.66, 1.43 
   Amides 23 6.4 217 5.7 1.14 0.73, 1.77 1.18 0.75, 1.85 
8
th
 month 
 
No nitrosatable drugs 338 82.2 3620 81.5 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 73 17.8 822 18.5 0.95 0.73, 1.24 1.03 0.79, 1.36 
   Secondary amines 40 10.6 527 12.7 0.81 0.58, 1.14 0.90 0.64, 1.28 
   Tertiary amines 32 8.7 367 9.2 0.93 0.64, 1.36 1.00 0.68, 1.48 
   Amides 26 7.1 181 4.8 1.54 1.00, 2.36 1.57 1.02, 2.44 
9
th
 month 
 
No nitrosatable drugs 338 84.1 3620 85.0 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 64 15.9 640 15.0 1.07 0.81, 1.42 1.17 0.87, 1.56 
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Table 2.4 Continued. 
 
Timing of drug 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
b
 
 
 
95% CI 
 
Adjusted 
OR
b,c
 
 
 
95% CI 
 
No 
 
%
a 
 
No 
 
%
a 
   Secondary amines 36 9.6 405 10.1 0.95 0.67, 1.36 1.06 0.73, 1.53 
   Tertiary amines 30 8.2 286 7.3 1.12 0.76, 1.66 1.23 0.82, 1.84 
   Amides 20 5.6 130 3.5 1.65 1.02, 2.67 1.92 1.17, 3.17 
Abbreviations: OR, odds ratio; CI, confidence interval. 
a
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for 
secondary or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in 
the denominator.  
b
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates. 
c
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, and study center. 
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Table 2.5 Exposure to Nitrosatable Drugs by Each Month of Pregnancy and Risk of Full Terma Small-For-
Gestational-Age Births, National Birth Defects Prevention Study, 1997-2005  
 
Timing of 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
 
1
st
 month 
 
No nitrosatable drugs 
 
306 
 
81.8 3290 82.1 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 68 18.2 718 17.9 1.02 0.77, 1.34 1.10 0.82, 1.46 
   Secondary  amines 38 11.1 436 11.7 0.94 0.66, 1.33 1.01 0.71, 1.45 
   Tertiary amines 34 10.0 349 9.6 1.05 0.72, 1.52 1.15 0.78, 1.68 
   Amides 18 5.6 188 5.4 1.03 0.63, 1.69 1.10 0.66, 1.83 
2
nd
 month 
 
No nitrosatable drugs 306 81.6 3290 80.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 69 18.4 780 19.2 0.95 0.72, 1.25 1.02 0.77, 1.35 
   Secondary amines 30 8.9 418 11.3 0.77 0.52, 1.14 0.84 0.56, 1.25 
   Tertiary amines 32 9.5 393 10.7 0.88 0.60, 1.28 0.93 0.63, 1.38 
   Amides 24 7.3 205 5.9 1.26 0.81, 1.95 1.33 0.85, 2.08 
3
rd
 month 
 
No nitrosatable drugs 306 81.6 3290 80.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 69 18.4 790 19.4 0.94 0.72, 1.23 1.04 0.78, 1.38 
   Secondary amines 39 11.3 408 11.0 1.03 0.73, 1.46 1.13 0.79, 1.62 
   Tertiary amines 30 8.9 407 11.0 0.79 0.54, 1.17 0.88 0.59, 1.31 
   Amides 17 5.3 207 5.9 0.88 0.53, 1.47 1.03 0.61, 1.74 
 
4
th
 month 
 
No nitrosatable drugs 306 82.0 3290 81.1 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 67 18.0 765 18.9 0.94 0.71, 1.24 1.04 0.78, 1.38 
   Secondary  amines 36 10.5 455 12.2 0.85 0.59, 1.22 0.95 0.66, 1.38 
   Tertiary amines 27 8.1 371 10.1 0.78 0.52, 1.18 0.86 0.57, 1.31 
   Amides 20 6.1 195 5.6 1.10 0.69, 1.77 1.20 0.74, 1.94 
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Table 2.5 Continued. 
 
Timing of 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI 
 
No 
 
%
b 
 
No 
 
%
b 
5
th
 month 
 
No nitrosatable drugs 
 
306 
 
79.9 3290 81.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 77 20.1 740 18.4 1.12 0.86, 1.45 1.19 0.91, 1.57 
   Secondary amines 39 11.3 450 12.0 0.93 0.66, 1.32 1.03 0.72, 1.47 
   Tertiary amines 34 10.0 329 9.1 1.11 0.77, 1.61 1.18 0.80, 1.73 
   Amides 24 7.3 186 5.4 1.39 0.89, 2.16 1.49 0.95, 2.35 
6
th
 month 
 
No nitrosatable drugs 306 79.9 3290 81.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 77 20.1 733 18.2 1.13 0.87, 1.47 1.19 0.90, 1.56 
   Secondary amines 41 11.8 455 12.2 0.97 0.69, 1.36 1.05 0.74, 1.49 
   Tertiary amines 35 10.3 333 9.2 1.13 0.78, 1.63 1.16 0.79, 1.70 
   Amides 24 7.3 164 4.8 1.57 1.01, 2.45 1.74 1.10, 2.76 
 
7
th
 month 
 
No nitrosatable drugs 306 81.4 3290 80.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 70 18.2 783 19.2 0.96 0.73, 1.26 1.04 0.79, 1.38 
   Secondary  amines 39 11.3 484 12.8 0.87 0.61, 1.23 0.96 0.67, 1.38 
   Tertiary amines 31 9.2 336 9.3 0.99 0.67, 1.46 1.05 0.70, 1.56 
   Amides 22 6.7 192 5.5 1.23 078, 1.94 1.30 0.82, 2.07 
8
th
 month 
 
No nitrosatable drugs 306 81.2 3290 81.7 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 71 18.8 735 18.3 1.04 0.79, 1.36 1.13 0.86, 1.50 
   Secondary amines 38 11.1 465 12.4 0.88 0.62, 1.25 0.98 0.68, 1.40 
   Tertiary amines 30 8.9 333 9.2 0.97 0.65, 1.43 1.05 0.70, 1.57 
   Amides 25 7.6 158 4.6 1.70 1.10, 2.64 1.75 1.11, 2.74 
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Table 2.5 Continued. 
 
Timing of 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI 
 
No 
 
%
b 
 
No 
 
%
b 
 
9
th
 month 
 
No nitrosatable drugs 
 
306 
 
82.9 
 
3290 
 
84.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 Any nitrosatable 63 17.1 614 15.7 1.10 0.83, 1.47 1.20 0.89, 1.61 
   Secondary amines 35 10.3 388 10.6 0.97 0.67, 1.40 1.08 0.74, 1.56 
   Tertiary amines 29 8.7 277 7.8 1.13 0.75, 1.68 1.24 0.82, 1.87 
   Amides 19 5.9 124 3.6 1.65 1.00, 2.71 1.91 1.15, 3.20 
Abbreviations: OR, odds ratio; CI, confidence interval. 
     a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
       b
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for 
secondary or   tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups 
in the denominator. 
    c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates. 
    d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, and study center. 
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2.05 [95% CI 1.19, 3.52], respectively) (data not shown).     
With classification of nitrosatable drugs by indication of use, SGA was 
associated with tertiary amines across several types of indications such as 
analgesics, antiemetics, antihistamines and cough medications (Table 2.6). 
Case women were more likely than control women to have reported taken 
nitrosatable antihistamines during the third trimester of pregnancy (OR 1.63 
[95% CI 1.03, 2.56]). Mothers who reported use of analgesics, especially 
analgesic opioids, during the first trimester were more likely to have full term 
SGA births compared to mothers who did not report taking these drugs anytime 
during pregnancy (OR 2.40 [95% CI 1.26, 4.59]; and OR 2.36 [95% CI 1.20, 
4.64], respectively). Certain secondary amine drugs indicated for asthma and 
depression were associated with SGA. Use of asthma tocolytic agents during 
the second trimester was significantly associated with full term SGA births (OR 
3.25 [95% CI 1.28, 8.23]). Additionally, SGA was also associated with anti- 
infectives and cardiovascular medications classified as nitrosatable amides. 
Although the confidence intervals were wide, a higher unadjusted OR was noted 
for SGA with exposure to drugs indicated for cardiovascular disorders, during 
the second or third trimester of pregnancy (OR 4.03 [95% CI 1.06, 15.28]). 
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Table 2.6  Exposure to Nitrosatable Drugs Classified by Indication of Use and/or Pharmacologic Class and Risk of 
Full Terma Small-For-Gestational Age Births, National Birth Defects Prevention Study, 1997-2005       
 
Type of drug 
exposure 
 
Drug indication/ 
pharmacologic 
class
b 
 
Timing of drug 
exposure 
 
Cases 
 
Controls 
 
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI  
No. 
 
% 
 
No. 
 
% 
 
 
 
 
 
Secondary  
amines 
 
 
 
 
 
 
 
 
 
 
Asthma 
 
P1P3 13 4.1 138 4.0 
 
1.01 
 
0.57, 1.81 
 
1.05 
 
0.58, 1.88 
 P4P6 22 6.7 164 4.8 1.44 0.91, 2.29 1.51 0.95, 2.42 
 P7P9 19 5.9 198 5.7 1.03 0.64, 1.68 1.12 0.68, 1.83 
Asthma beta- 
adrenergic 
 
P1P3 12 
 
3.8 
 
136 
 
4.0 
 
0.95 
 
0.52, 1.73 
 
0.98 
 
0.53, 1.80 
 P4P6 16 5.0 143 4.2 1.20 0.71, 2.04 1.26 0.73, 2.15 
 P7P9 12 3.8 144 4.2 0.90 0.49, 1.63 0.95 0.51, 1.74 
 
Asthma tocolytic 
 
P1P3 1 0.3 
 
2 0.1 
 
5.38 
 
0.49, 59.5 
 
5.52 
 
0.49, 62.2 
 P4P6 6 1.9 22 0.7 2.93 1.18, 7.29 3.25 1.28, 8.23 
 P7P9 8 2.5 55 1.6 1.56 0.74, 3.31 1.79 0.83, 3.83 
 
Decongestant 
 
P1P3 28 
 
8.4 
 
425 
 
11.4 
 
0.71 
 
0.47, 1.06 
 
0.81 
 
0.54, 1.22 
 P4P6 23 7.0 434 11.6 0.57 0.37, 0.88 0.65 0.42, 1.01 
 P7P9 22 6.7 315 8.7 0.75 0.48, 1.18 0.83 0.52, 1.31 
 
 
 
 
 
Tertiary 
amines 
 
Analgesic 
 
P1P3 
 
12 
 
3.8 
 
57 
 
1.7 
 
2.26 
 
1.20, 4.26 
 
2.40 
 
1.26, 4.59 
 P4P6 13 4.1 81 2.4 1.73 0.95, 3.14 1.80 0.97, 3.31 
 P7P9 8 2.5 77 2.3 1.12 0.53, 2.34 1.19 0.56, 2.52 
 
Analgesic opioid 
 
P1P3 
 
11 
 
3.5 
 
53 
 
1.6 
 
2.23 
 
1.15, 4.32 
 
2.36 
 
1.20, 4.64 
 P4P6 13 4.1 78 2.3 1.79 0.98, 3.26 1.89 1.02, 3.49 
  P7P9  8 2.5 76 2.3 1.13 0.54, 2.37 1.21 0.57, 2.55 
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Table 2.6 Continued.    
 
Type of drug 
exposure 
 
Drug indication/ 
pharmacologic 
class
b 
 
Timing of drug 
exposure 
 
Cases 
 
Controls 
 
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI  
No. 
 
% 
 
No. 
 
% 
           
 P4P6 12 3.8 125 3.7 1.03 0.56, 1.89 1.08 0.58, 2.02 
 P7P9 8 2.5 81 2.4 1.06 0.51, 2.22 1.05 0.49, 2.25 
Anti-emetic 
phenothiazine P1P3 
 
14 
 
4.4 
 
180 
 
5.2 
 
0.84 
 
0.48, 1.46 
 
0.91 
 
0.51, 1.62 
 P4P6 11 3.5 107 3.1 1.11 0.59, 2.08 1.13 0.58, 2.17 
 P7P9 7 2.2 76 2.3 0.99 0.45, 2.17 0.97 0.43, 2.17 
Antihistamine 
 P1P3 
 
20 
 
6.1 
 
271 
 
7.6 
 
0.79 
 
0.50, 1.27 
 
0.89 
 
0.55, 1.44 
 P4P6 26 7.8 219 6.2 1.28 0.84, 1.95 1.39 0.90, 2.14 
 P7P9 24 7.3 172 5.0 1.50 0.96, 2.34 1.63 1.03, 2.56 
 
Cough P1P3 
 
8 
 
2.5 
 
114 
 
3.3 
 
0.75 
 
0.36, 1.56 
 
0.79 
 
0.38, 1.64 
 P4P6 7 2.2 85 2.5 0.89 0.41, 1.93 0.83 0.38, 1.84 
 P7P9 7 2.2 63 1.8 1.19 0.54, 2.63 1.32 0.59, 2.94 
 
 
 
 
Amides 
 
 
 
 
 
 
Anti-infective 
 
P1P3 
 
26 
 
7.8 
 
295 
 
8.2 
 
0.95 
 
0.62, 1.44 
 
1.00 
 
0.65, 1.54 
 P4P6 27 8.1 282 7.9 1.03 0.68, 1.55 1.07 0.70, 1.63 
 P7P9 28 8.4 238 6.7 1.26 0.84, 1.90 1.31 0.86, 1.99 
Anti-infective 
beta lactam 
 
P1P3 
 
22 
 
6.7 
 
264 
 
7.4 
 
0.90 
 
0.57, 1.41 
 
0.95 
 
0.60, 1.51 
 P4P6 23 7.0 255 7.2 0.97 0.62, 1.51 1.00 0.64, 1.57 
 P7P9 26 7.8 215 6.1 1.30 0.85, 1.99 1.33 0.86, 2.05 
 
Cardiovascular 
 
P1P3 
 
2 
 
0.6 
 
9 
 
0.3 
 
2.39 
 
0.51, 11.1 
 
2.28 
 
0.47, 11.0 
 
9
0
 
9
0
 
9
0
 
9
0
 
9
0
 
9
0
 
9
0
 
9
0
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Table 2.6 Continued. 
 
Type of drug 
exposure 
 
Drug indication/ 
pharmacologic 
class
b 
 
Timing of drug 
exposure 
 
Cases 
 
 
Controls 
 
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
 
95% CI 
No. % No. % 
 
Amides 
 
Cardiovascular 
 
P4P6 3 1.0 8 0.2 
 
4.03 
 
1.06, 15.3 
 
3.80 
 
0.97, 14.8 
P7P9 3 1.0 8 0.2 4.03 1.06, 15.3 3.80 0.98, 14.8 
Abbreviations: OR, odds ratio; CI, confidence interval; P1P3- first trimester; P4P6- second trimester; P7P9- third trimester 
 a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
       b
Results are presented for drugs with at least 5 exposed cases and controls except for cardiovascular amides <5 cases were exposed to 
these drugs. 
 c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates.    
 d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, and study center. 
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Discussion 
In this population-based case-control study, we found that maternal 
exposure to nitrosatable drugs and its specific functional groups (secondary 
amines, tertiary amines, or amides) any time during pregnancy was not 
associated with SGA. However, when nitrosatable drugs exposure was 
examined by each trimester of pregnancy, exposure to drugs classified as 
nitrosatable amides during the third trimester of pregnancy was significantly 
associated with SGA. Higher ORs were noted for SGA in relation to amide drug 
exposure during the eighth and ninth month of pregnancy. Furthermore, these 
associations were stronger when analyses were restricted to full term case- and 
control-infants, and exposure to amides during the sixth month of pregnancy 
was also associated with SGA in full term births.  
 The findings of our study were similar to those observed in a 
Collaborative Perinatal Project that examined the association between 
nitrosatable drug use during pregnancy and adverse pregnancy outcomes.93 
Women who took nitrosatable drugs anytime during pregnancy were less likely 
to have low birthweight (<2000 grams) infants compared to women who did not 
report taking these drugs (OR 0.67 [95% CI 0.55, 0.82]). However, nitrosatable 
drugs were not classified by functional groups (i.e., secondary and tertiary 
amines, or amides) and its relation with SGA was not examined. In the present 
study, we found that the odds of having an infant with birth weight <2000 grams 
was lower in women exposed to nitrosatable drugs anytime during pregnancy 
9
1
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(OR 0.83 [95% CI 0.52, 1.31]) compared to women with no nitrosatable drug 
exposure anytime during pregnancy; but the 95% CI included the null.    
Within the functional groups of nitrosatable drugs categorized by 
indication of use, we found null associations between several drugs indications 
and SGA except for a few notable exceptions. Prenatal use of antihistamines, 
classified as tertiary amines, during the third trimester of pregnancy was 
positively associated with full term SGA births in this study population. Oral 
antihistamines such as diphenhydramine, promethazine, meclizine, and cyclizine 
are generally used to control nausea and vomiting during pregnancy. Using data 
from the Swedish Medical Birth Registry, Asker and colleagues noted that 
women who reported any antiemetic drug use during pregnancy had a lower 
odds of having SGA births (OR 0.90 [95% CI 0.82, 0.99]).152 However, 
promethazine use, the second most commonly reported drug, during pregnancy 
slightly elevated the risk of SGA (OR 1.07 [95% CI 1.06, 1.39]). The better infant 
outcome observed with any antiemetic use might not be attributable to the 
treatment itself but probably to a well-functioning placenta; placental hormones 
are proposed to play a role in the etiology of nausea and vomiting. 
SGA was also associated with prenatal use of analgesic opioids, 
classified as tertiary amines, during the first or second trimester of pregnancy. 
Several studies have shown intrauterine growth restriction (IUGR) to be a 
common feature in pregnancies of opioid dependent mothers. Methadone, a 
synthetic opioid, generally used for the management of maternal opioid 
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dependency during pregnancy has been associated with SGA. Wouldes & 
Woodward found a significant linear association between maternal exposure to 
methadone and birthweight (p-value 0.001), especially with higher dose of 
methadone (>58 mg/day).142 Also, women exposed to increasing doses of 
methadone were more likely to have a SGA infant (p-value 0.005). In a 
retrospective cohort study, Liu et al. noted that the risk of SGA was four times 
higher ([95%CI 1.70, 7.14]) among opioid dependent mothers who received 
methadone treatment compared to mothers not dependent on opioids.143 
Although prenatal exposure to methadone increased the risk of SGA, the 
beneficial effects of minimizing illicit drug use and maintaining the pregnancy 
may outweigh the risks of neonatal outcomes associated with methadone 
treatment.  
With respect to nitrosatable secondary amines, maternal exposure to 
terbutaline, an asthma tocolytic agent, during the second trimester of pregnancy 
was significantly associated with SGA. Terbutaline, a β2 adrenergic agonist, is 
used to relieve acute symptoms of asthma and is generally considered safe 
during pregnancy. In a cohort of 2,123 asthmatic patients recruited from 16 
centers of the National Institute Child Health and Human Development Maternal 
Fetal Medicines Unit Network, Schatz et al. observed no significant difference in 
the incidence of SGA between women exposed to inhaled β2 agonists during 
pregnancy and those not exposed to these drugs.109 Bakhireva et al also found 
no increased risk of SGA births among women with asthma who reported 
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prenatal use of β2 agonists compared to non-asthmatic controls (OR 0.57 [95% 
CI 0.16, 2.12]).106  
Drugs indicated for cardiovascular conditions (classified as nitrosatable 
amides, or secondary or tertiary amines) were associated with SGA. However, 
very few women were exposed to these drugs in this study population. Several 
studies indicated that prenatal use of beta blockers, which are widely used for 
the treatment of hypertension and cardiac disorders, may increase the risk of 
SGA births. In a Danish birth cohort of 974,805 births between 1995 and 2008, 
Petersen et al. found that exposure to beta blockers during pregnancy was 
significantly associated with SGA (OR 1.97 [95% CI 1.75, 2.23]).119 Specifically, 
labetalol, a beta blocker considered to be safe during pregnancy was strongly 
associated with SGA (OR 2.02 [95% CI 1.72, 2.37]). Furthermore, Lydakis et al. 
noted a significantly higher proportion of SGA babies (70%; p-value 0.01) among 
women who received atenolol during early pregnancy (<20 weeks) compared to 
39.3% of women exposed later during pregnancy (>30 weeks).123 These findings 
were corroborated by Bayliss et al., who found that the risk of SGA was higher 
among women exposed to atenolol <15 weeks of gestation (OR 2.81 [95% 1.27, 
6.24]) than those not exposed to these drugs.121   
The present study had several strengths. The study population was well 
representative of the US population. Cogswell et al. found that NBDPS control 
participants were generally characteristic of their base populations with respect 
to age, previous live births, and smoking.179 Slight differences were noted by 
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maternal race/ethnicity, education, and infant characteristics if controls were 
selected from hospitals than from birth certificates. Also, since the study 
population did not include infants with any major birth defects, it allows a clearer 
interpretation of the study results because SGA and other neonatal outcomes 
are more commonly observed in infants with congenital malformations.180, 181 
 The findings of our study should be interpreted in context of the following 
limitations. First, a potential recall bias of drug exposures during pregnancy due 
to maternal self-report of drug use. Because the study utilized exposure data for 
all NBDPS controls who had births without congenital malformations, the 
possibility of recall bias is less likely. Previous studies have found little evidence 
for differential recall of drugs classified as nitrosatable in the present study. No 
difference in recall was observed for several drugs that have nitrosatable 
components including analgesics, antibiotics, and antinauseants between 
women with normal or adverse pregnancy outcomes.197 The sensitivity and 
specificity of maternal recall for antibiotic, antinauseant, and any drug use during 
pregnancy was noted to be similar between low birth weight and control-
infants.196 To reduce recall bias, the NBDPS utilizes a two-level approach to 
assess drug usage by asking participants about drugs by indication of use and 
medication names. This approach has shown to be more accurate than an open 
ended questionnaire.198, 199 In the NBDPS, women were asked about medication 
use during pregnancy and the drugs were later classified into secondary amines, 
tertiary amines, and amides depending on their nitrosatability. Because, women 
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were not aware of the nitrosatable components in the drugs, recall bias would 
have been unlikely. However, it is possible that some type of drugs within the 
various categories of nitrosatable drugs might have been recalled differently 
between case and control-women. 
 Another limitation pertains to missing exposure data due to lack of 
published literature on nitrosatability of the drugs. An extensive review of 
nitrosatable medicinal compounds published by Brambilla & Martelli89 and 
McKean Cowdin et al.185; and published literature on nitrosatable drugs was 
used to classify drugs based on nitrosatable functional groups present. 
However, components of some of the drugs reported might not have been tested 
for nitrosatability, and results of such tests may not be published. 
 Information on dose of the drugs was not collected in the NBDPS 
interview. However, drug dose may not correspond to the quantity of N-nitroso 
compounds formed since conversion of nitrosatable drugs to N-nitroso 
compounds is dependent on presence and concentration of nitrite in stomach, 
gastric pH, reaction time, and other catalysts and inhibitors of the reaction.89, 200  
In this study, multiple logistic regression models were fit to examine the 
relation between nitrosatable drug exposure during pregnancy and SGA birth. A 
total of 104 statistical tests were conducted to assess this association (52 for 
SGA and 52 for full term SGA births). Six statistically significant associations 
(adjusted OR >1.0 and 95% excluded the null value) were observed whereas 
only five tests would be expected by chance alone. However, given the number 
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of regression models analyzed and few significant results observed, there is 
insufficient evidence to conclude that prenatal use of nitrosatable drugs may be 
associated with SGA. 
Overall, prenatal use of drugs that have nitrosatable components was not 
found to be associated with SGA except maternal use of nitrosatable amides 
during the third trimester of pregnancy slightly elevated the risk of SGA births. 
Our study focused only on the relation of nitrosatable drugs with SGA; however, 
nitrosatable amines or amides can react with nitrosating agents such as nitrite to 
form N nitroso compounds. Evidence from animal models suggested that 
combined exposure to nitrite and nitrosatable compound might influence fetal 
growth.92 Future studies should explore the possible role of nitrosatable drugs 
and dietary nitrites on risk of SGA births.     
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3. DIETARY NITRATES AND NITRITES, NITROSATABLE 
DRUGS, AND SMALL-FOR-GESTATIONAL-AGE BIRTHS 
 
Overview 
Exposure to nitrates and nitrites from diet is fairly common and 
contributes a significant portion of daily nitrite exposure. Nitrites can react with 
amine or amide containing nitrosatable drugs to form N-nitroso compounds.  
Experimental data suggest that exposure to these compounds might reduce fetal 
birthweight. Using data from the National Birth Defects Prevention Study 
(NBDPS) control-mothers, we examined the association between maternal 
dietary intake of nitrates and nitrites and small-for-gestational-age (SGA) among 
526 case-mothers of infants with birthweight <10th percentile and 5970 control-
mothers during 1997-2005.  The daily intake of nitrates, nitrites, and total nitrites 
was estimated from information collected using a 58-item food frequency 
questionnaire. Tertiles of each dietary component were calculated based on the 
control-mothers’ distribution. Higher estimated intake of dietary nitrates, nitrites, 
and total nitrites was significantly associated with SGA, but none of these 
associations were significant after adjustment for covariates. Dietary nitrites 
modified the associations between nitrosatable drugs and SGA but lower odds 
of SGA were observed among women with higher nitrite intake. Strong 
associations were noted between exposure to nitrosatable amides during the 
third trimester of pregnancy and SGA among mothers with the lowest estimated 
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intake of dietary nitrite (OR 1.91 [95% CI 1.00, 3.66]) and animal nitrite (OR 2.31 
[95% CI 1.22, 4.35]). Maternal exposure to dietary nitrite and total nitrite did not 
appear to be associated with SGA, nor did higher nitrite intake strengthen the 
association between nitrosatable drugs and SGA. 
Background  
 Fetal growth is an important indicator of the individual’s chance of survival 
and health in later life.206 Babies born small-for-gestational-age (SGA) are at 
increased risk of development of poor cognitive and neurological disorders, and 
chronic diseases in adulthood.3-6 The causes of SGA are not well established. 
Evidence suggests that reduced substrate delivery to the fetus caused by 
placental insufficiency or poor maternal nutrition may play a role in the etiology 
of small-for-gestational-age (SGA).7 Several aspects of maternal diet have been 
hypothesized to influence fetal growth including dietary patterns;8-10 vegetable 
and fruit consumption;11-13 nutrient intake;12, 14-16 and vitamin C and folic acid 
supplementation.14, 15, 18 Kwong et al. demonstrated that changes in maternal 
diet during pregnancy can cause structural and functional abnormalities in organ 
and tissue development, and reduce fetal growth rate in animal models.17 Small 
variations in maternal dietary patterns during early pregnancy and adoption of a 
healthy and nutrient rich diet have been associated with reduced risk of SGA 
birth.8, 9, 18 However, limited studies have examined the effect of dietary nitrates 
and nitrites on risk of SGA birth.  
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 Exposure to nitrates and nitrites can occur from diet, drinking water, 
certain medications, and environmental or occupational sources of which dietary 
consumption accounts for a significant portion of daily nitrite exposure. Nitrates 
are usually present in vegetables and root crops; and cured meat, baked goods, 
and cereals are common sources of dietary nitrite.189 Approximately 5% of the 
nitrates ingested are converted to nitrites in the saliva and a portion of the nitrite 
is reduced to nitric oxide in the acidic environment of the stomach.20, 87, 189 Nitric 
oxide is also produced endogenously by endothelial cells from L-arginine and it 
plays an important role in preimplantation embryo development, and placental 
vascular development.22 Higher nitric oxide levels have been shown to arrest the 
cell cycle division that could result in apoptosis but their effect on fetal growth is 
unknown. In an experimental study in pregnant rats, an increase in serum 
nitrate/nitrite concentrations, following administration of diethylenetriamine-nitric 
oxide, decreased both placental and fetal weight compared to the control rats.82 
Studies have detected elevated nitric oxide levels in placenta and umbilical cord 
blood of pregnancies with intrauterine growth restriction compared to normal 
pregnancies.83, 84 Additionally, Hata et al. noted maternal and fetal nitrate and 
nitrite concentrations to be significantly lower among women with SGA infants 
than those with  appropriate for gestational age births suggesting that nitric oxide 
synthesis may be decreased in pregnancies with SGA infants.85 
 Ingested nitrates and nitrites could also react with nitrosatable amine 
(secondary or tertiary amine) or amide containing drugs to form N-nitroso 
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compounds.24 Endogenous formation of these compounds contributes to 40 to 
75% of human exposure.88 Several N-nitroso compounds have been shown to 
cause congenital malformations in animal models;90, 202-204 however very few 
studies have examined the relation between exposure to N-nitroso compounds 
and SGA. Only one experimental study observed fetal weight to be significantly 
reduced when pregnant mice were exposed to nitrite in combination with 
ethylenethiourea (a nitrosatable compound) but no effect was observed when 
exposed separately suggesting that N-nitroso compounds, formed from 
combination of nitrosatable compound and nitrite, might influence fetal growth.92   
 In this study, we examined 1) the relation between maternal consumption 
of dietary nitrates and nitrites and SGA births; and 2) whether higher intake of 
dietary nitrates and nitrites modified the association between nitrosatable drugs 
use during pregnancy and SGA births.  
Methods 
 We used data from control participants of the National Birth Defects 
Prevention Study (NBDPS), a large population-based case control study of birth 
defects in the United States. Since the study’s inception in 1997, ten Centers for 
Birth Defects Research and Prevention (CBDRP) including Arkansas, California, 
Georgia, Iowa, Massachusetts, New York, and Texas (from 1998 to present); 
New Jersey (from 1998 to 2002); and North Carolina and Utah (from 2003 to 
present) have participated in the study. 
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Study population 
 We focused on NBDPS control mothers who had live births without major 
birth defects with estimated dates of delivery (EDDs) between October 1, 1997, 
and December 31, 2005; and were residents of one of the geographic areas 
covered by the CBDRP population registries. They were randomly sampled from 
either birth certificates (Arkansas, for EDDs after 2000; Georgia, for EDDs after 
2000; Iowa; Massachusetts; New Jersey; North Carolina; and Utah) or hospital 
records (Arkansas, for EDDs prior to 2001; California; Georgia, for EDDs prior to 
2001; New York; and Texas).179 States that selected controls from hospitals 
utilized a systematic random sampling scheme so that infants selected were in 
proportion to the number of births at each hospital in the geographic area.178 The 
controls-infants were ineligible if they were stillborn, had a major birth defect, 
were adopted or in foster care, had a deceased mother, or were born outside the 
study area. We included data only on mothers who delivered singleton births 
since multiple births have been identified as a major risk factor for SGA. The 
institutional review boards in each state and the Center for Disease Control and 
Prevention approved the NBDPS protocol, and the institutional review board of 
Texas A&M University approved this study.   
Case and control definition  
Cases were defined as infants with birthweight less than the 10th 
percentile for given gestational age, gender, and race/ethnicity. Infants with 
birthweight at or greater than 10th percentile were identified as controls. The US 
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singleton birthweight percentiles for gestational age by maternal race, parity, and 
infant gender, published by Overpeck et al.182 and Zhang & Bowes,183 were used 
for classification of SGA. Infant with gestational ages less than 20 weeks or 
more than 44 weeks were excluded. In NBDPS, information on gestational age 
and birthweight at delivery were obtained from medical records or birth 
certificates of the participants. If not available, the following criteria was used for 
calculation of gestational age: 1) estimated due date reported by mother in the 
interview; 2) ultrasound <14 weeks; 3) last menstrual period; 4) ultrasound >14 
weeks; or 5) standard neonatal exam.  
Data collection  
The NBDPS utilized a standard procedure for contacting the mothers and 
enrolling them in the study. The interviews were targeted for completion within 
six months of EDD until 24 months post-delivery. In the original study, women 
were not interviewed until six weeks after the EDD or actual date of delivery to 
reduce recall bias between women with preterm and full term births. After oral 
informed consent was obtained, the interviews were conducted either in English 
or Spanish by trained female interviewers using a computer-assisted telephone 
interview. It took approximately 1-1½ hours to complete and covered topics 
regarding maternal health (including medications taken); diet (food consumption 
in the year before pregnancy); work history; demographic characteristics; and 
water use.178 A pregnancy calendar was provided that helped mothers to 
recollect exposures by date, month, or trimester of pregnancy. Data from the 
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NBDPS with EDDs from 1997-2005 had a total of 6807 (66.2%) control mothers 
who participated in the interview and the median length of time from EDD to 
interview was 7.7 months. 
Estimation of dietary intake of nitrates and nitrites 
 Information on foods consumed during the year prior to conception was 
collected using a 58-item food frequency questionnaire (FFQ) which was 
adapted from the Short Willett Food Frequency Questionnaire. Women were 
also asked about consumption of breakfast cereals from three months prior to 
conception through the end of pregnancy. Additional questions regarding certain 
region-specific food items such as avocados, raw chili peppers, salsa, refried 
beans, and tortillas were added to the questionnaire to incorporate the diverse 
diet of the NBDPS population. 
 The maternal dietary intake of nitrates and nitrites was estimated using a 
multi-step procedure developed by Griesenbeck and colleagues.188 Briefly, the 
nitrate and nitrite values for each food item or group listed in the FFQ were 
estimated based on extensive review of published literature. Weighted means of 
the nitrates and nitrites values in mg/100g were calculated for each food item 
and multiplied by the serving size in grams. The mean nitrate and nitrite 
estimates in each serving size were multiplied by the number of servings per 
month, summed across all food items, and divided by 30 to calculate the 
average daily intake of nitrate and nitrite in mg for each participant. Since 
approximately 5% of the nitrates ingested are converted endogenously to 
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nitrites, the estimate for total dietary nitrite was calculated as [dietary nitrite + 
(0.05 X nitrate intake)] based on the method suggested by Choi et al.189 Tertiles 
of nitrates, nitrites from either plant or animal sources, and total nitrites were 
generated based on the distribution of control women. Complete data for total 
nitrite and covariates was available for 94.9% and 95.9% of the case and control 
participants.  
Classification of nitrosatable drugs 
 As a part of the NBDPS interview, women were questioned about 
prescription and non-prescription drugs taken (medication name), the 
corresponding dates and frequency of use from three months prior to conception 
to the date of birth of index pregnancy. Information was collected on drugs used 
for specific illness and diseases (e.g., asthma, diabetes, hypertension etc.), and 
about specific products (e.g., ampicillin, phenytoin, metoprolol). The Slone 
Epidemiology Center Drug Dictionary was used to link the reported drugs to their 
active ingredients.184  
 Detailed methods used to classify drugs with respect to nitrosatability, 
functional groups, and indications were described in previous publications.25, 174 
The methodology used for classification included: 1) active ingredients for all 
orally administered drugs, and orally inhaled medications were identified; 2) 
these active ingredients were cross referenced with a comprehensive list of 
nitrosatable medicinal compounds published by Brambilla & Martelli89 and 
McKean Cowdin et al.;185 3) identified nitrosatable compounds were categorized 
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based on the presence of amine (secondary or tertiary) and amide functional 
groups; and further 5) classified by the drug’s primary indication (e.g., 
antihistamine, antiepileptic) and pharmacologic class (e.g., opioid, macrolide). 
We focused on maternal exposure to nitrosatable drugs anytime or by each 
trimester (first, second, or third) of pregnancy. For each nitrosatable drug, 
information on whether the drug was taken and frequency of use was used to 
estimate exposure for each month and trimester of pregnancy. Complete 
information on nitrosatable drug use anytime during pregnancy was available for 
99% and 98.5% of case and control participants.  
Statistical analyses 
 Unconditional binary logistic regression was used to analyze the 
association of maternal dietary intake of nitrates, nitrites (plant or animal 
source), and total nitrites with SGA. Tertiles of nitrates, nitrites, and total nitrites 
were calculated based on the distributions among control mothers; and the 
lowest tertile of each dietary component was used as the referent group. All 
dietary analyses were conducted using Stata 11205 and were restricted to 
women who had daily caloric intake between 500-5000 kcal. These limits were 
recommended by Willett190 and have been previously used by dietary studies 
and those utilizing the NBDPS database.174, 191    
 Covariates included in the logistic models were selected based on their 
association with SGA and maternal risk factors associated with nitrosatable 
drugs use from previous literature. Maternal race/ethnicity, education, and study 
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center were important predictors of nitrosatable drug use among control 
participants of NBDPS as noted in a previous publication.25 Non-significant 
covariates as well as those that did not change the odds ratio by 10 percent or 
more were eliminated from the final model using forward selection. The following 
covariates were included in the final model: maternal race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic, Asian/Pacific Islander, other), 
maternal education (<12 years, 12 years, 13-15 years, >15 years), study center, 
maternal smoking (yes, no), and chronic hypertension prior to pregnancy (yes, 
no). Only participants with complete information available for all covariates 
included in the final logistic models were used for both crude and adjusted 
analyses. 
 We examined whether dietary nitrite intake modified the association 
between nitrosatable drug exposure and SGA. Stratum specific odds ratio and 
95% confidence intervals were estimated for each tertile of dietary nitrites and 
total nitrites with adjustment for aforementioned covariates and total energy 
intake. Additive and multiplicative interaction was assessed for the associations 
of SGA with nitrosatable drugs by dietary nitrites and total nitrites. We tested for 
additive interaction using a statistical program developed by Andersson & 
colleagues that estimated measures of relative excess risk due to interaction 
(RERI) and attributable proportion due to interaction (AP).193 If either or both 
measures differed from zero and their 95% confidence intervals excluded 0, 
significant additive interaction was considered present. To assess multiplicative 
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interaction, the product term of nitrosatable drug functional groups with dietary 
nitrite and total nitrite were included in the logistic models and was considered 
significant if the p-value was less than 0.05.      
 We also examined the association between dietary intake of nitrites and 
total nitrites and SGA among a subgroup of full term case and control infants 
with gestational ages restricted between 37 and 41 weeks. Since the 
associations observed between nitrosatable drugs and SGA stratified by dietary 
nitrites and total nitrites were similar for analyses including all study participants 
and with restriction to full term case and control infants, we present findings only 
for full term SGA infants.   
Results 
 A total of 526 infants classified as SGA and 5,970 controls-infants with an 
EDD from 1997-2005 participated in the NBDPS. The median length of time 
from EDD to interview was eight months for both case and control participants. 
Compared to control mothers, case mothers were more likely to be Hispanic or 
Asian/Pacific Islander, had less than 12 years of education, delivered between 
20-24 years of age, and reported smoking during pregnancy (Table 3.1). A 
higher percentage of case mothers (10.5%) had body mass index (BMI) less 
than 18.5 kg/m3 than control mothers (4.8%). Case mothers were also more 
likely to have a lower gestational weight gain of <25lbs (34.0%) compared to 
control mothers (25.0%). The distributions of maternal characteristics including 
race/ethnicity, education, age at delivery, study center, BMI, smoking, gender, 
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Table 3.1 Selected Maternal Characteristics of Small-For-Gestational-Age Infants 
(Cases) and Controls in the National Birth Defects Prevention Study, 1997-2005 
 
Characteristics of 
Participants 
Controls 
n=5,970 
Cases 
n=526 
 
OR 
 
95% CI 
No. % No. % 
Race-ethnicity*       
 Non-Hispanic white 3573 59.9 289 54.9 1.00 Referent 
 Non-Hispanic black 685 11.5 44 8.4 0.79 0.57, 1.10 
 Hispanic 1310 21.9 141 26.8 1.33 1.08, 1.64 
 Asian/Pacific Islander 165 2.8 27 5.1 2.02 1.32, 3.09 
 All others 237 4.0 25 4.8 1.30 0.85, 2.00 
 Missing 0 0 0 0 - - 
Education (years)*       
 >15 1882 31.5 114 21.7 1.00 Referent 
 13-15 1597 26.8 142 27.0 1.47 1.14, 1.89 
 12 1448 24.3 140 26.6 1.60 1.23, 2.06 
 <12 960 16.1 126 24.0 2.17 1.66, 2.82 
 Missing 83 1.4 4 0.8 - - 
Age at delivery (years)*       
 <18 219 3.7 22 4.2 0.91 0.57, 1.46 
 18-19 420 7.0 42 8.0 0.91 0.64, 1.30 
 20-24 1356 22.7 149 28.3 1.00 Referent 
 25-29 1601 26.8 133 25.3 0.76 0.59, 0.97 
 30-34 1569 26.3 98 18.6 0.57 0.44, 0.74 
 >34 805 13.5 82 15.6 0.93 0.70, 1.23 
Study center*       
 Arkansas 747 12.5 78 14.8 1.00 Referent 
 California 760 12.7 62 11.8 0.78 0.55, 1.11 
 Georgia 674 11.3 55 10.5 0.78 0.54, 1.12 
 Iowa 742 12.4 62 11.8 0.80 0.56, 1.13 
 Massachusetts 492 8.2 49 9.3 0.95 0.66, 1.39 
 North Carolina 539 9.0 46 8.8 0.82 0.56, 1.20 
 New Jersey 675 11.3 82 15.6 1.16 0.84, 1.61 
 New York 648 10.9 44 8.4 0.65 0.44, 0.95 
 Texas 360 6.0 23 4.4 0.61 0.38, 0.99 
 Utah 333 5.6 25 4.8 0.72 0.45, 1.15 
Body mass index (kg/m
2
)*       
 <18.5 289 4.8 55 10.5 2.08 1.52, 2.84 
 18.5–24.9 3205 53.7 293 55.7 1.00 Referent 
 25.0–29.9 1308 21.9 95 18.1 0.79 0.62, 1.01 
 >29.9 948 15.9 54 10.3 0.62 0.46, 0.84 
 Missing 220 3.7 29 5.5 - - 
Smoking*       
 No 4809 81.5 392 75.0 1.00 Referent 
 Yes 1094 18.5 131 25.0 1.47 1.19, 1.81 
 Missing 0 0 0 0 - - 
Gender*       
 Male 2992 50.1 297 56.5 1.00 Referent 
 Female 2978 49.9 229 43.5 1.29 1.08, 1.54 
 Missing 0 0 0 0 - - 
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Table 3.1 Continued. 
  
Characteristics of 
Participants 
Controls  
n=5,970 
Cases  
n=526 
 
OR 
 
95% CI 
No. % No. % 
Parity       
 Nulliparous 2392 40.1 204 38.8 1.00 Referent 
 Primiparous 1993 33.4 187 35.6 1.10 0.89, 1.35 
 Multiparous 1585 26.6 135 25.7 1.00 0.80, 1.25 
Gestational weight gain*       
 <25lbs 1492 25.0 179 34.0 1.27 1.03, 1.57 
 25-35lbs 2088 35.0 197 37.5 1.00 Referent 
 >35lbs 2154 36.1 127 24.1 0.62 0.50, 0.79 
 Missing 236 4.0 23 4.4 - - 
Abbreviations: OR, odds ratio; CI, confidence interval. 
* p < 0.05; statistically significant difference  in distribution between cases and controls 
participants 
 
 
and gestational weight gain were significantly different between case and control 
mothers.  
 Estimated maternal dietary intake of nitrates, nitrites, total nitrites, and 
animal nitrites was significantly associated with SGA, but none of these 
associations remained significant after adjustment for covariates (Table 3.2). 
Compared to the lowest tertile of dietary nitrate intake (<31.43 mg/day), women 
who consumed nitrates of more than 51.74 mg/day were slightly more likely to  
have SGA births (adjusted odds ratio (aOR) 1.06 [95% CI 0.82, 1.39]). Higher 
estimated intake of animal source of dietary nitrite (>1.20 mg/day) (aOR 1.05 
[95% CI 0.81, 1.35], respectively) was associated with SGA but the 95% 
confidence interval included the null. Restriction of analyses to full term case 
and control infants did not materially change the adjusted ORs for SGA with 
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Table 3.2  Maternal Dietary Intake of Nitrates and Nitrites and Risk of Small-For-Gestational-Age Births, 
National Birth Defects Prevention Study, 1997-2005    
 
Dietary 
contaminant 
 
Tertiles 
mg/day 
Cases Controls  
Unadjusted 
OR
a
 
 
 
95% CI 
 
Adjusted 
OR
a,b
 
 
 
95% CI 
 
No. 
 
% 
 
No. 
 
% 
 
Nitrates <31.43 146 29.3 1909 33.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 31.43-51.74 165 33.1 1909 33.3 1.13 0.90, 1.42 1.05 0.82, 1.33 
 >51.74 188 37.6 1909 33.3 1.29 1.03, 1.61 1.06 0.82, 1.39 
 
Nitrites <1.28 144 28.8 1910 33.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 1.28-1.90 155 31.0 1914 33.4 1.07 0.85, 1.36 0.95 0.75, 1.22 
 >1.90 201 40.2 1910 33.3 1.40 1.12, 1.74 0.94 0.70, 1.25 
Total Nitrites <3.02 144 28.9 1906 33.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 3.02-4.54 161 32.3 1914 33.4 1.11 0.88, 1.41 1.00 0.79, 1.28 
 >4.54 194 38.8 1907 33.3 1.35 1.08, 1.69 0.99 0.75, 1.31 
 
Animal Nitrites <0.74 150 29.9 1918 33.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 0.74-1.20 150 29.9 1926 33.4 1.00 0.79, 1.26 0.94 0.74, 1.20 
 >1.20 202 40.2 1916 33.3 1.35 1.08, 1.68 1.05 0.81, 1.35 
 
Plant Nitrites <0.46 157 31.2 1919 33.3 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 0.46-0.70 153 30.4 1918 33.3 0.98 0.77, 1.23 0.86 0.68, 1.10 
 >0.70 194 38.4 1915 33.3 1.24 0.99, 1.54 0.82 0.61, 1.10 
Abbreviations: OR, odds ratio; CI, confidence interval. 
a
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates, and 
whose daily caloric intake was between 500 and 5000 kcal. 
b
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center. 
 
 112 
 
Table 3.3.  Maternal Dietary Intake of Nitrates and Nitrites and Risk of Full Terma Small-For-Gestational Age 
Births, National Birth Defects Prevention Study, 1997-2005  
 
Dietary 
contaminant 
 
Tertiles 
mg/day 
Cases Controls  
Unadjusted 
OR
b
 
 
 
95% CI 
 
Adjusted 
OR
b,c
 
 
 
95% CI 
 
No. 
 
% 
 
No. 
 
% 
 
Nitrates <31.43 137 29.9 1719 33.2 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 31.43-51.74 153 33.3 1723 33.2 1.11 0.88, 1.42 1.04 0.81, 1.33 
 >51.74 169 36.8 1741 33.6 1.22 0.96, 1.54 1.01 0.77, 1.34 
 
Nitrites <1.28 131 28.5 1731 33.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 1.28-1.90 142 30.9 1728 33.3 1.09 0.85, 1.39 0.96 0.75, 1.24 
 >1.90 187 40.6 1730 33.3 1.43 1.13, 1.80 0.97 0.72, 1.31 
Total nitrites <3.02 135 29.4 1717 33.1 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 3.02-4.54 150 32.7 1736 33.5 1.10 0.86, 1.40 0.99 0.76, 1.27 
 >4.54 174 37.9 1730 33.4 1.28 1.01, 1.62 0.93 0.70, 1.25 
 
Animal nitrites <0.74 136 29.4 1740 33.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 0.74-1.20 138 29.8 1739 33.4 1.02 0.79, 1.30 0.95 0.74, 1.23 
 >1.20 189 40.8 1732 33.2 1.40 1.11, 1.76 1.09 0.83, 1.41 
 
Plant nitrites <0.46 146 31.5 1729 33.2 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
 0.46-0.70 142 30.7 1731 33.3 0.97 0.76, 1.24 0.86 0.67, 1.11 
 >0.70 175 37.8 1746 33.5 1.19 0.94, 1.49 0.77 0.57, 1.05 
Abbreviations: OR, odds ratio; CI, confidence interval. 
 a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
b
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates, and 
whose daily caloric intake was between 500 and 5000 kcal. 
c
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center. 
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dietary nitrates and animal nitrites in the highest tertile (versus the lowest tertile) 
(aOR 1.01 [95% CI 0.77, 1.34] and aOR 1.09 [95% CI 0.83, 1.41], respectively) 
(Table 3.3).  
 Overall, higher dietary consumption of nitrites or total nitrites in conjunction 
with nitrosatable drug use during pregnancy did not increase the risk of SGA 
births. However, a higher odds of SGA births was observed among women with 
the lowest estimated intake of dietary nitrites and total nitrites in relation to 
nitrosatable drugs exposure during pregnancy. Exposure to drugs classified as 
nitrosatable amides during the third trimester of pregnancy was significantly 
associated with SGA in women with lowest estimated intake of dietary nitrites 
(<1.28 mg/day) (aOR 1.91 [95% CI 1.00, 3.66]) (Table 3.4). Stronger 
associations were also noted between amide drug exposure during the eighth 
and ninth month of pregnancy and SGA for the lowest tertile of dietary nitrite 
intake (aOR 3.15 [95% CI 1.53, 6.51] and (aOR 2.43 [95% CI 1.02, 5.77], 
respectively) (data not shown). Exposure to amides during the 6th month of 
pregnancy was also significantly associated with SGA in women with the lowest 
estimate intake of dietary nitrite (aOR 2.39 [95% CI 1.13, 5.50]). A pattern of 
decreasing odds ratios was observed between nitrosatable drug exposure and 
SGA by increasing levels of total nitrite (sum of dietary nitrite and 5% dietary 
nitrate) (Table 3.5). A significant association was observed between amide 
exposure during the 8th month of pregnancy and SGA for the lowest tertile of 
total nitrite intake (aOR 2.91 [95% CI 1.45, 5.84]) (data not shown). 
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Table 3.4 Maternal Exposure to Nitrosatable Drugs by Each Trimester of Pregnancy and Small-For-Gestational Agea 
Births by Estimated Dietary Intake of Nitrites, National Birth Defects Prevention Study, 1997-2005     
Dietary intake 
mg/day 
Timing of 
exposure 
 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
Nitrites 
< 1.28 First  
No nitrosatable drug 
exposure 78 70.9 1057 71.7 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester   Secondary  amines 18 18.8 220 17.2 1.11 0.65, 1.89 1.16 0.67, 2.02 
    Tertiary amines 13 14.3 223 17.4 0.79 0.43, 1.45 0.82 0.44, 1.54 
    Amides 10 11.4 123 10.4 1.10 0.56, 2.18 1.15 0.57, 2.33 
1.28-1.90 
 No nitrosatable drug 
exposure 86 71.1 1027 71.2 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 17 16.5 217 17.4 0.94 0.54, 1.61 1.10 0.63, 1.93 
    Tertiary amines 13 13.1 204 16.6 0.76 0.42, 1.39 0.85 0.45, 1.60 
    Amides 10 10.4 137 11.8 0.87 0.44, 1.72 0.90 0.45, 1.82 
> 1.90 
 No nitrosatable drug 
exposure 127 78.4 1114 71.4 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 17 11.8 206 15.6 0.72 0.43, 1.23 0.76 0.44, 1.32 
    Tertiary amines 18 12.4 219 16.4 0.72 0.43, 1.21 0.76 0.44, 1.32 
    Amides 12 8.6 131 10.5 0.80 0.43, 1.49 0.81 0.42, 1.54  
Nitrites 
< 1.28 Second  
No nitrosatable drug 
exposure 78 69.6 1057 73.9 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester   Secondary amines 15 16.1 221 17.3 0.92 0.52, 1.63 1.03 0.57, 1.85 
    Tertiary amines 13 14.3 173 14.1 1.02 0.55, 1.87 1.04 0.55, 1.96 
    Amides 13 14.3 109 9.4 1.62 0.87, 3.00 1.60 0.84, 3.05 
1.28-1.90 
 No nitrosatable drug 
exposure 86 74.1 1027 72.4 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 17 16.5 235 18.6 0.86 0.50, 1.48 0.98 0.56, 1.72 
    Tertiary amines 8 8.5 180 14.9 0.53 0.25, 1.11 0.56 0.26, 1.20 
    Amides 11 11.3 116 10.2 1.13 0.59, 2.18 1.26 0.64, 2.46 
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Table 3.4 Continued. 
Dietary intake 
mg/day 
Timing of 
exposure 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI No. %
b 
No. %
b 
> 1.90 
 No nitrosatable drug 
exposure 127 77.4 1114 75.8 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 20 13.6 204 15.5 0.86 0.52, 1.41 0.90 0.53, 1.52 
    Tertiary amines  25 16.5 169 13.2 1.30 0.82, 2.05 1.33 0.81, 2.17 
     Amides 12 8.6 117 9.5 0.90 0.48, 1.68 0.90 0.47, 1.72 
Nitrites 
< 1.28 Third  
No nitrosatable drug 
exposure 78 69.6 1057 75.2 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester   Secondary  amines 17 17.9 205 16.2 1.12 0.65, 1.94 1.23 0.70, 2.17 
    Tertiary amines 17 17.9 159 13.1 1.45 0.84, 2.51 1.49 0.84, 2.63 
    Amides 13 14.3 91 7.9 1.94 1.04, 3.62 1.91 1.00, 3.66 
1.28-1.90 
 No nitrosatable drug 
exposure 86 74.8 1027 74.5 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 16 15.7 218 17.5 0.88 0.50, 1.52 1.02 0.57, 1.80 
    Tertiary amines 9 9.5 148 12.6 0.73 0.36, 1.47 0.75 0.36, 1.57 
    Amides 8 8.5 92 8.2 1.04 0.49, 2.21 1.14 0.53, 2.48 
>1.90 
 No nitrosatable drug 
exposure 127 79.4 1114 78.5 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 15 10.6 174 13.5 0.76 0.43, 1.32 0.82 0.46, 1.46 
    Tertiary amines 17 11.8 129 10.4 1.16 0.67, 1.98 1.23 0.69, 2.17 
    Amides 15 10.6 105 8.6 1.25 0.71, 2.22 1.31 0.72, 2.40 
Abbreviations: OR, odds ratio; CI, confidence interval. 
a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
b
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for secondary 
or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in the 
denominator. 
c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates, and whose 
daily caloric intake was between 500 and 5000 kcal. 
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center.  
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Table 3.5  Maternal Exposure to Nitrosatable Drugs by Each Trimester of Pregnancy and Small-For-Gestational-Agea 
Births by Estimated Dietary Intake of Total Nitrites, National Birth Defects Prevention Study, 1997-2005    
Dietary intake 
mg/day 
Timing of 
exposure 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
Total Nitrites 
< 3.02 First 
No nitrosatable drug 
exposure 83 75.5 1040 71.4 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester   Secondary  amines 14 14.4 219 17.4 0.80 0.45, 1.44 0.89 0.49, 1.62 
    Tertiary amines 13 13.5 215 17.1 0.76 0.41, 1.38 0.81 0.44, 1.52 
    Amides 7 7.8 121 10.4 0.72 0.33, 1.60 0.78 0.34, 1.76 
3.02-4.54 
 No nitrosatable drug 
exposure 85 66.4 1025 70.1 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 23 21.3 234 18.6 1.19 0.73, 1.92 1.30 0.79, 2.15 
    Tertiary amines 20 19.1 233 18.5 1.04 0.62, 1.72 1.12 0.66, 1.91 
    Amides 9 9.6 150 12.8 0.72 0.36, 1.47 0.76 0.37, 1.57 
>4.54 
 No nitrosatable drug 
exposure 122 79.2 1130 75.8 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 15 11.0 189 14.3 0.74 0.42, 1.28 0.79 0.44, 1.41 
    Tertiary amines 11 8.3 196 14.8 0.52 0.28, 0.98 0.56 0.29, 1.10 
    Amides 16 11.6 120 9.6 1.23 0.71, 2.15 1.29 0.72, 2.33 
Total Nitrites 
< 3.02 Second 
No nitrosatable drug 
exposure 83 72.8 1040 73.6 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester   Secondary amines 13 13.5 221 17.5 0.74 0.40, 1.35 0.84 0.45, 1.57 
    Tertiary amines 13 13.5 163 13.6 1.00 0.54, 1.83 1.01 0.53, 1.90 
    Amides 11 11.7 107 9.3 1.29 0.67, 2.49 1.31 0.66, 2.59 
3.02-4.54 
 No nitrosatable drug 
exposure 85 69.1 1025 71.8 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 23 21.3 234 18.6 1.19 0.73, 1.92 1.29 0.78, 2.12 
    Tertiary amines 15 15.0 193 15.9 0.94 0.53, 1.66 1.01 0.56, 1.82 
    Amides 13 13.3 134 11.6 1.17 0.64, 2.15 1.23 0.65, 2.31 
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Table 3.5 Continued. 
Dietary intake 
mg/day 
Timing of 
exposure 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
95% CI 
 
Adjusted 
OR
c,d
 
 
95% CI  
No. 
 
%
b 
 
No. 
 
%
b 
>4.54 
 No nitrosatable drug 
exposure 122 79.2 1130 76.7 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 16 11.6 205 15.4 0.72 0.42, 1.24 0.81 0.46, 1.43 
    Tertiary amines  18 12.9 166 12.8 1.00 0.60, 1.69 1.06 0.61, 1.84 
     Amides 12 9.0 101 8.2 1.10 0.59, 2.06 1.09 0.56, 2.12 
Total Nitrites 
< 3.02 Third 
No nitrosatable drug 
exposure 83 71.6 1040 75.3 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester   Secondary  amines 14 14.4 205 16.5 0.86 0.48, 1.54 0.96 0.53, 1.77 
    Tertiary amines 16 16.2 147 12.4 1.36 0.78, 2.39 1.42 0.79, 2.55 
    Amides 14 14.4 95 8.4 1.85 1.01, 3.38 1.83 0.98, 3.42 
3.02-4.54 
 No nitrosatable drug 
exposure 85 71.4 1025 73.9 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 18 17.5 219 17.6 0.99 0.58, 1.68 1.12 0.65, 1.93 
    Tertiary amines 14 14.1 167 14.0 1.01 0.56, 1.82 1.05 0.57, 1.95 
    Amides 10 10.5 94 8.4 1.28 0.64, 2.55 1.32 0.65, 2.68 
>4.54 
 No nitrosatable drug 
exposure 122 80.8 1130 78.9 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
    Secondary amines 16 11.6 173 13.3 0.86 0.50, 1.48 0.95 0.54, 1.68 
    Tertiary amines 13 9.6 122 9.7 0.99 0.54, 1.80 1.04 0.55, 1.96 
    Amides 12 9.0 99 8.1 1.12 0.60, 2.10 1.15 0.60, 2.21 
 Abbreviations: OR, odds ratio; CI, confidence interval. 
a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
b
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for secondary 
or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in the 
denominator. 
c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates, and whose 
daily caloric intake was between 500 and 5000 kcal. 
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center. 
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 Higher ORs were noted between nitrosatable drugs exposure and SGA 
among women with lower estimated dietary intake of animal nitrite, especially 
with exposure to nitrosatable amides during the second and third trimester of 
pregnancy (aOR 2.11 [95% CI 1.12, 3.97) and (aOR 2.31 [95% CI 1.22, 4.35], 
respectively) (Table 3.6). When exposure to amides was examined by each 
month of pregnancy, stronger associations were observed between SGA and 
amide drug exposures during the 5th (aOR = 3.17), 6th (aOR= 3.34), 8th (aOR = 
3.40) and 9th (aOR = 3.11) months of pregnancy for the lowest tertile of animal 
nitrite intake (<0.74 mg/day). Although some fruits and vegetables are known to 
contain vitamin C that may inhibit nitrosation, maternal intake of plant nitrites had 
minimal effect on the association between nitrosatable drugs and SGA (Table 
3.7). But exposure to amides during the 5th month of pregnancy was associated 
with SGA in women with estimated daily intake of 0.46-0.70 mg (middle tertile) of 
plant nitrite (aOR 2.19 [95% CI 1.10, 4.37]) (data not shown).    
Discussion 
 In this population based case-control study, we found that maternal 
exposure to higher dietary intake of nitrates, nitrites, and total nitrites were not 
significant risk factors for SGA. Moreover, women with the lowest estimated 
intake of nitrite and total nitrites were more likely to have SGA offspring if they 
reported exposure to drugs classified as nitrosatable amides during the third 
trimester of pregnancy. A lower intake of animal source of dietary nitrites in 
conjunction with exposure to amide drugs was significantly associated with SGA,  
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Table 3.6 Maternal Exposure to Nitrosatable Drugs by Each Trimester of Pregnancy and Small-For-Gestational Agea 
Births by Estimated Dietary Intake of Animal Nitrites, National Birth Defects Prevention Study, 1997-2005     
 
Dietary intake 
mg/day 
 
Timing of 
exposure 
 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
Animal Nitrites 
< 0.74 First  
No nitrosatable drug 
exposure 83 69.8 1113 74.3 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester  Secondary  amines 19 18.6 209 15.8 1.22 0.72, 2.05 1.37 0.79, 2.36 
      Tertiary amines 15 15.3 197 15.0 1.02 0.58, 1.81 1.16 0.64, 2.13 
      Amides 13 13.5 112 9.1 1.56 0.84, 2.88 1.90 1.00, 3.62 
0.74-1.20 
 No nitrosatable drug 
exposure 89 77.4 1048 71.7 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 14 13.6 218 17.2 0.76 0.42, 1.35 0.88 0.48, 1.62 
      Tertiary amines 11 11.0 206 16.4 0.63 0.33, 1.20 0.73 0.37, 1.44 
      Amides 5 5.3 136 11.5 0.43 0.17, 1.08 0.46 0.18, 1.18 
>1.20 
 No nitrosatable drug 
exposure 121 74.7 1053 71.4 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 19 13.6 219 17.2 0.76 0.46, 1.25 0.82 0.48, 1.39 
      Tertiary amines 19 13.6 243 18.8 0.68 0.41, 1.13 0.74 0.43, 1.26 
      Amides 14 10.4 145 12.1 0.84 0.47, 1.50 0.88 0.48, 1.60 
Animal Nitrites 
< 0.74 Second  
No nitrosatable drug 
exposure 83 72.2 1113 75.6 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester  Secondary amines 14 14.4 218 16.4 0.86 0.48, 1.55 1.02 0.56, 1.88 
      Tertiary amines 11 11.7 164 12.8 0.90 0.47, 1.72 1.03 0.52, 2.02 
      Amides 14 14.4 104 8.6 1.81 0.99, 3.29 2.11 1.12, 3.97 
0.74-1.20 
 No nitrosatable drug 
exposure 89 76.1 1048 74.0 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 16 15.2 219 17.3 0.86 0.50, 1.49 0.97 0.54, 1.72 
      Tertiary amines 11 11.0 168 13.8 0.77 0.40, 1.47 0.83 0.42, 1.63 
      Amides 8 8.3 112 9.7 0.84 0.40, 1.78 0.90 0.41, 1.97 
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Table 3.6 Continued. 
 
Dietary intake 
mg/day 
 
Timing of 
exposure 
 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
>1.20 
 No nitrosatable drug 
exposure 121 74.2 1053 72.6 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 22 15.4 226 17.7 0.85 0.53, 1.36 0.93 0.56, 1.53 
      Tertiary amines  25 17.1 194 15.6 1.12 0.71, 1.77 1.18 0.73, 1.90 
      Amides 14 10.4 128 10.8 0.95 0.53, 1.70 0.96 0.52, 1.75 
Animal Nitrites 
< 0.74 Third  
No nitrosatable drug 
exposure 83 72.2 1113 77.0 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester  Secondary  amines 17 17.0 200 15.2 1.14 0.66, 1.96 1.33 0.75, 2.34 
      Tertiary amines 14 14.4 148 11.7 1.27 0.70, 2.29 1.39 0.75, 2.59 
      Amides 14 14.4 90 7.5 2.09 1.14, 3.82 2.31 1.22, 4.35 
0.74-1.20 
 No nitrosatable drug 
exposure 89 74.2 1048 75.5 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 17 16.0 207 16.5 0.97 0.56, 1.66 1.01 0.58, 1.78 
      Tertiary amines 13 12.8 137 11.6 1.12 0.61, 2.05 1.18 0.62, 2.25 
      Amides 7 7.3 88 7.8 0.94 0.42, 2.08 0.99 0.43, 2.25 
>1.20 
 No nitrosatable drug 
exposure 121 78.1 1053 76.0 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 14 10.4 190 15.3 0.64 0.36, 1.14 0.71 0.39, 1.29 
      Tertiary amines 16 11.7 151 12.5 0.92 0.53, 1.60 0.97 0.55, 1.71 
      Amides 16 11.7 110 9.5 1.27 0.73, 2.21 1.33 0.74, 2.40 
 Abbreviations: OR, odds ratio; CI, confidence interval. 
a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
b
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for secondary 
or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in the denominator. 
c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates, and whose daily 
caloric intake was between 500 and 5000 kcal. 
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and center.  
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Table 3.7 Maternal Exposure to Nitrosatable Drugs by Each Trimester of Pregnancy and Small-For-Gestational-Agea 
Births by Estimated Dietary Intake of Plant Nitrites, National Birth Defects Prevention Study, 1997-2005  
Dietary intake 
mg/day 
Timing of 
exposure 
 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
Plant Nitrites 
< 0.46 First  
No nitrosatable drug 
exposure 84 71.2 1031 70.3 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester  Secondary  amines 15 15.2 224 17.9 0.82 0.47, 1.45 0.86 0.48, 1.54 
      Tertiary amines 15 15.2 218 17.5 0.84 0.48, 1.49 0.90 0.50, 1.62 
      Amides 10 10.6 145 12.3 0.85 0.43, 1.67 0.85 0.42, 1.70 
0.46-0.70 
 No nitrosatable drug 
exposure 86 69.9 974 67.9 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 21 19.6 248 20.3 0.96 0.58, 1.58 0.96 0.58, 1.61 
      Tertiary amines 17 16.5 261 21.1 0.74 0.43, 1.26 0.72 0.41, 1.27 
      Amides 13 13.1 137 12.3 1.07 0.58, 1.98 1.17 0.62, 2.21 
>0.70 
 No nitrosatable drug 
exposure 122 78.7 1207 78.8 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 16 11.6 173 12.5 0.92 0.53, 1.58 1.13 0.64, 2.02 
      Tertiary amines 13 9.6 168 12.2 0.77 0.42, 1.39 0.97 0.51, 1.84 
      Amides 11 8.3 110 8.4 0.99 0.52, 1.89 1.10 0.56, 2.18 
Plant Nitrites 
< 0.46 Second  
No nitrosatable drug 
exposure 84 67.7 1031 72.4 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester  Secondary amines 18 17.7 231 18.3 0.96 0.56, 1.62 1.02 0.59, 1.77 
      Tertiary amines 15 15.2 175 14.5 1.05 0.59, 1.86 1.10 0.61, 1.98 
      Amides 12 12.5 121 10.5 1.22 0.65, 2.29 1.20 0.62, 2.29 
0.46-0.70 
 No nitrosatable drug 
exposure 86 71.1 974 69.3 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 19 18.1 261 21.1 0.82 0.49, 1.38 0.85 0.50, 1.45 
      Tertiary amines 16 15.7 212 17.9 0.85 0.49, 1.49 0.80 0.45, 1.43 
      Amides 15 14.9 122 11.1 1.39 0.78, 2.49 1.46 0.79, 2.69 
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Table 3.7 Continued. 
Dietary intake 
mg/day 
Timing of 
exposure 
 
Type of drug 
exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
>0.70 
 No nitrosatable drug 
exposure 122 81.3 
 
1207 
 
80.3 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 15 11.0 170 12.4 0.87 0.50, 1.53 1.11 0.61, 2.01 
      Tertiary amines  15 11.0 135 10.1 1.10 0.62, 1.93 1.37 0.75, 2.53 
      Amides 11 8.3 100 7.7 1.09 0.57, 2.08 1.16 0.59, 2.28 
Plant Nitrites 
< 0.46 Third  
No nitrosatable drug 
exposure 84 70.0 1031 74.6 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
 trimester  Secondary  amines 17 16.8 225 17.9 0.93 0.54, 1.59 0.99 0.57, 1.73 
      Tertiary amines 18 17.7 152 12.9 1.45 0.84, 2.49 1.51 0.87, 2.64 
      Amides 11 11.6 88 7.9 1.53 0.79, 2.98 1.64 0.82, 3.26 
0.46-0.70 
 No nitrosatable drug 
exposure 86 73.5 974 71.3 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 15 14.9 224 18.7 0.76 0.43, 1.34 0.74 0.41, 1.33 
      Tertiary amines 11 11.3 180 15.6 0.69 0.36, 1.32 0.66 0.34, 1.29 
      Amides 14 14.0 114 10.5 1.39 0.77, 2.53 1.45 0.77, 2.74 
>0.70 
 No nitrosatable drug 
exposure 122 79.7 1207 82.2 
 
Referent 
 
Referent 
 
Referent 
 
Referent 
   Secondary amines 16 11.6 149 11.0 1.06 0.61, 1.84 1.36 0.76, 2.42 
      Tertiary amines 14 10.3 104 7.9 1.33 0.74, 2.40 1.71 0.90, 3.23 
      Amides 13 9.6 86 6.7 1.50 0.81, 2.76 1.53 0.80, 2.92 
 Abbreviations: OR, odds ratio; CI, confidence interval. 
a
Data was restricted to participants with gestational ages between 37 and 41 weeks.  
b
Percentages for no nitrosatable drug exposure are based on total participants with complete information whereas percentages for secondary 
or tertiary amines or amides includes complete information for the given drug group and excludes other nitrosatable groups in the 
denominator. 
c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates, and whose 
daily caloric intake was between 500 and 5000 kcal.    
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center. 
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but consumption of plant source of nitrites had no effect on risk of SGA births.   
 Several studies have examined the individual associations of SGA with 
dietary patterns, single food nutrients, and vegetable and fruit consumption 
during pregnancy. Using data from a Danish National Birth Cohort of 44,612 
women, Knudsen and colleagues found that women classified in the health 
conscious group characterized by higher intake of vegetables, fruits, fish, and 
poultry, had lower odds of having a SGA infant (OR 0.74 [95% CI 0.64, 0.86]) 
than women with high intake of red and processed meat.8 These findings were 
corroborated by Thompson & colleagues who reported that women who adopted 
a traditional diet during early pregnancy, that included mostly fruits and 
vegetables, were less likely to have SGA births (OR 0.86 [95% CI 0.75, 0.99]).9 
Furthermore, a retrospective cohort study conducted in Spain observed that 
women in the lowest quintile of vegetable intake during the third trimester of 
pregnancy had higher odds of having a SGA infant (OR 2.1 [95% CI 1.0, 4.7]).13 
Vegetables, particularly spinach contain the highest amount of nitrates per 
serving (189 mg/serving).188 In the present study, we found a negative 
association between higher dietary intake of plant source of nitrites and SGA but 
the 95% confidence interval included the null (OR 0.82 [95% CI 0.61, 1.10]).     
 Experimental studies have demonstrated that drugs containing 
nitrosatable groups such as amines or amides can react with nitrosating agents 
such as nitrite under simulated gastric conditions to form N-nitroso compounds 
or nitrosamines. Choi et al. reported that if the nitrite concentration is high, the 
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formation of N nitroso compounds would be to a greater extent.189 Only one 
published study examined the association between N-nitroso compounds and 
adverse pregnancy outcomes. In pregnant mice exposed to nitrite in 
combination with ethylenethiourea (a nitrosatable compound), fetal weight was 
significantly reduced when both compounds were administered together, but no 
effect was observed when given separately.92  In this study population, a 
decreasing trend was noted in odds of SGA with exposure to nitrosatable drugs 
by increasing levels of nitrite intake. We observed strongest associations 
between nitrosatable amides and SGA among participants with the lowest intake 
of dietary nitrites and total nitrites. 
 To our knowledge this is one of the first studies that examined the relation 
of maternal dietary consumption of nitrates and nitrites with SGA. One of the 
strengths of the study was the large study population from multiple regions in the 
United States. Cogswell et al. found that NBDPS control participants were 
generally characteristic of their base populations with respect to age, previous 
live births, and smoking.179 Slight differences were noted by maternal 
race/ethnicity, education, and infant characteristics if the control participants 
were selected from hospitals compared to birth certificates. Also, since the study 
population did not include infants with any major birth defects, it allows a clearer 
interpretation of the study results because SGA and other neonatal outcomes 
are more commonly observed in infants with congenital malformations. Lastly, 
the nitrate and nitrite estimates used in the study were based on extensive 
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review by Griesenbeck and colleagues of all published literature regarding 
nitrates and nitrite content of food items listed in the Willett FFQ. 
The study had several limitations.  In the NBDPS, participants were 
interviewed about the frequency of foods consumed a year prior to conception 
which could be subject to participants’ recall and may have resulted in 
misclassification of foods consumed during pregnancy.  However, the 
misclassification might be non-differential with respect to the outcome (SGA) as 
the same period of dietary assessment was used for all NBDPS participants. 
Further, studies have indicated that consumption of vegetables and meats, 
major source of nitrates and nitrites, respectively, measured by consecutive 7-
day dietary records did not significantly differ before and during pregnancy, and 
strong correlations have been reported between vegetable intake at the 
beginning and end of pregnancy.13, 195  
Data collected from the FFQ could possibly have some degree of 
measurement error due to participants’ self-report of dietary consumption. 
However, when the dietary data used in this study were examined for 
measurement error using the Simulation Extrapolation (SIMEX) algorithm, Huber 
et al. found no difference in statistical significance or effect size for models in 
which the amount of error varied from 0 to 60% additional variance in increment 
of 10%.207 Furthermore, studies of validity and reproducibility of the original 
Willett FFQ indicate that the dietary questionnaire provides useful information 
about women’s nutrient intake over a one year period compared to four one 
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week diet records.186 The assessment of dietary intake of nutrients using the 
Willett FFQ was also comparable to nutrient intakes estimated using 24 hour 
recalls.187 
Another limitation pertains to the potential maternal recall bias of drug 
exposures during pregnancy. Because the study utilized exposure data for all 
NBDPS controls who had births without congenital malformations, the possibility 
of recall bias is less likely. Previous studies have found little evidence for 
differential recall of drugs classified as nitrosatable in the present study. No 
difference in recall was observed for several drugs that have nitrosatable drug 
components including analgesics, antibiotics, and antinauseants between 
women with normal or adverse pregnancy outcomes.197 The sensitivity and 
specificity of maternal recall for antibiotic, antinauseant, and any drug use during 
pregnancy was noted to be similar between low birth weight and control-
infants.196 To reduce recall bias, the NBDPS utilizes a two-level approach to 
assess drug usage by asking participants about drugs by indication of use and 
medication names. This approach has shown to be more accurate than an open 
ended questionnaire.198, 199 In the NBDPS, women were asked about medication 
use during pregnancy and the drugs were later classified into secondary amines, 
tertiary amines, and amides depending on their nitrosatability. Because, women 
were not aware of the nitrosatable drug components in the drugs, recall bias 
would have been less likely. However, it is possible that some type of drugs 
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within the various categories of nitrosatable drugs might have been recalled 
differently between case and control-women. 
 Exposure to some drugs may have been missed due to lack of published 
information on their nitrosatability. An extensive review of nitrosatable medicinal 
compounds published by Brambilla & Martelli89 and McKean Cowdin et al.185; 
and published literature on nitrosatable drugs was used to classify drugs based 
on nitrosatable functional groups present. However, components of some of the 
drugs reported might not have been tested for nitrosatability, and results of such 
tests may not be published.  
 Multiple analyses and comparisons were performed with respect to 
nitrosatable drug use stratified by dietary nitrite (plant and animal nitrite) and 
total nitrite. In study analyses, 108 logistic models were fit to assess the 
association between nitrosatable drugs and SGA by tertiles of dietary nitrite and 
total nitrite. Five associations would be expected by chance but only three 
adjusted odds ratios had 95% confidence intervals that excluded the null. To 
assess the interaction between nitrosatable drugs and dietary nitrites and total 
nitrites with SGA, 36 statistical tests were conducted. Two tests would be 
expected by chance but no significant interaction was observed. 
 In conclusion, findings from this study suggest that higher consumption of 
dietary nitrites and total nitrites during pregnancy may not increase the risk of 
SGA. We examined if higher intake of dietary nitrites and total nitrites 
strengthened the associations between nitrosatable drugs and SGA; but a 
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reverse trend was noted with modest associations observed for the highest 
tertile of dietary nitrites intake. Few significant results were found between 
nitrosatable amides and SGA for the lowest estimated intake of nitrite and 
animal source of nitrites. Although endogenous formation of N-nitroso 
compounds is one of the suggested mechanisms in the etiology of SGA, 
exposure to other environmental toxicants and other sources of nitrates such as 
drinking water might contribute to fetal growth restriction and their effect on the 
relation between dietary nitrates and SGA needs to be further examined.   
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4. PRENATAL EXPOSURE TO NITROSATABLE DRUGS, 
VITAMIN C, AND RISK OF SMALL-FOR-GESTATIONAL-AGE 
BIRTHS 
Overview 
Certain drugs, which contain secondary or tertiary amines or amides, can 
react with nitrite in the stomach to form N-nitroso compounds. These 
compounds have been associated with reduced birthweight in some animal 
models. Vitamin C is known nitrosation inhibitor. We examined the effect of 
vitamin C on the relation between maternal use of nitrosatable drugs during 
pregnancy and small-for-gestational-age (SGA) birth. Data were analyzed from 
control participants (mothers of babies without major birth defects) of the 
National Birth Defects Prevention Study that included 526 mothers who 
delivered infants with birthweight < 10th percentile and 5,970 mothers of control 
infants (birthweight ≥ 10th percentile for gestational age) born during 1997-2005. 
Maternal reports of vitamin C supplement use and data collected from a food 
frequency questionnaire was used to estimate daily intake of vitamin C. Daily 
use of supplements containing vitamin C presented inconsistent findings on the 
association between nitrosatable drugs and SGA. Higher intake of dietary 
vitamin C (≥85 mg/day) in conjunction with daily vitamin C supplementation 
slightly reduced the associations between SGA and secondary amines during 
the second trimester of pregnancy (adjusted odds ratio [aOR] 1.0 [95% 
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confidence interval [CI] 0.65, 1.6]) compared with <85mg of dietary vitamin C 
and less than daily use of vitamin C supplement (OR 4.0 [95% CI 1.5, 10.9]). 
Prenatal use of dietary and supplemental vitamin C may modify the association 
between SGA and selected nitrosatable drugs.  
Background 
 Low birthweight (<2500 g) is an important determinant of infant mortality. 
In 2011, disorders related to low birthweight and short gestation were the 
second leading cause of all infant deaths in the United States.208 However, low 
birth weight could represent both infants born prematurely and those with 
intrauterine growth restriction (IUGR). Small-for-gestational-age (SGA), usually 
defined as infants with birthweight less than 10th percentile for gestational age, is 
a commonly used proxy measure for assessment of IUGR. SGA infants are at 
increased risk of mortality during the first year of life, growth deficits and poor 
developmental outcomes in childhood, and chronic diseases in adulthood such 
as cardiovascular disease, insulin resistance, diabetes mellitus, dyslipidemia, 
and renal disease.3-6 Size at birth is dependent on the fetal growth rate which is 
influenced by a wide range of factors such as maternal body mass index, 
gestational weight gain, smoking and maternal nutrition during pregnancy.7, 11, 27-
29, 209 In the Dutch Famine of 1994-1945, severe malnutrition of mothers during 
the third trimester of pregnancy was associated with reduced fetal and placental 
weight.210 Although maternal undernutrition is uncommon in developed 
countries, the relative deficiency or lower levels of certain micronutrients such as 
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vitamin C might affect fetal growth. Vitamin C, a hydrophilic antioxidant, negates 
the effect of oxygen free radicals and it may help protect against cellular damage 
in the fetus.211 But the role of vitamin C on risk of SGA births in women exposed 
to nitrosatable drugs during pregnancy is not known.  
 A variety of prescription and over-the-counter medications, which contain 
nitrosatable amines (secondary or tertiary amines) or amides, react with 
nitrosating agents such as nitrites in the acidic environment of the stomach to 
form N-nitroso compounds.24 Endogenous formation of these compounds 
accounts for 40 to 75% of human exposure.88 N-nitroso compounds have been 
found to be associated with limb malformations, oral clefts, and neural tube and 
craniofacial defects in animal models.90, 202-204 However, relatively few studies 
have examined the relation between exposure to these compounds and birth 
outcomes. In pregnant mice exposed to ethylenethiourea (a nitrosatable 
compound) and nitrite, fetal weight was observed to be significantly reduced 
when both compounds were administered together but no effect was observed 
when given separately suggesting that N-nitroso compounds, formed from 
combination of nitrosatable compound and nitrite, might influence fetal growth.92   
 Vitamin C is a well-documented inhibitor of nitrosation. Studies have 
found vitamin C to reduce formation of N-nitroso compounds in vivo when 
administered with a nitrosatable compound. Mirvish et al. demonstrated that 
ascorbic acid inhibits in vivo nitrosation by rapid reduction of nitrite to nitrous 
oxide followed by production of dehydroascorbic acid.172 In a clinical trial 
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conducted with human volunteers, concomitant administration of increasing 
doses of ascorbic acid (1.76-1000mg) with nitrate and nitrosatable precursor 
such as proline significantly reduced the excretion of N-nitroso compounds by 
44% compared to combined exposures to nitrate and proline without ascorbic 
acid.173 In our previous study, we found that relative to women with no vitamin C 
supplementation, daily use of vitamin C supplement in conjunction with first 
trimester exposure to nitrosatable drugs was associated with lower odds of 
several birth defects including transverse limb deficiency with secondary amines, 
cleft lip without cleft palate with tertiary amines, and several congenital heart 
defects with tertiary amines and amides.175 No published study has examined 
the effect of vitamin C supplementation on SGA in relation to nitrosatable drug 
exposure during pregnancy. 
 In the present study, we examined the individual and joint effects of 
vitamin C supplementation and dietary vitamin C on the relation between SGA 
and maternal exposure to nitrosatable drugs (secondary or tertiary amines, or 
amides) during pregnancy.  
Methods  
 To address the study objectives, data were used from control participants 
(mothers of babies without major birth defects) of the National Birth Defects 
Prevention Study (NBDPS), a large population-based case control study of birth 
defects in the United States that began in 1997. Ten Centers for Birth Defects 
Research and Prevention (CBDRP) including Arkansas, California, Georgia, 
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Iowa, Massachusetts, New York, and Texas (from 1998 to present); New Jersey 
(from 1998 to 2002); and North Carolina and Utah (from 2003 to present) have 
participated or are currently participating in the national study. 
Study population 
 The present study included NBDPS control mothers who had live births 
without major birth defects with estimated dates of delivery (EDDs) between 
October 1, 1997, and December 31, 2005; and were residents of one of the 
geographic areas covered by the CBDRP population registries. These controls 
were randomly sampled from either birth certificates (Arkansas, for EDDs after 
2000; Georgia, for EDDs after 2000; Iowa; Massachusetts; New Jersey; North 
Carolina; and Utah) or hospital records (Arkansas, for EDDs prior to 2001; 
California; Georgia, for EDDs prior to 2001; New York; and Texas).179 For states 
that selected controls from hospitals, a systematic random sampling scheme 
was used so that infants selected were in proportion to the number of births at 
each hospital in the geographic area.178 The controls-infants were not eligible if 
they were stillborn, had a major birth defect, were adopted or in foster care, had 
a deceased mother, or were born outside the study area. Data only on mothers 
who delivered singleton births were included in the study analyses since multiple 
births have been identified as a major risk factor for SGA. The institutional 
review boards in each state and the Center for Disease Control and Prevention 
approved the NBDPS protocol, and the institutional review board of Texas A&M 
University approved this study.    
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Case and control definition  
Cases were defined as infants with birthweight less than the 10th 
percentile for given gestational age, gender, and race/ethnicity. Infants with 
birthweight at or greater than 10th percentile were identified as controls. 
Classification of SGA was based on the US singleton birthweight percentiles for 
gestational age by maternal race, parity, and infant gender, published by 
Overpeck et al.182 and Zhang & Bowes.183 Infant with gestational ages less than 
20 weeks or more than 44 weeks were excluded. Data on birthweight in grams 
and gestational age in weeks were obtained from either medical records or birth 
certificates of the participants. If not available, the following criteria was used for 
calculation of gestational age: 1) estimated due date reported by mother in the 
interview; 2) ultrasound <14 weeks; 3) last menstrual period; 4) ultrasound >14 
weeks; or 5) standard neonatal exam.  
Data collection  
In the NBDPS, women were interviewed via telephone by trained female 
interviewers in either English or Spanish using a structured questionnaire after 
oral consent was obtained.178 The interview took approximately 1-1½ hours to 
complete and covered topics regarding maternal health (including medications 
taken); diet (food consumption in the year before pregnancy); work history; 
demographic characteristics; and water use. Interviews were targeted for 
completion within six months of EDD until 24 months post-delivery. Women were 
not interviewed until six weeks after the EDD or actual date of delivery to reduce 
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recall bias between women with preterm and full term births. Data from the 
NBDPS with EDDs from 1997-2005 had a total of 6807 (66.2%) control mothers 
who participated in the interview. 
Classification of nitrosatable drugs 
 As part of the NBDPS interview, women were questioned about 
prescription and non-prescription drugs taken (medication name), the 
corresponding dates and frequency of use from three months prior to conception 
to the date of birth of index pregnancy. Women were also asked about drugs 
used for specific illness and diseases (e.g., asthma, diabetes, hypertension etc.), 
and specific products (e.g., ampicillin, phenytoin, metoprolol). The Slone 
Epidemiology Center Drug Dictionary was used to link the reported drugs to their 
active ingredients.184  
 Detailed methods used to classify drugs with respect to nitrosatability, 
functional groups, and indications were described in previous publications.25, 174 
The methodology used for classification included: 1) active ingredients for all 
orally administered drugs, and orally inhaled medications were identified; 2) 
these active ingredients were cross referenced with a comprehensive list of 
nitrosatable medicinal compounds published by Brambilla & Martelli89 and 
McKean Cowdin et al.;185 3) identified nitrosatable compounds were categorized 
based on the presence of amine (secondary or tertiary) and amide functional 
groups; and further 5) classified by the drug’s primary indication (e.g., 
antihistamine, antiepileptic) and pharmacologic class (e.g., opioid, macrolide). 
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We focused on maternal exposure to nitrosatable drugs during each trimester 
(first, second, or third) of pregnancy. Complete information on nitrosatable drug 
use anytime during pregnancy was available for 99% and 98.5% of case and 
control participants.  
Assessment of vitamin C intake  
The NBDPS collects information regarding the start and stop dates, 
duration, and frequency of vitamin supplement use (single, prenatal, and 
multivitamins) from three months prior to conception through the end of 
pregnancy. Vitamin C supplementation was categorized into none, less than 
daily, and daily depending on the frequency of intake. Women who reported 
using a daily vitamin C supplement during the first, second, or third trimester of 
pregnancy were classified as “daily” and those who no reported no vitamin C 
supplementation during the same period were classified as “none.” If women 
reported taking vitamin C supplement less than 90 days in a given trimester or 
less than every day in a given period, they were classified as “less than daily.” 
Due to small numbers, women with none and less than daily intake of vitamin C 
supplement were combined together. Complete information was available for 
97.0% and 97.2% of case- and control-mothers with nitrosatable drug use 
anytime during pregnancy and vitamin C supplementation during the first and 
second trimester of pregnancy. Because of incomplete information available on 
vitamin C supplement use during the third trimester of pregnancy, findings are 
presented only for the first and second trimester of pregnancy.  
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Information on foods consumed during the year prior to conception was 
collected using a 58-item food frequency questionnaire (FFQ) which was 
adapted from the short Willett Food Frequency Questionnaire. Data was also 
obtained regarding consumption of cereal intake from three months prior to 
conception through the end of pregnancy. The Willett FFQ has been validated 
and reproduced in other studies and provides useful information about nutrient 
intake over a one-year period compared to 24-hour or one week dietary 
recalls.186, 187 Daily intake of dietary vitamin C was calculated based on 
estimates from the NBDPS Nutrient Database for Standard Reference 19. 
Complete information on nitrosatable drug use anytime during pregnancy 
stratified by dietary vitamin C was available for 96.8% and 97.1% of the case 
and control participants.  
Statistical analyses 
Logistic regression was used to analyze the association between 
nitrosatable drug and SGA by supplemental and dietary intake of vitamin C. 
Nitrosatable drug exposure during the first, second, and third trimester of 
pregnancy was stratified by categories of vitamin C supplement use (<daily and 
daily). Women who reported no nitrosatable drug use anytime during pregnancy 
served as the referent group. We also examined the effect of dietary vitamin C 
(<85 mg/day or ≥85mg/day) in relation to nitrosatable drug use. The cut points 
were based on the recommended daily dietary vitamin C allowance for pregnant 
women over 18 years of age which corresponded to the 41st percentile for 
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control participants in this study.  All dietary vitamin C analyses were restricted 
to women who had daily caloric intake between 500-5000 kcal. These limits 
were recommended by Willett190 and have been previously used by dietary 
studies and those utilizing the NBDPS database.174, 191      
We calculated daily intake of total vitamin C by combining estimates of 
dietary and supplemental vitamin C. Women with daily vitamin C 
supplementation and ≥85mg of dietary vitamin C were classified as “high/daily” 
and those with less than daily intake of vitamin C supplement and lower intake of 
dietary vitamin C were categorized as “low/none”. We also examined the relation 
between nitrosatable drugs and SGA stratified by supplemental and dietary 
vitamin C among full term case and control infants with gestational ages 
restricted between 37 and 41 weeks. All analyses were performed using Stata 
11.205 
Covariates included in the logistic models were selected based on their 
association with SGA and maternal risk factors associated with nitrosatable drug 
use from previous literature. Maternal race/ethnicity, education, and study center 
were important predictors of nitrosatable drug use among control participants of 
NBDPS as noted in a previous publication.25 Non-significant covariates as well 
as those that did not change the odds ratio by 10 percent or more were 
eliminated from the final model using forward selection. The following covariates 
were included in the final model: maternal race/ethnicity (non-Hispanic white, 
non-Hispanic black, Hispanic, Asian/Pacific Islander, other), maternal education 
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(<12 years, 12 years, 13-15 years, >15 years), study center, maternal smoking 
(yes, no), and chronic hypertension prior to pregnancy (yes, no). Total caloric 
intake was included in the models of dietary vitamin C analyses in addition to the 
above mentioned covariates. Only participants with complete information 
available for all covariates included in the final logistic models were used for 
both crude and adjusted analyses. 
 Additive and multiplicative interaction was assessed for the associations 
of SGA with nitrosatable drugs by supplemental and dietary vitamin C. We 
tested for additive interaction using a statistical program developed by 
Andersson & colleagues that estimated measures of relative excess risk due to 
interaction (RERI) and attributable proportion due to interaction (AP).193 If either 
or both measures differed from zero and their 95% confidence intervals 
excluded 0, significant additive interaction was considered present. To assess 
multiplicative interaction, the product term of nitrosatable drug functional groups 
with supplemental and dietary vitamin C were included in the logistic models and 
was considered significant if the p-value was less than 0.05.      
Results 
 A total of 526 infants classified as SGA and 5,970 controls-infants (not 
classified as SGA) with an EDD from 1997-2005 participated in the NBDPS. The 
median length of time from EDD to interview was eight months for both case and 
control participants. Compared to control mothers, case mothers were more 
likely to be Hispanic or Asian/Pacific Islander, less educated, smokers, delivered 
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between 20-24 years of age, had a BMI less than 18.5 kg/m3 and a gestational 
weight gain of <25lbs (Table 4.1). A lower proportion of case mothers than 
control mothers reported taking a daily supplement of vitamin C during the first 
and second trimester of pregnancy. The distributions of maternal characteristics 
including race/ethnicity, education, age at delivery, study center, BMI, smoking, 
gender, gestational weight gain, and vitamin C supplementation during the 
second trimester of pregnancy were significantly different between case and 
control mothers.   
 Daily use of supplements containing vitamin C presented discordant 
results on the association between nitrosatable drug use during pregnancy and 
SGA (Table 4.2). Among women who took a daily supplement of vitamin C, a 
higher odd of SGA was observed in conjunction with exposure to nitrosatable 
amides during the first trimester of pregnancy (OR 1.03 [95% CI 0.54, 1.96]) 
compared to women exposed to these drugs and less than daily intake of 
vitamin C supplement (OR 0.88 [95%CI 0.56, 1.38]). In contrast, exposure to 
secondary amines during the second trimester of pregnancy was strongly 
associated with SGA in women who did not take a vitamin C supplement on a 
daily basis (OR 1.63 [95% CI 0.88, 3.01] compared to women with daily vitamin 
C supplementation during the same time period (OR 0.83 [95% CI 0.59, 1.17]).  
 Higher intake of dietary vitamin C (≥85 mg/day) slightly reduced the 
associations between SGA and tertiary amines during the third trimester of 
pregnancy, and amide drug exposure during the second trimester of pregnancy 
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Table 4.1 Selected Maternal Characteristics of Small-For-Gestational-Age Infants 
(Cases) and Controls in the National Birth Defects Prevention Study, 1997-2005 
 
Characteristics of 
Participants 
Controls  
n=5,970 
Cases 
n=526 
 
OR 
 
95% CI 
No. % No. % 
Race-ethnicity*       
 Non-Hispanic White 3573 59.9 289 54.9 1.00 Reference 
 Non-Hispanic Black 685 11.5 44 8.4 0.79 0.57, 1.10 
 Hispanic 1310 21.9 141 26.8 1.33 1.08, 1.64 
 Asian/Pacific Islander 165 2.8 27 5.1 2.02 1.32, 3.09 
 All others 237 4.0 25 4.8 1.30 0.85, 2.00 
 Missing 0 0 0 0 - - 
Education (years)*       
 >15 1882 31.5 114 21.7 1.00 Reference 
 13-15 1597 26.8 142 27.0 1.47 1.14, 1.89 
 12 1448 24.3 140 26.6 1.60 1.23, 2.06 
 <12 960 16.1 126 24.0 2.17 1.66, 2.82 
 Missing 83 1.4 4 0.8 - - 
Age at delivery (years)*       
 <18 219 3.7 22 4.2 0.91 0.57, 1.46 
 18-19 420 7.0 42 8.0 0.91 0.64, 1.30 
 20-24 1356 22.7 149 28.3 1.00 Reference 
 25-29 1601 26.8 133 25.3 0.76 0.59, 0.97 
 30-34 1569 26.3 98 18.6 0.57 0.44, 0.74 
 >34 805 13.5 82 15.6 0.93 0.70, 1.23 
Study center*       
 Arkansas 747 12.5 78 14.8 1.00 Reference 
 California 760 12.7 62 11.8 0.78 0.55, 1.11 
 Georgia 674 11.3 55 10.5 0.78 0.54, 1.12 
 Iowa 742 12.4 62 11.8 0.80 0.56, 1.13 
 Massachusetts 492 8.2 49 9.3 0.95 0.66, 1.39 
 North Carolina 539 9.0 46 8.8 0.82 0.56, 1.20 
 New Jersey 675 11.3 82 15.6 1.16 0.84, 1.61 
 New York 648 10.9 44 8.4 0.65 0.44, 0.95 
 Texas 360 6.0 23 4.4 0.61 0.38, 0.99 
 Utah 333 5.6 25 4.8 0.72 0.45, 1.15 
Body mass index (kg/m
2
)*       
 <18.5 289 4.8 55 10.5 2.08 1.52, 2.84 
 18.5–24.9 3205 53.7 293 55.7 1.00 Reference 
 25.0–29.9 1308 21.9 95 18.1 0.79 0.62, 1.01 
 >29.9 948 15.9 54 10.3 0.62 0.46, 0.84 
 Missing 220 3.7 29 5.5 - - 
Smoking*       
 No 4809 81.5 392 75.0 1.00 Reference 
 Yes 1094 18.5 131 25.0 1.47 1.19, 1.81 
 Missing 0 0 0 0 - - 
Gender*       
 Male 2992 50.1 297 56.5 1.00 Reference 
 Female 2978 49.9 229 43.5 1.29 1.08, 1.54 
 Missing 0 0 0 0 - - 
Parity       
 Nulliparous 2392 40.1 204 38.8 1.00 Reference 
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Table 4.1 Continued. 
  
Characteristics of 
Participants 
Controls  
n=5,970 
Cases 
n=526 
 
OR 
 
95% CI 
No. % No. % 
 Primiparous  1993 33.4 187 35.6 1.10 0.89, 1.35 
 Multiparous 1585 26.6 135 25.7 1.00 0.80, 1.25 
Gestational weight gain*       
 <25lbs 1492 25.0 179 34.0 1.27 1.03, 1.57 
 25-35lbs 2088 35.0 197 37.5 1.00 Reference 
 >35lbs 2154 36.1 127 24.1 0.62 0.50, 0.79 
 Missing 236 4.0 23 4.4 - - 
Vitamin C supplement use       
 First trimester* <daily 3988 67.9 372 72.2 1.23 1.00, 1.50 
  daily 1882 32.1 143 27.8 1.00 Reference 
 Second trimester* <daily 1075 18.3 126 24.4 1.44 1.17, 1.78 
  daily 4796 81.7 390 75.6 1.00 Reference 
Dietary vitamin C       
 <85 mg/day 2432 41.0 201 38.2 0.89 0.74, 1.07 
 ≥85 mg/day 3507 59.0 325 61.8 1.00 Referent 
Abbreviations: OR, odds ratio; CI, confidence interval. 
* p < 0.05; statistically significant difference  in distribution between cases and controls participants. 
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Table 4.2 Effects of Maternal Nitrosatable Drug Exposures by Each Trimester of Pregnancy on Small-For-
Gestational-Age Births Stratified by Vitamin C Supplementation, National Birth Defects Prevention Study, 1997-2005 
Frequency of 
vitamin C 
supplement
 
Timing of 
exposure
a 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
<Daily P1P3 No nitrosatable drug 
exposure 243 76.7 2495 73.9 1.00 Referent 1.00 Referent 
   Secondary  amines 36 12.9 457 15.5 0.81 0.56, 1.16 0.87 0.60, 1.27 
      Tertiary amines 32 11.6 474 16.0 0.69 0.47, 1.02 0.77 0.51, 1.14 
      Amides 24 9.0 287 10.3 0.86 0.55, 1.33 0.88 0.56, 1.38 
Daily  No nitrosatable drug 
exposure 
 
85 
 
71.4 
 
1072 
 
68.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 17 16.7 272 20.2 0.79 0.46, 1.35 0.85 0.49, 1.48 
      Tertiary amines 14 14.1 246 18.7 0.72 0.40, 1.28 0.74 0.41, 1.35 
      Amides 12 12.4 160 13.0 0.95 0.51, 1.77 1.03 0.54, 1.96 
<Daily P4P6 No nitrosatable drug 
exposure 
 
85 
 
74.6 
 
697 
 
76.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary  amines 17 16.7 107 13.3 1.30 0.74, 2.28 1.63 0.88, 3.01 
      Tertiary amines 14 14.1 113 14.0 1.02 0.56, 1.85 1.29 0.67, 2.48 
      Amides 8 8.6 65 8.5 1.01 0.47, 2.18 1.05 0.47, 2.36 
Daily  No nitrosatable drug 
exposure 
 
244 
 
74.6 
 
2870 
 
73.0 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 42 14.7 642 18.3 0.77 0.55, 1.08 0.83 0.59, 1.17 
      Tertiary amines 38 13.5 481 14.4 0.93 0.65, 1.33 0.95 0.66, 1.38 
      Amides 30 11.0 323 10.1 1.09 0.74, 1.62 1.11 0.74, 1.66 
   
Abbreviations: OR, odds ratio; CI, confidence interval; P1P3, first trimester; P4P6, second trimester 
  
a
Refers to timing of exposure for nitrosatable drugs and vitamin C supplement use. 
b
Percentages for no nitrosatable drug exposure are based on total participants with complete information, while percentages for secondary 
or tertiary amines and amides includes complete information for the given drug group and excludes other nitrosatable groups in the 
denominator. 
c
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates. 
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, and study center. 
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(Table 4.3). Among women whose estimated daily intake of dietary vitamin C 
was 85 mg or more, a lower OR was observed for SGA in association with 
nitrosatable amide use during the second trimester of pregnancy (OR 0.84 [95% 
CI 0.50, 1.43]) than among women who took these drugs and lower estimated 
intake of dietary vitamin C (OR 1.39 [95% CI 0.84, 2.31]). On the other hand, 
higher ORs were noted for SGA in women who reported 85 mg or more of 
dietary vitamin C intake in conjunction with exposure to secondary amines 
during the first, second, and third trimester of pregnancy and nitrosatable amides 
during the first trimester of pregnancy. Restriction of analyses to full term case 
and control infants did not change the overall conclusion; however, nitrosatable 
amide use during the fifth month of pregnancy was associated with lower odds 
of SGA in women with 85 mg or more of daily dietary vitamin C intake (OR 1.09 
[95% CI 0.56, 2.11]) compared with <85 mg of dietary vitamin C (OR 2.31 [95% 
CI 1.21, 4.42]) (data not shown). Exposure to amides during the sixth month of 
pregnancy was also associated with lower odds of SGA among women with 
higher intake of dietary vitamin C (OR 1.29 [95% CI 0.64, 2.58]) compared to 
those with less than 85mg of dietary vitamin C (OR 2.04 [95% CI 1.10, 3.81]) 
(data not shown).  
 With stratification by total vitamin C, a pattern of decreasing OR was 
observed for SGA among women with 85mg or more of dietary vitamin C and 
daily vitamin C supplementation in conjunction with exposures to secondary and 
tertiary amines during the second trimester of pregnancy (Table 4.4). The odds   
 
 
145 
 
Table 4.3 Effects of Maternal Nitrosatable Drug Exposures by Each Trimester of Pregnancy on Small-For-
Gestational-Age Births Stratified by Dietary Vitamin C, National Birth Defects Prevention Study, 1997-2005 
Dietary 
Vitamin C 
mg/day
 
Timing of 
drug 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
b
 
 
 
95% CI 
 
Adjusted  
OR
b,c
 
 
 
95% CI 
 
No. 
 
%
a 
 
No. 
 
%
a 
<85 P1P3 No nitrosatable drug 
exposure 115 71.4 1329 67.3 1.00 Referent 1.00 Referent 
   Secondary  amines 21 15.4 345 20.6 0.70 0.44, 1.14 0.76 0.46, 1.24 
      Tertiary amines 25 17.9 359 21.3 0.80 0.51, 1.26 0.87 0.54, 1.38 
      Amides 15 11.5 211 13.7 0.82 0.47, 1.43 0.82 0.46, 1.44 
≥85  No nitrosatable drug 
exposure 
 
213 
 
77.2 
 
2238 
 
75.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 33 13.4 383 14.6 0.91 0.62, 1.33 0.96 0.65, 1.44 
      Tertiary amines 22 9.4 359 13.8 0.64 0.41, 1.01 0.70 0.44, 1.12 
      Amides 21 9.0 232 9.4 0.95 0.60, 1.52 1.00 0.61, 1.62 
<85 P4P6 No nitrosatable drug 
exposure 
 
115 
 
68.9 
 
1329 
 
69.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary  amines 24 17.3 343 20.5 0.81 0.51, 1.28 0.87 0.54, 1.39 
      Tertiary amines 25 17.9 293 18.1 0.99 0.63, 1.55 1.00 0.63, 1.60 
      Amides 21 15.4 170 11.3 1.43 0.87, 2.33 1.39 0.84, 2.31 
≥85  No nitrosatable drug 
exposure 
 
213 
 
78.6 
 
2238 
 
76.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 34 13.8 404 15.3 0.88 0.61, 1.29 0.99 0.67, 1.47 
      Tertiary amines 26 10.9 299 11.8 0.91 0.60, 1.40 0.96 0.62, 1.50 
      Amides 17 7.4 219 8.9 0.82 0.49, 1.36 0.84 0.50, 1.43 
<85 P7P9 No nitrosatable drug 
exposure 
 
115 
 
72.3 
 
1329 
 
71.4 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary  amines 19 14.2 314 19.1 0.70 0.42, 1.15 0.74 0.45, 1.24 
      Tertiary amines 25 17.9 250 15.8 1.16 0.73, 1.82 1.18 0.74, 1.88 
      Amides 19 14.2 158 10.6 1.39 0.83, 2.32 1.40 0.82, 2.37 
≥85  No nitrosatable drug 
exposure 
 
213 
 
78.9 
 
2238 
 
78.8 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 31 12.7 361 13.9 0.90 0.61, 1.34 0.99 0.66, 1.49 
      Tertiary amines 20 8.6 238 9.6 0.88 0.55, 1.42 0.91 0.56, 1.50 
      Amides 21 9.0 169 7.0 1.31 0.81, 2.10 1.30 0.80, 2.13 
   
Abbreviations: OR, odds ratio; CI, confidence interval; P1P3, first trimester; P4P6, second trimester; P7P9, third trimester 
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Table 4.3 Continued. 
a
Percentages for no nitrosatable drug exposure are based on total participants with complete information, while percentages for secondary 
or tertiary amines and amides includes complete information for the given drug group and excludes other nitrosatable groups in the 
denominator. 
b 
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates and whose 
daily caloric intake was between 500 and 5000 kcal. 
c
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center. 
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Table 4.4 Effects of Maternal Nitrosatable Drug Exposures by Each Trimester of Pregnancy on Small-For-
Gestational-Age Births Stratified by Total Vitamin C (Supplement and Diet), National Birth Defects Prevention Study, 
1997-2005 
 
Total  
Vitamin C
a 
 
Timing of 
exposure 
 
Type of drug exposure 
Cases Controls  
Unadjusted 
OR
c
 
 
 
95% CI 
 
Adjusted  
OR
c,d
 
 
 
95% CI 
 
No. 
 
%
b 
 
No. 
 
%
b 
Low/None P1P3 
No nitrosatable drug 
exposure 84 71.8 881 67.5 1.00 Referent 1.00 Referent 
   Secondary  amines 16 16.0 221 20.1 0.76 0.44, 1.32 0.80 0.45, 1.41 
      Tertiary amines 17 16.8 245 21.8 0.73 0.42, 1.25 0.77 0.44, 1.35 
      Amides 10 10.6 141 13.8 0.74 0.38, 1.47 0.73 0.37, 1.47 
High/Daily  
No nitrosatable drug 
exposure 
 
55 
 
71.4 
 
632 
 
70.0 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 13 19.1 150 19.2 1.00 0.53, 1.87 1.02 0.53, 1.97 
      Tertiary amines 7 11.3 132 17.3 0.61 0.27, 1.37 0.61 0.26, 1.41 
      Amides 7 11.3 90 12.5 0.89 0.39, 2.02 0.98 0.42, 2.28 
Low/None P4P6 
No nitrosatable drug 
exposure 
 
20 
 
58.8 
 
249 
 
70.9 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary  amines 10 33.3 55 18.1 2.26 1.00, 5.11 4.03
e 
1.49, 10.93 
      Tertiary amines 8 28.6 57 18.6 1.75 0.73, 4.17 2.68 0.95, 7.58 
      Amides 1 4.8 26 9.5 0.48 0.06, 3.71 0.48 0.06, 4.04 
   
No nitrosatable drug 
exposure 
 
146 
 
77.3 
 
1770 
 
75.6 
 
1.00 
 
Referent 
 
1.00 
 
Referent 
   Secondary amines 27 15.6 350 16.5 0.94 0.61, 1.43 1.01
e 
0.65, 1.57 
      Tertiary amines 20 12.1 244 12.1 0.99 0.61, 1.62 1.04 0.63, 1.73 
      Amides 10 6.4 180 9.2 0.67 0.35, 1.30 0.72 0.37, 1.41 
   
Abbreviations: OR, odds ratio; CI, confidence interval; P1P3, first trimester; P4P6, second trimester; P7P9, third trimester 
  
a
Low/none refers to <85mg of dietary vitamin C intake and no vitamin C supplementation; high/daily refers to ≥85 mg of dietary vitamin C intake and daily 
vitamin C supplementation. 
b
Percentages for no nitrosatable drug exposure are based on total participants with complete information, while percentages for secondary or tertiary 
amines and amides includes complete information for the given drug group and excludes other nitrosatable groups in the denominator. 
c 
Crude and adjusted odds ratios include only cases and controls with complete information for drug exposures and covariates and whose daily caloric 
intake was between 500 and 5000 kcal. 
d
Adjusted for maternal race/ethnicity, education, smoking, chronic hypertension, caloric intake, and study center. 
e
Significant additive interaction (95% confidence levels for RERI and/or AP exclude 0). 
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of SGA in association with secondary amine exposure during the second 
trimester of pregnancy were notably lower among women with 85 mg or more of 
dietary vitamin C intake and daily vitamin C supplementation (OR 1.01 [95% CI 
0.65, 1.57]) compared to those with lower intake of dietary vitamin C and less 
than daily vitamin C supplementation (OR 4.03 [95% CI 1.49, 10.93]). Significant 
additive interaction (AP 0.57 [95% CI 0.22, 0.93]) was noted between total 
vitamin C and secondary amine exposure in relation to SGA.  
Discussion 
In this large population-based case-control study, the effects of vitamin C 
supplementation on associations between SGA and nitrosatable drugs appeared 
variable during the first and second trimester of pregnancy. Among women who 
took a daily supplement of vitamin C, lower ORs were observed for SGA with 
secondary and tertiary amines exposures during the second trimester of 
pregnancy compared to women with less than daily intake of vitamin C 
supplement. Conversely, higher ORs were noted for SGA in relation to 
nitrosatable amide use during the first trimester of pregnancy among women 
with daily vitamin C supplementation. 
Although dietary vitamin C appeared to diminish the association between 
specific nitrosatable drugs and SGA, inconsistent findings were observed. 
Higher intake of dietary vitamin C slightly lowered the associations between 
tertiary amines during the third trimester of pregnancy, and amide drug exposure 
during the second and third trimester of pregnancy. The odds of SGA were 
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notably lower among mothers of full term case and control infants who reported 
85 mg or more of dietary vitamin C intake in conjunction with nitrosatable amide 
exposure during the fifth and sixth month of pregnancy compared to those with 
lower intake of dietary vitamin C. In contrast, higher odds of SGA were observed 
with secondary amines exposure during the first, second, and third trimester of 
pregnancy and amide use during the first trimester in women with 85 mg or more 
of dietary vitamin C intake. Total vitamin C also modified the associations 
between nitrosatable drug and SGA, with lower ORs observed for SGA among 
women who reported higher intake of dietary vitamin C and daily vitamin C 
supplementation in conjunction with exposure to secondary and tertiary amines 
during the second trimester of pregnancy.   
  Limited epidemiologic studies have assessed the effect of vitamin 
supplementation on risk of SGA birth. In a prospective cohort study, Alwan et al. 
observed no significant association between daily vitamin supplementation 
during pregnancy and SGA. The ORs marginally decreased from 1.3 ([95% CI 
0.8, 1.9]) to 0.9 ([95% CI 0.5, 1.7]) with vitamin supplement use from the first to 
third trimester of pregnancy.176 These findings were consistent with a case 
control study conducted in Australia in which maternal use of vitamin 
supplement during the last month of pregnancy was associated with a slightly 
lower risk of SGA birth (OR 0.76 [95% CI 0.55, 1.05]).18 Mathews et al. found 
total vitamin C (estimated from food and supplement) intake during early 
pregnancy to be positively associated with birthweight, with a mean difference of 
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100g between the lowest (< 55 mg/day) and highest thirds (≥ 98 mg/day) of 
intake.15 Furthermore, Lee et al. noted that serum concentrations of maternal 
vitamin C measured during the second trimester of pregnancy were positively 
correlated with birth weight in full term births.212 In the present study, we found 
that mothers who took less than daily supplement of vitamin C were more likely 
to have SGA births (OR 1.23 [95% CI 1.00, 1.50]) compared to those with daily 
vitamin C supplementation during the first trimester of pregnancy. Less than 
daily use of vitamin C supplement during the second trimester of pregnancy was 
significantly associated with SGA (OR 1.44 [95% CI 1.17, 1.78]).  
Vitamin C is known to inhibit N-nitroso compound formation when 
administered concurrently with a nitrosatable precursor.172 However, in the 
NBDPS, participants were not questioned about the specific timing of dietary or 
supplemental vitamin C in relation to nitrosatable drug use. Hence, any effect 
modification observed may not be due to the effect of vitamin C itself but 
possibly due to other nutrients such as vitamin E commonly found in prenatal or 
multivitamins or healthy behaviors correlated with vitamin C supplementation or 
higher intake of dietary vitamin C.  
The study had several other limitations. Misclassification of foods 
consumed during pregnancy might have occurred. In the NBDPS, women were 
interviewed about the frequency of foods consumed a year prior to conception. 
Because the same period of dietary assessment was used for all NBDPS 
participants, the misclassification would most likely be non-differential with 
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respect to the outcome (SGA), and it would have minimal effect on any 
association observed with nitrosatable drugs by dietary vitamin C. Furthermore, 
Cuco et al. found no significant difference in average consumption of vegetables 
as measured before pregnancy and in weeks 6, 10, 26, and 38 of pregnancy.195 
Findings from another study indicated no change in mean intake of vegetables 
but a difference in fruit intake was noted between the first and third trimester of 
pregnancy. Strong correlations were also observed between the first and third 
trimester consumption of vegetables and fruits. 13 Vegetables and fruits are 
common sources of vitamin C.  
Another limitation was the potential maternal recall bias of drug 
exposures during pregnancy. Studies have found little evidence for differential 
recall of several drugs that have nitrosatable drug components including 
analgesics, antibiotics, and antinauseants between women with normal or 
adverse pregnancy outcomes.196, 197 In the NBDPS, participants were 
questioned about medications by indication of use and drug names. This two-
level approach has shown to be more accurate than an open ended 
questionnaire.198, 199 Also, women were not aware of the nitrosatable drug 
components in the drugs. The reported drugs were later classified into 
secondary amines, tertiary amines, and amides depending on their 
nitrosatability. Further, analyses of the study included exposure data for all 
NBDPS controls who had births without congenital malformations; hence it is 
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less likely that recall bias may have occurred than what might be expected 
among mothers of babies without major birth defects. 
Moreover, smaller sample sizes were available for some of the models 
examining the association between nitrosatable drugs and SGA by supplemental 
or dietary vitamin C. Among women who reported less than daily use of vitamin 
C supplement, the minimum detectable ORs were 1.5 and 1.7, respectively, with 
tertiary amine and amide exposures during the first trimester of pregnancy. But 
in women with secondary amines exposure during the second trimester, the 
smallest detectable OR was 2.0 at the same power level. Additionally, in women 
with lower intake of dietary vitamin C (<85 mg/day), we could detect ORs 
between 1.8 and 2.0 with 80% power in relation to tertiary amine and amide drug 
exposure.  Findings were not presented for the association between SGA and 
nitrosatable drugs stratified by vitamin C supplementation during the third 
trimester of pregnancy due to incomplete data available on vitamin C 
supplement use during this period.   
In conclusion, findings of this study suggest that supplemental and dietary 
vitamin C intake during pregnancy presented variable effects on the associations 
between nitrosatable drugs and SGA depending on trimester of use and type of 
nitrosatable drug. Daily vitamin C supplementation in combination with higher 
dietary vitamin C intake (≥85 mg/day) also modified the association between 
nitrosatable drugs and SGA.  Based on what is known regarding the role of 
vitamin C in inhibiting N-nitroso compound formation when given together with a 
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nitrosatable compound, more research is needed to examine the relation 
between SGA and nitrosatable drugs with respect to timing of vitamin C 
supplement use and nitrosatable drugs exposure.       
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5. SUMMARY AND CONCLUSIONS 
Summary 
The causes and mechanism of SGA are not well understood. Numerous 
environmental contaminants including maternal exposure to air pollutants and 
tobacco smoke have been associated with SGA but evidence is limited on the 
association between nitrate and nitrite exposure from diet, nitrosatable drugs 
and SGA. Nitrate is a ubiquitous contaminant in food and water. Certain 
medications, which contain nitrosatable amines (secondary or tertiary amines) or 
amides can react with nitrosating agents such as nitrite in the acidic environment 
of the stomach to form N-nitroso compounds.24 Evidence from animal models 
suggested that combined exposure to nitrite and a nitrosatable compound were 
associated with reduced birthweight in offspring.92 No published study has 
examined the association between maternal exposure to nitrosatable drugs and 
dietary nitrate/nitrite intake and SGA.   
In this population-based case-control study, we found that maternal 
exposure to nitrosatable drugs and their specific functional groups (secondary 
amines, tertiary amines, or amides) any time during pregnancy was not 
generally associated with SGA. However, maternal use of drugs classified as 
nitrosatable amides during the third trimester of pregnancy was significantly 
associated with SGA. Higher ORs were noted for SGA in relation to amide drug 
use during the eighth and ninth month of pregnancy. Furthermore, these 
associations were stronger when analyses were restricted to full term case- and 
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control-infants, and exposure to amides during the sixth month of pregnancy 
was also associated with SGA in full term births.  
 Dietary consumption accounts for a significant portion of daily nitrite 
exposure. Ingested nitrates are converted to nitrites in the saliva (approximately 
5%) and a portion of the nitrites is converted to nitric oxide in the acidic 
environment of the stomach.20, 21 Studies have detected elevated nitric oxide 
levels in cord blood and placental tissue of pregnancies with intrauterine growth 
retardation.83, 84 In the present study, higher consumption of dietary nitrates, 
nitrites, and total nitrites were not significantly associated with SGA. Moreover, 
we examined if higher intake of dietary nitrites and total nitrites strengthened the 
associations between nitrosatable drugs and SGA; but a reverse trend was 
noted with modest associations observed for the highest tertile of dietary nitrite 
intake. Women with the lowest estimated intake of nitrite and total nitrites were 
more likely to have a SGA offspring if they reported exposure to drugs classified 
as nitrosatable amides during the third trimester of pregnancy. A lower intake of 
dietary nitrites from animal sources in conjunction with exposure to amide drugs 
was significantly associated with SGA, but consumption of plant source of 
nitrites had no effect on risk of SGA births.   
 Vitamin C is known to inhibit N-nitroso compound formation when 
administered concurrently with a nitrosatable precursor. We examined whether 
supplemental and dietary vitamin C diminished the association between 
nitrosatable drugs and SGA. The effects of vitamin C supplementation on the 
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associations between SGA and nitrosatable drugs appeared variable during the 
first and second trimester of pregnancy. Among women who took a daily 
supplement of vitamin C, higher odds of SGA were observed in conjunction with 
exposure to nitrosatable amides during the first trimester of pregnancy 
compared to women exposed to these drugs and less than daily intake of 
vitamin C supplement. Conversely, lower ORs were noted for SGA in women 
with daily vitamin C supplementation in conjunction with exposure to secondary 
amines during the second trimester of pregnancy than ORs for women who took 
these drugs and less than daily intake of a vitamin C supplement. 
 Dietary vitamin C presented inconsistent findings on the association 
between SGA and nitrosatable drug use during pregnancy. Higher intake of 
dietary vitamin C (≥85 mg/day) slightly lowered the associations between SGA 
and amide drug use during the second trimester of pregnancy. On the other 
hand, higher odds of SGA were observed with amide use during the first 
trimester in women with 85 mg or more of dietary vitamin C intake. Total vitamin 
C also modified the associations between nitrosatable drug and SGA. The odds 
of SGA in association with secondary and tertiary amines during the second 
trimester of pregnancy were lower among women who reported higher intake of 
dietary vitamin C (≥85 mg/day) and daily vitamin C supplementation compared 
to women with <85 mg of dietary vitamin C and less than daily use of vitamin C 
supplement. 
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Conclusions 
 Prenatal use of drugs that have nitrosatable components did not appear 
to increase the odds of delivering a SGA infant except for a few notable 
exceptions. Higher consumption of dietary sources of nitrates and nitrites was 
not found to be associated with SGA, nor did higher nitrite intake strengthen the 
association between nitrosatable drugs and SGA. Exposure to other 
environmental toxicants and other sources of nitrates such as drinking water 
might contribute to fetal growth restriction. Drinking water nitrates below the 
maximum contaminant level of 10 mg/L have been associated with intrauterine 
growth retardation.213 However, the combined effect of nitrate exposure from diet 
and drinking water on the relation between nitrosatable drugs and SGA needs to 
be further examined.     
 Daily use of supplements containing vitamin C in conjunction with higher 
intake of dietary vitamin C slightly lowered the odds of SGA in relation to 
nitrosatable drug use during pregnancy. Women should be recommended to 
take a daily supplement containing vitamin C and to increase the intake of 
vegetables and fruits; these health habits may reduce the risk of SGA 
associated with nitrosatable drug use during pregnancy; many of such drugs 
being over the counter. Although adverse health outcomes associated with 
being born SGA are well known, limited research has focused on the 
determinants of SGA, some of which may be modifiable.  
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